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0.2 Abstract
Senescent cells play an important role in normal biological processes such as wound
healing and cancer prevention. If not effectively cleared by the immune system however,
senescent cells can accumulate and have been linked to negative events; most notably
fibrosis and ageing.
To understand more about the molecular mechanisms underpinning senescence as
well as the effects senescent cells have on surrounding cells, the organism as a whole
and why some cells evade the immune system, it is necessary to study and manipulate
senescent cells in vitro and in vivo. In order to do this, accurate identification of
senescent cells is required, something which can currently only be achieved by staining
for multiple markers, a process that requires invasive tissue sampling when using in
vivo models, and is a limitation in human studies in particular. A secreted biomarker
that is detectable in bio-fluids such as blood would facilitate more informative human
and animal studies.
In this thesis un-targeted metabolomic screens were performed using fibroblasts
from multiple tissue types and two well characterised models of senescence: replicative
senescence and irreparable DNA double strand break induced senescence. Controls for
transient growth arrest and repairable DNA damage were also included and all groups
were compared to young dividing cells. These investigations not only give insight into
the metabolic changes occurring in senescence but also provided candidate biomarkers
that were then more closely studied using targeted techniques. Extracellular citrate
was identified as the most robust candidate, and its regulation was investigated at the
molecular level.
The work presented in this thesis represents a novel contribution to the field of
senescence both in terms of the metabolic profiles of senescent and quiescent fibroblasts
and the strong candidate biomarker, citrate, which has the potential to broaden studies
of senescence in humans in vivo.
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Chapter 1
An introduction to the use of
metabolic biomarkers of senescence
1.1 Cellular senescence
Senescence, defined as a state of irreversible growth arrest, has been observed since
biologists first succeeded in culturing explanted cells in vitro, and attempts to explain
the phenomenon are still being refined to this day. In 1921 the Nobel laureate Alexis
Carrel published his observations that the growth rate and in vitro lifespan of chicken
fibroblasts cultured in serum was related to the age of the animal the serum was de-
rived from, and suggested that cells did not suffer loss of an “accelerating factor” but
stopped multiplying only because of an external inhibiting factor (Carrel, 1921). This
idea was contradicted 40 years later when Leonard Hayflick and Paul Moorhead fam-
ously observed that one population of human embryonic fibroblasts had a cumulative
population doubling limit in vitro of between 40 and 60 doublings before proliferation
eventually stopped, but cells from older individuals had a lower replication limit. Hay-
flick and Moorhead made the link that each cell can only go through a finite number of
divisions, which the cell can keep count of (hence why the cells from older individuals
went through less divisions in vitro, because they had already been through more divi-
sions in vivo), before an internal blocking mechanism comes into effect (Hayflick and
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Moorhead, 1961). This became known as the Hayflick Limit.
Hayflick is the one most often remembered, as he correctly identified that cells
contain an internal mechanism that stops proliferation, however it is now clear that
the internal mechanism which brings about senescence can be activated independently
of the Hayflick Limit. For example, external factors that stress the cell can induce
senescence, and could explain Carrel’s findings (why such factors were present in the
serum of Carrel’s aged chickens will be discussed later). Furthermore, it is now apparent
that senescence entails much more than just growth arrest and this introduction will
give an overview of what we know of the mechanisms underpinning senescence, the
resulting phenotype and its importance in biological processes and pathologies in vivo.
1.1.1 Senescence requires irreversible cell cycle arrest
A permanent growth arrest requires exit from the cell cycle (see figure 1.1). The cell
cycle is a sequence of phases during which the integrity of the cell’s genetic material is
checked, DNA is duplicated and finally the cell divides. Each phase is tightly regulated
by two groups of proteins: cyclins and cyclin dependent kinases (CDKs), which work
together to ensure that relevant transcription factors are active at each stage of the cell
cycle. The most important of these transcription factors when considering senescence
is E2F, a family of 5 transcription factors that target nucleotide sequences present in
the promoter regions of several genes essential for cell growth control, including c-myc,
CDK1 and E2F-1 itself.1 E2F is prevented from acting as a transcription factor by
the Retinoblastoma protein (Rb) (Hiebert et al., 1992). The Rb family of proteins are
the products of the Retinoblastoma gene originally identified in the eye and they act
1Three of the members of the E2F family, namely E2F1-3, are known as ‘activators’ because they
are potent activators of transcription of cyclins that promote S phase entry. Inactivation of these three
transcription factors results in a complete failure to proliferate, as shown by the use of conditional
mutant E2F1-3 by Wu et al (Wu et al., 2001)(however, it is also known that E2F1, which is stabilised
by the DNA damage response proteins ATM and ATR (Lin et al., 2001), also promotes apoptosis
if expressed at high enough levels). In contrast E2F4 and E2F5 repress the E2F response genes
by recruiting pocket proteins (Rb and its family members p107 and p130), and histone modifying
enzymes. E2F6, the final family member, is also a repressor but through a pocket protein independent
mechanism.
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as ‘gatekeepers’, controlling whether the cell cycle continues through from G1 phase to
S phase via their interactions with certain transcription factors and promoter regions.
When in a de-phosphorylated state, Rb binds E2F in the trans-activation domain, so
the E2F-Rb complex is still able to bind to the promoter regions of the E2F target
genes, but E2F’s ability to recruit transcriptional machinery is disabled. Instead of
recruiting transcriptional machinery, the complex recruits factors that enhance tran-
scriptional repression such as histone deacetylase enzymes (HDACs) and the histone
methyl-transferase SUV39H1. This inhibition is stopped at the G1/S checkpoint by
CDK4/6 and cyclin D combined with CDK2 and cyclin E, which phosphorylate Rb.
Phosphorylation of Rb causes it to release E2F, facilitating transcription of S phase
genes and the continuation of the cell cycle (Zhang et al., 2000). During S phase multi-
vulval class B (MuvB) complexes with the transcription factor BMYB to control gene
expression, while gene expression in late G2 and M phase is controlled by the MuvB
core binding to the transcription factors BMYB and FOXM1 (reviewed in Sadasivam
and DeCaprio (2013)). During G0 MuvB binds to p130-E2F dimerisation partner (DP),
forming the DP, Rb-like, E2F and MuvB (DREAM) complex which represses all cell
cycle dependent gene expression (Litovchick et al., 2007).
30
Figure 1.1: Schematic showing the stages of the cell cycle. The early part of
the first gap phase (G1) is mitogen dependent and driven forward by the action of cyc-
lin D in combination with CDKs 4 and 6, however once past the G1 restriction point
progression no longer requires mitogens to be present. The late stage of G1 is driven
by cyclin E and CDK2. The G1/S checkpoint is the point at which the cell commits
to synthesising duplicate copies of its DNA ready for cell division. If there are are no
inhibitory signals then the actions of CDK4/6 with cyclin D combined with CDK2 and
cyclin E phosphorylate Rb, which throughout G1 had been hypo-phosphorylated allow-
ing it to remain bound to the transcription factor E2F. Once hyper-phosphorylated, Rb
dissociates from E2F and the transcription of proteins required for S phase can begin.
Following S phase the cell enters a second gap phase (G2) and the cell prepares for
division by synthesising the necessary proteins. A final checkpoint (G2/M) must then
be passed before mitosis can begin, the cell will not be able to proceed if DNA damage
response pathways are active. Late G2-M gene expression is controlled by multi-vulval
class B (MuvB) binding the transcription factors BMYB and FOXM1. G0 is a resting
phase entered into by cells which are not preparing to divide, such as terminally dif-
ferentiated cells (which may only re-enter the cell cycle under specific circumstances),
quiescent cells (which will re-enter the cell cycle once stimulated to do so), and senes-
cent cells (which have permanently exited the cell cycle and cannot re-enter, but remain
metabolically active). Cell cycle dependent gene expression is repressed during G0 by
the p130-E2F4 dimerisation partner (DP), Rb-like, E2F and MuvB (DREAM) complex.
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1.1.2 Quiescence and geroconversion
As already mentioned, cells in G0 that are not in a permanent or stable state of arrest
are known as quiescent, and can remain quiescent indefinitely. The transition from
this reversible growth arrest to senescence is known as ’geroconversion’ and there is
evidence to suggest it is caused by continued signals to divide, in particular from the
target of rapamycin (TOR) pathway, while the cell cycle is still arrested (Demidenko
and Blagosklonny, 2008; Blagosklonny, 2012).
1.1.3 Key senescence effector proteins
Although senescence is induced and maintained by a host of complex pathways and
processes, there are some key proteins that play particularly important roles. These are
p53, its downstream effector CDK inhibitor p21WAF1, and the CDK inhibitor p16INK4A.
1.1.3.1 p53
At the time of writing, a Pub Med search for ’p53’ returned 128045 articles. It is
one of the most studied proteins, which is not surprising because p53 and its family
members are involved in numerous cellular functions; development (Gannon and Jones,
2012), metabolic regulation (Gottlieb and Vousden, 2010) and apoptosis (Giorgi et al.,
2015) to name just a few. p53 is most famous for its role as the ’guardian of the
genome’, because of its involvement in maintaining the integrity of the germ line (Muller
et al., 2000) and its role as a tumour suppressor protein (Olivier et al., 2010), which
is ironic because when it was first discovered it was believed to be an oncoprotein;
many groups had identified p53 cooperating with oncogenic Ras in several forms of
cancer, but it was later discovered that all of these oncogenic examples of p53 were
actually mutant p53; wild type p53 prevents oncogenic transformation in many cases
(reviewed in Lane and Levine, 2010). As we shall see, p53’s role in maintaining genomic
integrity and preventing neoplastic transformation involves the regulation of senescence,
via several mechanisms. p53 is known to be activated by various post translational
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modifications, and in 2000 Karen Webley and co-workers published a detailed account
of the different phosphorylation states of p53 at the N and C termini in response to
different senescence inducing stimuli. They demonstrated, using antibodies specific to
particular phosphorylated amino acid residues, that cells which had senesced due to
reaching the Hayflick limit had p53 phosphorylated on different residues to cells treated
with the DNA damaging agent bleomycin, ultraviolet (UV) radiation, and ionising
radiation, although all of these conditions had the phosphorylation of serine 15 on p53
in common. This lead to the hypothesis that different kinases were involved in the
regulation each of these mechanisms leading to activation of p53 (Webley et al., 2000).
1.1.3.2 p21WAF1
p21WAF1(also known as p21CIP1, and referred to in some papers as senescent cell derived
inhibitor 1) is a member of the Cip and Kip family of CDK inhibitors that also includes
p27 and p57, encoded by the gene CDKN1A (reviewed in Abbas and Dutta, 2009).
p21WAF1 is best known for functions in cell cycle inhibition; this role was discovered
when immunoprecipitation experiments showed the 21 KDa protein to be interacting
with and inhibiting cell cycle regulating proteins (Harper et al., 1993) and it was found
to be elevated in senescent cells (Noda et al., 1994), but it can also protect against
apoptosis (Sheikh et al., 1995). The activity of p21WAF1 in response to DNA damage
is dependent on transcriptional activation by p53, and p53 can also activate 21 tran-
scription in response to Ras activation (Macleod et al., 1995), although it can also be
transcriptionally regulated independently of p53 by Ras and Raf and by other stim-
uli such as nuclear receptors, vitamin D receptors and androgens via the transcription
factor E2F1. Alternatively the Kru¨ppel-like transcription factor (Klf) family member
KLF6 can co-operate with p300-CREB binding protein (a transcriptional co-activator)
to activate CDKN1A transcription (reviewed in Abbas and Dutta, 2009).
In addition, p21WAF1 regulation by post translational modifications is very important
as it is a highly unstable protein that is targeted for ubiquitination or proteolysis unless
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it is protected by chaperone proteins, which are recruited following binding of adaptor
proteins to p21WAF1 (Jascur et al., 2005). Furthermore, post-translational modifications
such as phosphorylation facilitate the transport of p21WAF1 to different cell compart-
ments, where its function is different. For example nuclear p21WAF1 acts as a cell cycle
inhibitor whereas the anti-apoptotic functions require the protein to be localised to
the cytoplasm, which occurs following phosphorylation by the serine threonine protein
kinase AKT1 (Ping et al., 2006).
1.1.3.3 p16INK4A
The only known function of p16INK4A is the inhibition of CDK4 and CDK6. It has
been shown to accumulate in senescence (Hara et al., 1996) and is also a functional
marker of ageing (Krishnamurthy et al., 2004; Liu et al., 2009; Baker et al., 2016).
Since its discovery in 1993 (Serrano et al., 1993) mutations in or loss of the gene have
been associated with several cancers (Li et al., 2011). p16INK4A is encoded by the
gene CDKN2A, which also includes an alternative reading frame (ARF) that encodes
p14ARF. Activation of these genes is independent of p53 and is regulated by polycomb
group proteins (PcG) (Bracken et al., 2007).
1.1.3.4 Inhibition of the cell cycle by senescence effector proteins
Activation of p53 in response to DNA damage, oncogenic signalling or other cellular
stress results in the transcription of several downstream targets, which have both direct
and indirect effects on the senescence growth arrest (although the relationship between
senescence and p53 is complex and in some contexts p53 can inhibit senescence induction
(Salama et al., 2014)). One such downstream target is micro RNA 34A (miR34A) (He
et al., 2007), which negatively regulates the expression of Sirtuin 1 (SIRT1) (Yamakuchi
et al., 2008). SIRT1 itself is capable of negatively regulating p53 by deacetylating
lysine 382, which disables p53 transcriptional activity (Langley et al., 2002), so p53
dependent transcription of miR34A results in a positive feedback loop, stabilising p53
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and therefore promoting the induction of senescence. In addition, SIRT1 also negatively
regulates nuclear factor kappa light chain enhancer of activated B cells (NFkB) which is
activated in response to senescence inducing stimuli such as DNA double strand breaks
(DSB) and has important but incompletely understood roles in senescence; silencing of
NFkB has been shown to result in senescence bypass, suggesting it could be necessary
for growth arrest in some contexts (Rovillain et al., 2011), however it has also been
demonstrated that non-canonical activities of NFkB can suppress senescence by directly
modulating the CDKs and even p21WAF1 (Iannetti et al., 2014).
Another downstream transcriptional target of p53 is p21WAF1 Qian and Chen, 2013).
p21WAF1 is a potent inhibitor of CDKs and can inhibit the phosphorylation of Rb
by cyclin A-CDK2, cyclin E-CDK2, cyclin Dl-CDK4, and cyclin D2-CDK4 complexes
(Harper et al., 1993). In addition, p21WAF1 influences the cell cycle by binding to
proliferating cell nuclear antigen (PCNA), preventing access by Cyclin D, which is
required for cell cycle progression (Stein et al., 1999).
Increased expression of p16INK4A following PcG protein regulation (due to DNA
damage or oncogenic signalling) specifically inhibits CDK4 and CDK6 via stearic hindrance
(Alcorta et al., 1996; Stein et al., 1999; Brookes et al., 2004).
In karatinocytes it has been shown that p53 levels decline in established senescence
(Kim et al., 2015) and in human diploid fibroblast (HDF) cells undergoing senescence
it has been observed that p21WAF1 is elevated in the early stages of growth arrest and
p16INK4A gradually increases so that in late senescence p21WAF1 levels (and also pre-
sumably activated p53) are low and p16INK4A levels are high (Stein et al., 1999) however
neither protein is essential to all modes of senescence (Stein et al., 1999; Prieur et al.,
2011).
The summary diagram in figure 1.2 shows how cell cycle arrest can be brought about
through a variety of pathways initiated by either proliferative exhaustion, genotoxic
stress, or oncogene expression. These routes to senescence will be discussed in the
following subsections.
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Figure 1.2: Simplified overview of senescence induction showing the three gen-
eral senescence inducing stimuli; proliferative exhaustion, genotoxic stress and oncogene
expression. These modes of induction often converge on DNA damage signalling which
is regulated by proteins such as ataxia telangiectasia mutated (ATM) and ataxia tel-
angiectasia and Rad3-related (ATR) which induce p16INK4A. Activation of p53 results
in the transcription p21WAF1, and these CDK inhibitors prevent CDKs from phos-
phorylating Rb. Phosphorylation of Rb is required for it to release the transcription
factor E2F which is responsible for transcription of genes needed for synthesis (S) phase,
so inhibition of E2F leads to cell cycle arrest in G1. Oncogene expression activates the
mitogen activated protein kinase 38 (p38 MAPK) pathway, also resulting in CDK in-
hibition. Cell cycle arrest can occur in G2 via a separate route involving alterations in
heterochromatin structure.
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1.1.4 Proliferative exhaustion induces senescence via telomere
shortening
Hayflick and Moorhead observed that somatic cells can only go through a finite number
of divisions and cells are able to keep track of how many they have already been through,
as evidenced by the observation that cells from older individuals have less capacity to
proliferate once explanted to culture than cells from a young individual, even when given
the same culturing conditions (Hayflick and Moorhead, 1961). Subsequent research has
identified the mechanism that keeps track of the number of cell divisions as telomere
erosion via end-replication inhibition (Olovnikov, 1971). These multifunctional hetero-
chromatin structures, made from up to 15kB of DNA 5’-TTAGGG-3’ repeats (Moyzis
et al., 1988) bound to associated proteins (including the shelterin complex), are found at
the ends of all linear eukaryotic chromosomes. Telomeres form loops, called ‘T Loops’,
that act as a cap; stabilising the end of the telomere (Griffith et al., 1999), protecting
the ends of DNA from being recognised as a DNA double strand break and getting
degraded as part of a DNA damage response (DDR), also preventing end fusion events
and helping to position the chromosomes within the nucleus. The basic structure of a
telomere is shown in figure 1.3.
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Figure 1.3: The simplified structure of a telomere. Telomeres are structures
of heterochromatin that form ’caps’ in concert with various proteins (which form the
shelterin complex) on the ends of linear DNA of eukaryotic chromosomes, preventing
recognition as a strand break and also protecting coding DNA from sequence loss due
to the end replication problem. The cap structure contains a T Loop, which houses
proteins involved in maintenance of chromosomal integrity and telomere elongation, as
well as a smaller D loop. Schematic made with help from Katie R. James.
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Another function of telomeres is to facilitate the complete replication of entire chro-
mosomes, although at the cost of the telomere sequence itself. With each cell division
some of the telomere sequence is lost during S phase due to the ‘end replication prob-
lem’ which occurs as an inevitable result of DNA polymerase working to replicate DNA
in the 5’3’ direction, and exonuclease digestion of the C tail (Olovnikov, 1971). By
sacrificing some of the telomere sequence, the DNA that encodes the genome is spared.
Furthermore, the structure of the telomere prevents the repair of DNA double strand
breaks by non-homologous end joining, which could explain the build up of DNA double
strand breaks in post mitotic tissues, such as brain and liver, with age (Muraki et al.,
2013). Once a critical telomere length is reached disruption in the proteins associated
with the telomere allows it to be recognised as dysfunctional and a DDR is launched,
resulting in senescence (d’Adda di Fagagna et al., 2003; Takai et al., 2003). Senescence
induced via proliferative exhaustion will henceforth be referred to as PEsen.
1.1.4.1 Telomerase prevents PEsen
Germ line cells and embryonic stem cells do not encounter the problem of telomere
erosion because they are able to replenish their telomeres using a ribonucleoprotein
enzyme called telomerase. The enzyme contains a telomerase reverse transcriptase
enzymatic sub unit (TERT) and an RNA template (TERC ) (Kim et al., 1994), and
works by copying the repeating sequence directly onto the end of the chromosome (Feng
et al., 1995). Although telomerase is not expressed in most somatic cells, some cancer
cells are able to switch on telomerase and can become immortal (Kim et al., 1994;
Killela et al., 2013).
1.1.4.2 Non canonical functions of telomerase
Telomerase is also known to have functions other than lengthening telomeres, some
of which require both the TERT and TERC components (non-canonical I functions)
and some which only require the TERT component (non-canonical II functions). Non-
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canonical I functions are associated with neoplasia formation and an insensitivity to
transforming growth factor beta (TGF-β) and epidermal growth factor whereas non-
canonical II functions are involved in apoptosis resistance and the activation of WNT
and MYC signalling (reviewed in Parkinson et al., 2008).
1.1.4.3 Alternative lengthening of telomeres (ALT) can also prevent PEsen
Cancer cells that do not express telomerase can also lengthen telomeres using an al-
ternative lengthening of telomeres (ALT); a mechanism that is not completely under-
stood. The evidence suggests that ALT occurs via recombination using proteins that are
present in all normal somatic cells such as the members of the MRN complex (meiotic
recombination 11 (MRE1), RAD50 and Nibrin (NBS1)), and it is suggested that some
proteins, such as telomere repeat binding factors 1 and 2 (TRF1 and TRF2), which can
be lost in cancer, are usually preventing ALT (reviewed in Cesare and Reddel, 2010).
1.1.5 Premature senescence in the absence of telomere attri-
tion
In the absence of shortened telomeres cells can still enter senescence via other routes
if necessary. The expression of oncogenes, certain histone modifications and genotoxic
stress can all lead to senescence, and can occur independently of each other, although
sometimes the pathways overlap. Oncogene expression and genotoxic stress, along with
telomere attrition, are all thought to illicit senescence ultimately via a DNA damage
response (DDR).
1.1.5.1 Oncogene induced senescence (OIS)
A key role of senescence in vivo is thought to be tumour suppression, so it is no surprise
that genes coding for p53, Rb and p16INK4A are among the top 10 most commonly
mutated genes in cancer (Atlas, 2015). It was initially demonstrated in vitro that
oncogenic Ras expression in the presence of functional p53 or p16INK4A leads to a short
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period of hyper-proliferation that then triggers a permanent cell cycle arrest in G1
(Serrano et al., 1997) and subsequent work showed that a downstream effector of Ras
signalling; the Raf/MEK/MAP Kinase signalling cascade, is also capable of causing
senescence (Zhu et al., 1998; Lin et al., 1998). These signalling cascades are now known
to bring about a growth arrest via p38 MAP Kinase driven histone modifications (more
detail on this is given in subsection 1.1.5.2) leading to elevation of p16INK4A (Wang
et al., 2002; Deng, 2003) .The mechanism was observed not to be overcome by TERT
in early studies (Wei S.; Sedivy, J. M., 1999) suggesting a mechanism independent of
telomere shortening but more recent work suggests that stochastic damage at telomeres
following oncogene expression can also contribute to the senescence induction in some
cases (Suram et al., 2012).
In addition to expression of oncogenes, loss of tumour suppressor genes can also
trigger of OIS and evidence of this occurring in vivo came in 2005 from murine models
of cancer which showed p53 mediated senescence in response to loss of the tumour sup-
pressor protein Pten prevented tumour formation (Chen et al., 2005). Loss of Pten (as
well as over-expression/activating mutation of cellular homologue of murine thymoma
virus Akt8 oncoprotein (AKT) or phosphoinositide 3-kinase (PI3K)) causes senescence
via activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway:
AKT inhibits forkhead transcription factor FOXO3, a transcription factor for radical
scavenger manganese superoxide dismutase (MnSOD), resulting in lower MnSOD levels
and therefore increased radicals and reactive oxygen species (ROS) which activates p53
and leads to p21WAF1induced senescence (reviewed in Xu et al., 2014).
1.1.5.2 Histone modifications can lead to premature senescence
Changes in chromatin structure, i.e. the ways in which DNA is organised around
histone protein octamers, are seen in senescence in the form of senescence associated
heterochromatic foci (SAHFS) (Narita et al., 2003a). These foci are the result of large
scale chromatin condensation (Funayama et al., 2006), facilitated by histone chaperone
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proteins such as HIRA, ASF1a and UBN1 (Zhang et al., 2005; Banumathy et al., 2008).
The two main modifications that occur in chromatin are acetylation/de-acetylation
and methylation/de-methylation of histones, which are the main proteins in chromatin.
Acetylation, by histone acetyl transferases (HATs), adds an acetyl group from a donor
such as acetyl Co A, to the N terminal of the histone protein, removing the positive
charge and allowing the chromatin to de-compact. De-acetylation by histone deacetylase
enzymes (HDACs) restores a positive charge on the histone N terminus, and thereby
attracts the negative phosphate groups of DNA, causing the DNA to wrap more tightly
around the histone proteins, and preventing transcription factors from interacting with
the DNA (reviewed in de Ruijter et al., 2003).
Methylation of histones by methyl-transferases can either activate or repress tran-
scription, depending on the level of methylation and the amino acid being methylated.
For example the tri-methylation of an amino acid might activate transcription, but
di-methylation of the same amino acid may cause silencing, again by regulating the
access transcription factors have to the DNA (reviewed in Greer and Shi, 2012). These
events are regulated by a complex web of pathways; of particular relevance here are the
polycomb group complexes, or ‘PcG’s. These multi-subunit transcriptional repressor
complexes are comprised of, among other things, a histone H3 lysine 27 methyl trans-
ferase (EZH2) and a RING finger protein (BMI1). In proliferating cells a PcG complex
binds to a non coding antisense RNA known as ANRIL (Pasmant et al., 2007; Yap
et al., 2010) and to the CDKN2a locus, which is the locus of the p16INK4A protein
and the indirect activator of p53 ARF, and BMI1 represses expression of both genes.
However, under senescence inducing conditions, such as oncogenic Ras activity, de-
methylation of lysine 27 on histone H3 by histone demethylase JMJD3 (Barradas et al.,
2009), and lower expression of EZH2 results in loss of binding and therefore loss of
repression by PcG, contributing to the increased expression of p16INK4A (Bracken et al.,
2007). Also contributing to the up-regulation of p16INK4A in senescence is another
methyl-transferase; MLL1, which methylates H3 on lysine 4, activating transcription
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(Kia et al., 2008). In addition, it is possible to induce senescence using HDAC inhibitors
(HDACIs), predominantly through a p16INK4A dependent mechanism that has not yet
been fully defined (Munro et al., 2004).
Further studies into the links between OIS and histone modifications show that
PcGs are also involved in the up-regulation of p16INK4A via p38MAP Kinase (Deng,
2003) because the p38MAP Kinase target MAPKAPK3 phosphorylates PcG proteins,
causing dissociation of PcG from chromatin and preventing the repression of CDKN2a
(Voncken et al., 2004).
1.1.5.3 Genotoxic stress induces premature senescence
In this thesis genotoxic stress is considered as a condition that results in the generation
of DNA double strand breaks, the best characterised of which are ionising radiation
and ROS.
Ionising radiation refers to high energy particles or waves that are capable of re-
moving an electron from atoms or molecules. X rays, gamma rays, beta particles (high-
speed electrons), alpha particles (the nucleus of the helium atom), neutrons, protons,
and other heavy ions such as the nuclei of elements are all forms of ionising radiation,
and when they pass through a cell the energy released is absorbed by nearby atoms,
causing either the gain of an electron, i.e. excitation, or the loss of an electron, i.e.
ionisation, from any orbital (not necessarily the outer orbital). The removal of elec-
trons from inner orbitals creates highly unstable radicals that quickly react with nearby
atoms to replace the electron, causing the breakage of chemical bonds and oxidation
of molecules. This damage can occur directly to the DNA, causing base lesions such
as oxidation of deoxyribose, the formation of adducts and cross-links as well as both
single and double strand breaks (reviewed in O’Neill and Fielden, 2013) however, be-
cause cells are approximately 70% water the majority of the DNA damage induced
by ionising radiation is thought to occur through an indirect route, whereby cellular
components, for example water and proteins, form free radicals (predominantly HO
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and RO2) which then in turn react with DNA. Defining the damage inflicted on DNA
by radicals generated from the ionisation of water as “indirect” has been called into
question by O’Neill et al (O’Neill and Fielden, 2013), who have pointed out that close
interaction with water is important for the secondary and tertiary structures of DNA,
with approximately 20 water molecules being required per nucleotide.
ROS, released as a by-product of oxidative metabolism (reviewed in Murphy, 2009),
also cause DNA damage by forming radicals predominantly from water. The most
common species are the hydroxyl radical HO and also the non radical H2O2. The
mechanisms of lesion formation are the same as those which occur when ionising radi-
ation hits the water associated with DNA; HO can force its way into a double bond
in a heterocyclic DNA base (this is known as addition) and remove a H atom from the
methyl group on thymine or any of the C-H bonds on 2-deoxyribose (this is known as
abstraction) to form C- or N- centred radicals of DNA bases as well as radicals of the
sugar backbone of DNA, which continue to react with neighbouring molecules to form
a variety of products (explained in detail in von Sonntag, 2006). The overall result is
disruption in the structure of the DNA double helix so that single and double strand
breaks can form.
Genotoxic stress is not only acquired following a large insult such as ionising radi-
ation, it can occur following a gradual built up of radicals, for example due to excessive
electron leakage from the mitochondrial electron transport chain. Elevated ROS level
is a common effect of mitochondrial damage and forms the basis of the ’free radical
theory of ageing’ (Harman, 1992). This theory states that ageing occurs because of
accumulated molecular damage, however there is compelling evidence that the inevit-
able accumulation of molecular damage over time is correlated with, but not a cause
of, physiological ageing (reviewed in Speakman and Selman, 2011). The link between
senescence, ROS and physiological ageing will be discussed further in section 1.3.4 on
page 68.
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1.1.5.4 Non-cell autonomous senescence
It is possible for senescent cells to induce senescence in neighbouring cells via soluble
factors released as part of the senescence associated secretory phenotype (SASP, de-
scribed in more detail later in section 1.2.3), as demonstrated by Juan Carlos Acosta
and colleagues, who showed that co-culture of OIS senescent cells with non- senescent
cells, distinguished using the fluorescent marker mCherry which was only expressed in
the non-senescent cells, resulted in a stable growth arrest in the mCherry positive cells
after just a few days. The authors identified members of the TGF-β family and VEGF
as key mediators in this effect (Acosta et al., 2013).
1.1.6 The DNA damage response (DDR) plays a key role in
initiating senescence induction pathways
Although senescence can be induced by a variety of events, a common factor in the
induction and maintenance of the senescence phenotype in many cases is activation of
the DDR signaling pathway. As we have seen in the previous sections of this intro-
duction, DNA integrity is compromised once a telomere becomes critically short and
the shelterin complex protecting the end of the linear DNA becomes disrupted (subsec-
tion 1.1.4 on page 37), when radical scavenger levels are transcriptionally repressed (sub-
section 1.1.5.1 on page 40) and also when excessive numbers of radicals are produced,
for example following radiation or mitochondrial dysfunction (subsection 1.1.5.3). Cells
are adept at dealing with various types of DNA damage including single and double
strand breaks; often the damage can be repaired but if it cannot the cell must undergo
either apoptosis or senescence to prevent passing mutated DNA on to daughter cells.
Below is an outline of the key processes involved in the DDR and resulting repair or
senescence/apoptosis induction.
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Figure 1.4: Main components of the DNA damage response (DDR) pathway
(adapted from Sulli et al., 2012). MRN complex binds to RPA and 9-1-1 complex and is
stabilised by ATRIP. These sensors recruit ATM and ATR, which recruit DNA damage
mediators. Phosphorylation of H2AX facilitates recruitment of MDC1, amplifying DDR
signalling with activation of ATM. 53BP1 sustains DDR signalling via ATM activation,
and TOPB1 further reinforces the DDR by activating ATR (Kumagai et al., 2006).
BRCA1 is also recruited by ATM and ATR and is involved in coordinating DNA repair
(Cortez et al., 1999; Huen et al., 2010). CHK1 and CHK2 are also recruited. Negative
regulation of CDC25 by CHK1 can lead to cell cycle arrest in G2, and the activation of
p53 by CHK2 can result in apoptosis or senescence via p21WAF1.
DNA damage ‘sensors’ such as the MRE11-RAD50-NBS1 (MRN) complex, which
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detects DNA double strand breaks, and replication protein A (RPA) and the RAD9-
RAD1-HUS1 (9-9-1) complex which detect exposed single stranded DNA, recruit the
protein kinases ataxia telangiectasia and Rad3-related (ATR) and ataxia telangiectasia
mutated (ATM) to the site of damage. The two kinases respond to specific kinds of DNA
damage; ATM is predominantly activated by double strand breaks (DSBs) whereas ATR
responds to the type of genotoxic stress that is caused by DNA replication stress, which
is also caused by oncogenes. Once at the site of damage ATM and ATR phosphorylate
proteins such as breast cancer susceptibility 1 (BRCA1) and p53 (Banin et al., 1998), as
well as provoking a second wave of phosphorylation by activating the kinase checkpoint
kinase 2 (CHK2). CHK2 is then able to phosphorylate p53 on serine 20, which lies in the
p53 binding site for E3 ubiquitin-protein ligase (MDM2) (Chehab et al., 1999). MDM2
is a protein that marks p53 for proteolysis, so blocking its binding acts to increase p53
activity. Furthermore, phosphorylation of the histone H2AX, to form GH2AX, causes
recruitment of more ATM in a positive feedback loop facilitated by p53-binding protein
1 (53BP1) and mediator of DNA-damage checkpoint 1 (reviewed in Marechal and Zou,
2013). Furthermore, phosphorylation of cell division cycle 25 (CDC25) on serine 216
by checkpoint kinase 1 (CHK1) negatively regulates CDC25, which usually facilitates
the transition from G2 into M phase resulting in a G2 arrest (Peng et al., 1997). The
DDR results in either apoptosis or stalled replication until the DNA can be repaired .
In the event that the damage is irreparable, DNA segments with chromatin alterations
reinforcing senescence (DNA-SCARS) can form and the cell will never regain the ability
to divide, therefore it becomes senescent.
To summarise, senescence is a state of permanent cell cycle arrest that can be in-
duced by proliferative exhaustion, oncogene expression, genotoxic stress or disruption
to heterochromatin structure. Most of these routes converge at the DNA damage re-
sponse and are ultimately enforced by either p53 or p16INK4A, although there is a lot of
variation in senescence induction and maintenance that we do not yet understand; for
example species and tissue specific differences, and what effect the surrounding envir-
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onment has. This variation can also be seen in the senescence phenotype, making the
identification of senescent cells with certainty quite challenging.
1.2 The cellular senescence phenotype
Observing the senescent phenotype helps us to identify senescent cells and can also give
us insights into what effect senescent cells might have in vivo. We do not yet understand
enough to have a fully defined phenotype of cellular senescence, let alone a single robust
marker with which to easily identify them in vivo, however we do have some knowledge
to work with.
1.2.1 Growth arrest
Although as yet there is not one clear marker of cellular senescence, the definition
of cellular senescence as a state of permanent growth arrest does offer some obvious
starting points when trying to identify a senescent population in vitro (of course this
excludes terminally differentiated/post mitotic cells, which will also not be prolifer-
ating). Monitoring the rate at which the population doubles when under favourable
conditions (sub-confluent distribution on a suitable surface, correct pH media, correct
temperature, enough nutrients, mitogens and growth factors, and not infected with my-
coplasma or other pathogen) is a good indicator of the replicative potential of the cells.
Generally, if the population has not completed one population doubling in one month,
it is likely that the population is senescent. Population growth can be monitored in a
number of ways, the most straight forward of which is to count the cells and compare
to the amount that were seeded originally, to calculate how many time the cells must
have divided. The replication of DNA can also be detected by addition of 5-bromo-2’-
deoxyuridine, which is de-aminated to BrdU, a synthetic analogue of thymidine which
has a Bromine (Br) in the place of a CH3 group, making it easy to detect. In theory,
incorporation of BrdU into DNA only occurs if the cells are in S phase, so if cells do
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not incorporate BrdU even after a long exposure it suggests the population is growth
arrested (Nowakowski et al., 1989), however active DNA repair would also allow for
incorporation of BrdU potentially creating false positives.
Alternatively, it is possible to assess the replicative potential of the cells by looking
for the expression of proteins necessary for cell division. One such protein is MCM7
(mini chromosome maintenance protein 7, also known as MCM2) which combines with
other MCMs to form a hetero-hexamer helicase complex, crucial for at least two known
functions: “licencing” of origins of replication to ensure that DNA is only copied once
in every cycle (Chong et al., 1995), and the formation of the DNA replication fork
(reviewed in Forsburg, 2004). Additionally, it has been reported that MCM7 interacts
with Rb and the possibility that Rb inhibits cell cycle progression by sequestering MCM
proteins has been raised (Sterner et al., 1998). Reduced levels of MCM7 therefore
indicate the cell is not capable of duplicating its DNA and cannot be dividing. Another
protein that signifies whether or not the cell is capable of dividing is Ki67. Although
the function of the Ki67 protein is unknown, it is always present in the nuclei of cells in
mitosis, G1, S or G2 phase (reviewed in Scholzen and Gerdes, 2000), so absence of Ki67
means the cell is in G0 and cannot divide at that moment. It is possible, when using
Ki67 to look for non-dividing cells, to get a false negative result if the cell is growth
arrested outside of G0. Growth arrest at the G1/S and G2/M checkpoints is known to
occur (see section 1.1.6 on page 45), and cells that become arrested at these points will
not affect Ki67 protein levels (Lundblad et al., 1991).
It is worth noting, however, that a non dividing cell, i.e. a cell that is growth
arrested, is not necessarily senescent. A transiently growth arrested (quiescent) cell in
G0 may re-enter the cell cycle if it is stimulated to do so, and a terminally differentiated
cell will also not divide but is not considered senescent, which is why it is important
to also consider other aspects of the senescent phenotype when trying to ascertain if a
cell is senescent or not.
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1.2.2 Morphological changes
It is often reported that cells induced to senescence by strand breaks or cellular stress
have an enlarged size and flattened morphology (Angello et al., 1989), and in some
cases become multi-nucleated (Kuilman et al., 2010), although these features appear
to be cell type specific. The most popular assay for senescence, the senescence asso-
ciated beta galactosidase (SAβ-gal) assay, capitalises on another morphological change
common in senescence; increased lysosome mass (Kurz et al., 2000). Although origin-
ally thought to be a form of galactosidase specific to senescence, it has been confirmed
that SAβ-gal and lysosomal β-gal are the same protein (Lee et al., 2006). The activity
of SAβ-gal is easy to detect by addition of colourless 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal), which is hydrolysed by SAβ-gal to yield galactose and 5-
bromo-4-chloro-3-hydroxyindole. The latter then spontaneously forms a dimer that is
oxidized to the insoluble blue precipitate 5,5’-dibromo-4,4’-dichloro-indigo, which can
be detected visually (Debacq-Chainiaux et al., 2009). When the assay is performed in
atmospheric ppCO2 the external environment of the cells is around pH 6.0, well above
the optimal working pH for the β-gal enzyme (pH 4.6) Under these conditions in growing
cells there is no detectable activity however because senescent cells have a large, acidic
lysosome compartment the enzyme activity in senescent cells is still enough to create
a characteristic blue crescent in the cytoplasm (Yang and Hu, 2005). An image of an
SAβ-gal positive fibroblast with a large flat morphology, which is most likely senescent,
next to some smaller SAβ-gal negative fibroblasts can be seen in figure 1.5. As increased
lysosomal size is not a feature only seen in senescence (it is also a feature of autophagy,
for example) the assay is prone to giving false positives. Despite this limitation it is
still a useful marker when performed carefully and in conjunction with other markers.
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Figure 1.5: Senescence associated beta galactosidase (SAβ-gal) staining of
IMR90 fibroblast cells. Black arrows point to SAβ-gal negative cells while the red
arrow points to an SAβ-gal positive cell. Scale bar represents 25µm.
1.2.3 The Senescence Associated Secretory Phenotype (SASP)
Another aspect of the senescence phenotype, and one which is undoubtedly important in
any functions senescent cells may have in vivo, is the secretome. It has been recognised
for some time that senescent cells have an altered secretome (Rinehart and Torti, 1997),
which has become known as the senescence associated secretory phenotype (SASP),
although it is yet to be fully characterised. So far a number of cytokines, chemokines,
growth factors, shed cell surface receptors and survival factors have been identified
through a combination of mRNA screens and ELISA assays (Kuilman et al., 2008;
Acosta et al., 2008; Downward et al., 2008). These molecules are are secreted from
senescent human cells in vitro as part of a cell strain specific secretory phenotype which
can also vary depending on senescence induction mechanism. A summary of some of
the factors identified as elevated in senescence can be seen in table 1.1.
The variability in the production of these factors is probably due to the fact that
many if not all of them are related to an event or process that is intertwined with the
processes that underpin senescence, but not directly senescence itself because although
the knock down or over-expression of the factor may inhibit or induce senescence in the
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given model, there isn’t one signature SASP that holds true for all cell types and all
induction modes. In support of this idea, Jean-Phillipe Coppe´ and colleagues demon-
strated that ectopic expression of p16INK4A and p21WAF1 caused a stable growth arrest
but not a detectable SASP, and in addition those growth arrested cells did not have any
paracrine effect on epithelial cells (Coppe´ et al., 2011). Furthermore, the only known
function of p16INK4A is to cause cell cycle arrest, whereas other aspects of the senescence
induction process, such as DDR or oncogene expression have effects in other areas of
the cell biology.
52
Table 1.1: A summary of SASP factors, shown to be elevated in the secretome of
senescent cells. Adapted from Young and Narita, 2009. This list is not exhaustive and
factors listed here may not be present in some instances of senescence depending on the
cell type and the mode of senescence induction.
1.2.3.1 Regulation of the SASP
Feedback loops and transcriptional regulation of the SASP
The SASP appears to be regulated by a combination of feedback loops and transcrip-
tional modulation. Interleukin 1 (IL1) and TGF-β, which are released by some senes-
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cent cells as part of the SASP, are capable of paracrine senescence transfer via oxidative
stress signalling as well as forming a positive feedback loop and re-enforcing senescence
in the original senescent cell (Hubackova et al., 2012; Acosta et al., 2013; Hassona et al.,
2013). Perhaps the presence of such factors in the serum of aged chickens were respons-
ible for the effects seen on young cells by Carrel in 1921 (Carrel, 1921). Furthermore
during OIS the transcription factors NFkB and CCAAT/enhancer-binding protein beta
(C/EBPβ) are known to regulate inflammatory molecules such as interleukin 6 (IL6) via
interactions with chromatin, but IL6 is also itself important for maintaining senescence
in the OIS model tested (Kuilman et al., 2008). Similarly, it has been observed that
OIS fibroblasts secreting interleukin 8 (IL8, also regulated by NFkB and C/EBPβ), a
chemokine that binds to CXCR2 (a chemokine receptor) also up-regulate the expres-
sion of CXCR2 to form a feedback loop that reinforces senescence (Acosta et al., 2008).
Further evidence of the importance of transcriptional modulation in regulation of the
SASP is the observation that histone deacetylase inhibitors (HDACIs) are capable of
modulating some components of the the SASP, such as osteopontin. Interestingly, and
in support of the idea that the SASP is related to the processes associated with senes-
cence rather than the stable growth arrest itself, this effect was shown to be independent
of senescence (Pazolli et al., 2012). The ability to modulate the SASP using HDACIs
was also found to be independent of the DDR, although most other factors have been
shown to be regulated by some aspect of the DDR (Coppe´ et al., 2010b).
Regulation of the SASP by p53 Interestingly, although p53 is important for the
induction of senescence in most cases, it was discovered by knocking down p53 prior
to induction of senescence by either DNA damage (caused by X-ray), proliferative ex-
haustion or RAS expression, that p53 actually acts to restrain the SASP both in terms
of the amount of SASP factors produced and how quickly they are produced, although
knock-down of p53 in cells that were already senescent (a state maintained by p16INK4A)
did not affect the SASP (Downward et al., 2008). This could suggest that a major com-
ponent of the SASP is driven by the senescence inducing stimulus, such as DDR or
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MAP kinase signalling which p53 works to minimise, rather than the ongoing cell cycle
arrest itself.
Regulation of the SASP by the DDR
It is acknowledged that for most SASP components, a sustained DDR response is neces-
sary, as it has been shown that ablation of DNA damage response factor ATM results
in a reduced secretion of the SASP components IL6 and IL8 in both DDR induced sen-
escence and OIS (Rodier et al., 2009). This effect may be at least partially explained by
the observation already mentioned previously; that IL6 and IL8 are regulated by NFkB
signalling, which is activated by ATM in response to the DDR (McCool and Miyamoto,
2012). Furthermore, recently a key molecule linking the DDR to the SASP has been
identified; the methyl-transferase MLL1 has epigenetic control over pro-proliferative
genes that enhance the DDR, and inhibition of MLL1 leads to a repression of the SASP
without affecting the stable growth arrest of the cell (Capell et al., 2016).
Metabolic enzymes can regulate the SASP
There is also an accumulating body of evidence that the SASP can be regulated by
metabolic enzymes. The protein kinase mechanistic target of rapamycin (mTOR) re-
sponds to a wide range of signals, including nutrient levels, by facilitating protein and
lipid synthesis (reviewed in Laplante and Sabatini, 2012) and it has been shown that
inhibition of mTOR in OIS fibroblasts also represses the SASP, by reducing the tran-
scription of SASP factors again without affecting the senescent growth arrest (Herranz
et al., 2015). Furthermore, the induction of several SASP proteins are reportedly me-
diated by the mitochondrial enzyme carnitine palmitoyl transferase 1 in OIS, but not
following PEsen (Quijano et al., 2012). The role of mitochondria in senescence and the
SASP has been the subject of several studies (reviewed in (Correia-Melo and Passos,
2015)) and recently it has been demonstrated that deleting mitochondria from senescent
cells ablates the inflammatory aspects of the SASP (Correia-Melo et al., 2016), confirm-
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ing that key elements of the SASP require mitochondria, although specific mechanisms
have not been thoroughly investigated.
Importantly, metabolic enzymes have been reported to affect not only the SASP
but also the senescence growth arrest itself. For example, forced expression of the malic
enzyme ME2 is sufficient to delay senescence in human fibroblasts (Jiang et al., 2013),
and 5’ adenosine mono-phosphate (AMP)- activated protein kinase (AMPK) can induce
premature senescence (Wang et al., 2003). AMPK is an energy sensor activated by
an elevated AMP: adenosine tri-phosphate (ATP) ratio, and usually cooperates with
SIRT1 to promote autophagy and survival, both features that are usually associated
with inhibition of senescence (Salminen and Kaarniranta, 2012), however it appears that
following chronic signalling AMPK promotes senescence via p53 activation, by phos-
phorylating p53 on serine 15 (Jones et al., 2005) and also by inhibiting the cytoplasmic
export of the RNA binding protein HuR, preventing it from regulating the expression
of proliferative genes (Wang et al., 2001, 2003).
1.2.4 Senescent cells have an altered metabolism
Given that some metabolic enzymes can regulate aspects of the SASP and even sen-
escence itself, it comes as no surprise that another feature of senescent cells is altered
metabolism. Cellular metabolic networks are highly complex, but here we will aim to
highlight some examples of alterations that are important in senescence.
1.2.4.1 Carbohydrate metabolism
Under normoxic conditions, the most efficient way to produce energy (stored in ATP)
from the carbohydrate glucose is via oxidative phosphorylation which occurs in the
mitochondria. This process requires glucose to be broken down to pyruvate in the
cytoplasm, a process known as glycolysis, and for the pyruvate to be converted to
acetyl-CoA by the pyruvate dehydrogenase complex in the mitochondria. Acetyl CoA
then enters the mitochondrial tri-carboxylic acid (TCA) cycle (also known as the citric
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acid cycle, or the Krebs cycle after Sir Hans Krebs, the biochemist who identified
the TCA cycle at University of Sheffield in 1937, for which he shared the 1953 Nobel
Prize for physiology) where it is further broken down in 9 more enzymatic steps to
oxaloacetate, producing reduced nicotinamide adenine dinucleotide (NADH) (see figure
1.6). NADH is an electron donor in the electron transport chain (ETC), where 30-
36 ATP molecules are produced per glucose molecule via oxidative phosphorylation
(OXPHOS), in the inter-membrane space of mitochondria.
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Figure 1.6: Carbohydrate metabolism pathways glycolysis, the tricarboxylic
acid (TCA) cycle and the pentose phosphate pathway (PPP). The blue boxes
represent some key enzymes in the TCA cycle CS: citrate synthase, IDH1: isocitrate de-
hydrogenase 1, MDH: malate dehydrogenase. BCAA: branched chain amino acids. FA:
fatty acid. FAD(H2/+): flavin adenine dinucleotide (reduced/oxidised). NAD(H/+):
nicotinamide adenine dinucleotide (reduced/oxidised).
OXPHOS relies on oxygen as an electron acceptor, so only occurs when oxygen is
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available and in functioning mitochondria. In the absence of one or both of these, cells
rely mainly on glycolysis, which produces two ATP per glucose molecule, but does not
require oxygen or functioning mitochondria. The use of glycolysis rather than OXPHOS
under normoxic conditions is a common feature of cancer cells and has been named the
Warburg effect, after Otto Warburg, the scientist who discovered the ‘oxidative glyco-
lytic’ phenotype, characterised by excessive lactate production (Warburg et al., 1924).
It has been hypothesised that this metabolic reprogramming confers a survival advant-
age on the cancer cells which will eventually reside in a hypoxic environment if the
tumour outgrows vascularisation. The acidic extracellular environment produced due
to the excess lactic acid secretion from glycolytic cells also favours survival of the can-
cer cells over normal cells, and may promote invasion, as well as preventing apoptosis
upon detachment (anoikis) thus facilitating metastasis (Kato et al., 2013). The War-
burg effect has also been reported in senescence (Do¨rr et al., 2013), and several other
groups have provided data that supports the theory that senescent cells are glycolytic
(Goldstein et al., 1982; James et al., 2015).
However, as would be expected from such a complex state as senescence, there is
clearly more to the altered metabolism than the Warburg effect. Jan Do¨rr and colleagues
observed that the Warburg effect they saw in their cells was regulated via the M1 isoform
of pyruvate kinase (PKM1), which promotes the breakdown of pyruvate in the TCA
cycle, so alongside the Warburg effect they also reported enhanced OXPHOS. The
authors named this phenotype ’hyper-metabolism’ (Do¨rr et al., 2013). A similar result
was reported by Werner Zwerschke and co-workers, who measured the rate of glucose
consumption and lactate production in senescent fibroblasts compared to proliferating
fibroblasts and found that while the relationship between glucose consumption and
lactate production was linear in proliferating cells, with 90% of the consumed glucose
being converted to lactate, the senescent cells were converting a lot less to lactate,
suggesting the carbon from glucose is shuttled elsewhere during senescence. This result
was unexpected as the authors had demonstrated that there was an up-regulation in
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glycolytic protein expression and also much higher catalytic activity of the M2 isoform of
pyruvate kinase (PKM2) which is usually associated with cell proliferation (Zwerschke
et al., 2003).
To further add to the complexity, a paradox exists between the observed over ex-
pression of glycolytic enzymes and the senescent growth arrest. Over-expression of the
glycolytic enzymes phosphoglycerate mutase (PGM) and glucose phosphate isomerase
(GPI) has been shown by Kondoh et al to facilitate bypass of senescence, while inhibi-
tion of those enzymes induced senescence. The authors drew the conclusion that cells
which were able to switch to glycolytic metabolism were more protected from oxidative
damage, due to a reduction in use of the oxidative mitochondrial pathways that are
known to produce large amount of ROS. In the absence of glycolysis the extra ROS
generation was enough to cause senescence (Kondoh et al., 2005).
It is possible that in certain contexts, for example depending on the levels of ROS,
that there is both repression and promotion of glycolysis in senescence. Supporting the
possibility of a heterogeneous, or perhaps temporal, metabolic phenotype in senescence
is the fact that the interactions of senescence effector proteins with glycolytic enzymes
are complex and sometimes contradictory. This is especially true for p53, which as
well as being an important mediator of senescence, also has well established roles in
energy homeostasis and response to nutrient deficiency (reviewed in Vousden and Ryan,
2009). In general p53 acts to inhibit glycolysis in favour of oxidative phosphorylation,
for example by inducing expression of TP53 induced glycolysis and apoptosis regulator
(TIGAR), a phosphatase that degrades fructose-2,6-bisphosphate, preventing activa-
tion of phosphofructokinase-1. Reduced activation of this glycolytic enzyme results in
a reduced glycolytic metabolism (Bensaad et al., 2006; Li and Jogl, 2008). Additional
anti-glycolytic activities of p53 include reduction of glucose intake via down-regulation
of glucose transporters GLUT1 and GLUT4 (Schwartzenberg-Bar-Yoseph et al., 2004)
and the suppression of pyruvate dehydrogenase kinase 2 (PDK2), therefore preventing
inhibition of the pyruvate dehydrogenase complex and facilitating the metabolism of
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pyruvate to acetyl CoA rather than lactate (Contractor and Harris, 2011). Although
this action does not directly inhibit glycolysis, it reduces the amount of NAD+ im-
mediately available for more glycolysis. PGM is also indirectly negatively regulated
by p53 via its downstream effector MDM2 (Mikawa et al., 2014). It may also be the
case that promotion of glycolysis by p53 is context specific, for example when oxidat-
ive metabolism pathways are compromised. Buzzai et al observed that treatment of
p53-/- cells with metformin, which inhibits oxidative mitochondrial metabolism via the
electron transport chain, caused cell death following nutrient deprivation but the same
treatment in p53+/+ cells provoked a switch to glycolysis and cell survival, suggesting
p53 is capable of activating glycolysis in the event of compromised mitochondrial meta-
bolism (Buzzai et al., 2007). p53 is also able to down-regulate the malic enzymes ME1
and ME2, which are TCA cycle associated enzymes important for production of the
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), lipogenesis
and glutamine metabolism. Repression of these enzymes has been shown to enhance
the senescence growth arrest mediated by p53 (Jiang et al., 2013).
There are also conflicting reports on the functionality of the TCA and OXPHOS in
senescent cells. Senescence, especially OIS, is associated with increased ROS, as evid-
enced by addition of hydrogen peroxide causing an increase in expression of senescence
effectors and inducing senescence, and the increase in ROS when senescence effector
proteins are expressed (Lee et al., 1999). ROS can cause oxidation of lipids in the mi-
tochondrial membrane, which reduces the capacity for the TCA cycle and OXPHOS to
occur. Intrinsically there is always some electron leakage from the mitochondrial com-
plex I and III during OXPHOS; these electrons are readily taken by oxygen to form a
superoxide ion (one form of ROS), even when mitochondria are healthy (Murphy, 2009).
This leads to the hypothesis that glycolytic metabolism, or at least mild uncoupling of
mitochondrial respiration, might be favoured if the cell is under stress and unable to
cope with more ROS from OXPHOS, even if the TCA cycle and OXPHOS are cap-
able of normal function. ROS is also known to inactivate glyceraldehyde-3-phosphate
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dehydrogenase (GAPDH), the 6th step of glycolysis. A reduction in the activity of
this enzyme results in a build-up of glyceraldehyde-3-phosphate, acting as a metabolic
switch to utilise the pentose phosphate pathway (PPP). This forms part of the cell’s
antioxidant response, as the first three reactions in the PPP generate NADPH; a redu-
cing agent. Inactivation GAPDH also inhibits the downstream reactions of glycolysis
(reviewed in Metallo and VanderHeiden, 2013).
To try and get a better view of the whole picture of what is happening to the meta-
bolic pathways in senescence, some groups are using metabolic screening techniques.
Toren Finkel and co-workers used a multi-platform approach to perform an unbiased
metabolic screen of OIS and PEsen fibroblasts. They were able to identify 292 com-
pounds in the cell pellets of IMR90 fibroblasts induced to senescence either by over
expression of Ras, or through proliferative exhaustion, including metabolites found in
a wide array of biochemical pathways, mainly amino acids, carbohydrates, lipids and
nucleotides. There were significant differences between the profile of the PEsen cells
and the profile of the OIS cells, which cannot be attributed to bias in measurement or
tissue specific differences (which might have explained some of the variability on the
other more targeted studies) as the same procedures were applied to all groups and the
cells were all IMR90. It was observed for example that in OIS the concentration of free
fatty acids was 5-10 fold higher than in the PEsen cells, and that there were higher
rates of fatty acid oxidation (Quijano et al., 2012). These findings further demonstrate
the difficulty in teasing out the effects specific to the senescent growth arrest from the
other effects of the cellular stress causing the senescent growth arrest. Compound-
ing this problem, Quijano and colleagues had no way of determining which metabolic
changes were associated with growth arrest that could be transient compared to the
irreversible growth arrest associated with senescence as they had no transiently growth
arrested cell control group.
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The senescence phenotype: summary
The phenotype of senescent cells is variable depending on tissue type, senescence in-
duction mechanism and external environment, so in order to identify senescent cells it
is necessary to look for more than one characteristic. The most common features used
for identification of senescent cells are a failure to replicate when stimulated, SAβ-gal
activity, a lack of proliferation markers and the presence of a known senescence inducer
(such as oncogene expression, telomere attrition, or irreparable DNA double strand
breaks (IrrDSB)) as well as cell cycle inhibitors such as p16INK4A. Despite the lack of
proliferation senescent cells remain highly metabolically active (Quijano et al., 2012)
and studying this metabolic activity gives insight into the molecular process underlying
the senescence phenotype, although it is difficult to separate the features related to
the senescent growth arrest from features resulting from the senescence inducing stress
itself.
Another major feature of senescent cells, although not well understood, is the SASP.
Furthermore, several factors included in the SASP are known to be regulated by meta-
bolic enzymes, possibly providing another link between metabolism and senescence
associated pathologies, as the collection of secreted collection of inflammatory mediat-
ors and other proteins that make up the SASP undoubtedly provide the link between
senescent cells and their role in vivo.
1.3 Senescence in vivo
Initially suspected of being an event that only occurred in cell culture due to sub-optimal
conditions, there is now mounting evidence that cellular senescence has important func-
tions in vivo. However, there may also be negative effects of senescence.
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1.3.1 Senescence during development
In 2013 it was reported that senescent cells had been found at certain stages in the
development of human embryos. Mun˜oz-Espin and colleagues showed that distinct
populations of cells within the mesonephric tubules (which act like a kidney for the
embryo while the kidneys develop, once the kidney structure is complete the mesoneph-
ric tubes disappear) and endolymphatic sac (which functions to help with hearing and
maintain balance by filtering and collecting the endolymph of the cochlear and ves-
tibular canals in the ear), are growth arrested before being cleared by the immune
system (Mun˜oz-Esp´ın et al., 2013). The cells were identified as senescent because they
were positive for SAβ-gal and negative for the proliferation marker Ki67, although the
cells were negative for γH2AX, a DDR protein, so the authors concluded that DNA
damage was not a mechanism in the senescence induction, the heterochromatin mark-
ers tri-methylated lysine 9 histone H3 (H3K9me3) and the heterochromatin protein 1
gamma (HP1γ) were detected and these are both associated with SAHFs (Aird and
Zhang, 2013). Further investigation using murine embryos found increased expression
of p21WAF1, the cell cycle inhibitor, that was regulated by TGF-β, Similar to Mothers
Against Decapentaplegic 2 (SMAD 2) and the PI3K/Forkhead Box O (FOXO) path-
way, but not p16INK4A or p53. This mechanism has not been observed in vitro however
another group also observed cells in what appeared to be a senescent state regulated by
p21WAF1 during embryonic development in chicks and mice, and suggested that senes-
cence evolved as a regulatory and instructive mechanism in development that can also
be activated under pathological conditions later in life (Storer et al., 2013).
1.3.2 Senescence in wound healing
The removal of senescent cells by macrophages observed in developing embryos (Mun˜oz-
Esp´ın et al., 2013) is also known to occur in other in vivo settings such as wound healing;
a function carried out by fibroblasts. As the main component of connective tissue, fibro-
blasts play a critical role in extracellular matrix (ECM) production and homeostasis,
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which is vital for support and repair in most tissues and organs throughout the hu-
man body (reviewed in McAnulty, 2007). The spindle shaped cells, characterised by
their expression of vimentin (the most abundant intermediate filament protein found
in fibroblasts), are of mesenchymal origin and form a variety of ‘subtypes’, from con-
tractile myofibroblasts in cardiac muscle to non-contractile dermal fibroblasts in skin.
Fibroblasts continuously synthesise ECM proteins such as procollagens, at a rate of 3.5
million procollagen molecules/cell/day (McAnulty et al., 1991) however between 10 and
90% of these are degraded before leaving the cell by cathepsins D, B and L. Regulation
of this process is important in adaptive collagen production during wound healing – and
is achieved via production of MMPs as well as MMP inhibitors (TIMPs), which regu-
late degradation of the ECM in response to cell-cell and cell-matrix interactions (Seltzer
et al., 1994). In the event of chronic wound healing, if excessive ECM is produced by
fibroblasts then fibrosis can occur, resulting in deleterious tissue scarring which can lead
to organ failure such as seen in liver fibrosis or pulmonary disease. There is evidence
to suggest that in order to prevent fibrosis in the later stages of normal wound healing,
fibroblasts are driven to a non-proliferative state by the matricellular protein CCN1 via
integrin signalling, resulting in growth arrest by p16INK4A (Jun and Lau, 2010). Sen-
escent cells ameliorate fibrosis by secreting MMPs (Pitiyage et al., 2011) which break
down the excess ECM before being cleared by the immune system (Krizhanovsky et al.,
2008) in what is termed ’immuno-surveilance’. Immuno-surveilance is carried out by
different immune cells depending on the context of the senescence (reviewed in Hoenicke
and Zender, 2012), probably because of different chemokine and cytokine messages be-
ing produced as part of the senescence induction and tissue specific SASP. Furthermore,
the observation that senescent fibroblasts and endothelial cells secrete platelet derived
growth factor -AA at wound sites, which promotes differentiation of myofibroblasts and
therefore accelerates wound closure provides another example of the in vivo biological
functions of senescent cells.
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1.3.3 Senescence and cancer
1.3.3.1 Senescence as a tumour suppressor mechanism
In vitro experiments where expression of oncogenes RAS and RAF (sometimes to supra-
physiological levels) were observed to induce senescence, as already described in section
1.1.5.1, leading to the hypothesis that senescence could be a tumour suppression mech-
anism in vivo. The first evidence in support of this hypothesis came in 2005 when
it was reported that Eµ-N-Ras transgenic mice (expressing constituently active Ras
in the haematopoietic compartment) that were also p53+/-or Suv39h (Suppressor of
variegation 3-9 homolog 1; a chromatin remodelling enzyme) negative succumbed to
invasive T-cell lymphoma while Eµ-N-Ras mice with functioning p53 or Suv39h eventu-
ally succumbed to non-lymphoid neoplasia much later. It was observed that the primary
lymphocyte proliferation, and therefore lymphoma formation, was directly stalled by
a Suv39h1-dependent senescent growth arrest (Braig et al., 2005). Further convincing
evidence came from the discovery that congenital human melanocytic nevi, which are
benign tumours that rarely progress to melanoma, contain activating murine sarcoma
viral (V-Raf) oncogene homolog B1 (BRAF) or neuroblastoma V-Ras oncogene homo-
log (NRAS) mutations and concomitantly displayed elevated levels of the senescence
effector protein p16INK4A (Michaloglou et al., 2005). Many subsequent examples of
senescence playing a role in preventing tumour formation in the presence of oncogene
expression or loss of a tumour suppressor protein have been documented (see reviews
Salama et al., 2014; Bennett, 2016), however it has been suggested that OIS is de-
pendent not only the oncogene expression but also the level of other molecules such
as p16INK4A, as freshly isolated neonatal fibroblasts do not senesce in response to RAS
(Benanti and Galloway, 2004).
As with wound healing, clearance of senescent cells appears to be an important
part of the response to the damage/pathological condition that induced the cells to
become senescent in the first place. Failure of the immuno-surveilance process can lead
to deleterious effects of senescence, and reasons for this failure are not fully understood;
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although a declining immune system with age would seem to be a reasonable explanation
in older individuals (Wang et al., 2011a).
1.3.3.2 Senescent cells as a driver of neoplastic transformation
A permanent growth arrest in response to oncogene expression or loss of a tumour
suppressor protein can prevent uncontrolled neoplastic growth in the offending cell but
there is evidence that subsequent changes in the senescent cell secretome may pro-
mote neoplastic transformation and cancer growth in neighbouring cells. Krtolica and
colleagues reported that senescent fibroblasts promoted growth of neoplastic epithelial
cells in culture, and moreover showed that when immortal human keratinocyte cell line
HaCaT cells were injected into severe combined immunodeficiency (SCID) mice with
senescent fibroblasts formed tumours more frequently and that were larger than when
HaCaT cells were injected with pre-senescent fibroblasts (and HaCaT cells injected
without any fibroblasts formed no tumours) (Krtolica et al., 2001). Subsequent stud-
ies have had similar results (Liu and Hornsby, 2007; Coppe´ et al., 2010b) and it has
also been suggested that energy metabolites that have been observed to be secreted by
senescent cells, such as lactate and 3-hydroxybutyrate (3OHB), can participate in the
SASP by providing energy to developing cancer cells (Bonuccelli et al., 2010; Capparelli
et al., 2012) and there is evidence that direct addition of these molecules can increase
mitochondrial activity in some cancer cell lines (Martinez-Outschoorn et al., 2010).
It seems paradoxical that having undergone what appears to clearly be a tumour
suppressor mechanism the cells would then promote tumourigenesis in other cells. Some
have proposed it to be an example of antagonistic pleiotropy; a biological process that
can be both beneficial and harmful to the organism depending on that organism’s age
(Williams, 1957), because once an organism has reproduced any process that affects
them negatively later in life does not get de-selected for by natural selection. In the
case of senescence and cancer, it is possible that in young organisms that harbour few
senescent and pre-malignant cells, the factors secreted by the senescent cells are not
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present in high enough concentration to have an effect the neighbouring cells, or cells in
young organisms respond differently to the signals, possibly because they harbour less
damage than cells in older organisms. Indeed, age is the biggest risk factor for cancer
(Fransen et al., 2013).
1.3.4 Senescence and ageing
Biological or organismal ageing is often defined by the functional capacity of organs
(Chang and Harley, 1995; Melk et al., 2000), which declines with both chronological
age and life-shortening conditions such as progeria (Burtner and Kennedy, 2010). This
decline in organ function is also sometimes referred to as ’functional senescence’ (Gro-
tewiel et al., 2005) and occurs at different rates in each individual, such that a person’s
chronological age might not exactly correspond with their biological age (Baker and
Sprott, 1988; Belsky et al., 2015). Functional senescence may well be driven by cellular
senescence, as it is accepted that the number of senescent cells increases with age in a
variety of mammalian tissues (Dimri et al., 1995; Paradis et al., 2001; Jeyapalan et al.,
2007). It is not known whether this rise is caused by increased generation, decreased
elimination, or both. Whatever the reason for their accumulation, the age-related in-
crease in senescent cells occurs in mitotically competent tissues, which are those that
give rise to cancer and ageing related disorders (Herbig et al., 2006; Jeyapalan et al.,
2007) and proof that the presence of senescent cells is not just correlated to these patho-
logies but is causal is mounting. For example Baker and colleagues used a pro-geroid
mouse model to show that elimination of the accumulated senescent cells prevents the
onset of signs of organismal ageing: cataracts, sarcopenia and loss of subcutaneous fat,
which are three major ageing phenotypes (Baker et al., 2011), and more recently using
the same model Baker and colleagues showed that naturally occurring p16INK4A cells
are involved in age related degeneration of multiple organs including heart and kidney
(Baker et al., 2016). Furthermore clearance of senescent cells using a senolytic drug can
also rejuvenate haematopoietic stem cells (Chang et al., 2015).
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The molecular mechanisms behind the effect of cellular senescence on functional
senescence and biological ageing are not yet well understood, although there are some
examples of experimental evidence which shed a little light on the subject, such as
work linking the aged appearance of wrinkled older skin to the matrix degrading factors
secreted by senescent dermal fibroblasts (Hornebeck, 2003). Also, it has recently been
confirmed using conplastic mice that mitochondrial DNA (mtDNA) affects health span
and longevity by influencing mitochondrial proteostasis, ROS generation, insulin sig-
nalling, obesity, telomere shortening and mitochondrial dysfunction (Latorre-Pellicer
et al., 2016). As already discussed in section 1.2.4 on page 56, mitochondria play an
important role in senescence and the SASP and so may prove to be a link between
cellular senescence and organismal ageing.
There is also an interest in astrocyte senescence in the context of age related neuro-
degenerative diseases like Parkinson’s and Alzheimer’s. It has been recorded that astro-
cytes cultured from the brains of aged rats stain positively for SAβ-gal and are less able
to maintain the survival of co-cultured neurons, suggesting an age related decline in
neuroprotective activity may be linked to senescence (Pertusa et al., 2007). This is sup-
ported by subsequent studies of autopsied human brain tissue; both p16INK4A and the
SASP factor MMP3 increase significantly with age and are even higher in affected cor-
tical brain tissues from patients who had suffered with Alzheimer’s disease, relative to
age-matched controls (Bhat et al., 2012). In autopsied brains of sufferers of Parkinson’s
disease an increase in the number of astrocytes with elevated p16INK4A expression and
γH2AX in the substantia nigra pars compacta (the region of the brain that specifically
degenerates in Parkinson’s disease), compared to age-matched controls has also been
observed (Chinta et al., 2015). Astrocytes play an extremely important role in synaptic
transmission and information processing by neural circuits as well as regulating blood
flow and metabolism in neurons and synapses (reviewed in Benarroch, 2005), so changes
to their metabolism and secretome, such as is associated with senescent cells would be
expected to cause disruption to surrounding cells.
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Although experimental evidence for the involvement of senescent cells in organismal
ageing in vivo is accumulating, there are many challenges to getting conclusive answers
to questions on why senescent cells are accumulating and how they are interacting with
surrounding cells.
1.3.5 The challenges of studying senescence in vivo
Although there are many in vivo models of functional senescence, including the nemat-
ode worm Caenorhabditis elegans, budding yeast (Saccharomyces cerevisiae), the fruit
fly Drosophila melanogaster (reviewed in Gems and Partridge, 2013), and mouse mod-
els such as the Senescence Accelerated Mouse (SAM), of which there are 12 strains
exhibiting accelerated onset of different aspects of ageing such as loss of bone density,
decline in cognitive function and hair loss (Takeda et al., 1997); the challenges faced
when studying cellular senescence in vivo are considerable. Firstly the lack of a single
defined phenotype and incomplete understanding of the regulation of the multiple sen-
escence phenotypes make it difficult to identify senescent cells with certainty. Because
multiple markers are required, including staining for SAβ-gal activity it is not possible to
monitor an individual organism’s levels of senescent cells repeatedly over multiple time
points. The pro-geroid model used by Baker et al, mentioned previously, which uses a
transgene called INK-ATTAC for inducible elimination of cells expressing p16INK4Acells
(Baker et al., 2011) goes some way to address this problem, in the case of p16INK4A
dependent senescence at least, because measurements can be taken in the same animal
before and after removal of p16INK4A positive senescent cells.
While these model systems are incredibly useful for deducing genetic and molecular
pathways involved in ageing and senescence, there are obvious differences between the
model organisms and humans which could limit our understanding of human ageing
and senescence. For example mice have a much shorter lifespan, much longer telomeres,
and metabolic profiling has shown them to have a very different metabolic phenotype
to humans (Toma´s-Loba et al., 2013). With this in mind, it would be helpful to have a
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biomarker of cellular senescence that could be measured non-invasively, so that multiple
measurements could be made in humans over a time period to assess links between
cellular senescence and phenomena such as functional senescence.
1.4 Biomarkers
Technically, a biomarker is defined as ‘a characteristic that is objectively measured
and evaluated as an indicator of normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic intervention’ (Group, 2001). In order to
measure dynamic effects of treatments or time, it is important to measure a feature
that is able to respond to these changes as quickly as possible, and increasingly more
studies are making use of the metabolome in order to do this (James and Parkinson,
2015). The metabolome is the collection of small molecules that are interacting as
reactants, intermediates and waste products of the countless biochemical reactions that
are constantly occurring to keep cellular processes going, such as the break down and
synthesis of carbohydrates, lipids and nucleotides. As we have already seen, all of these
processes are known to be altered in senescence. The study of the metabolome is known
as metabolomics.
1.4.1 Capturing the metabolome
Metabolomics as we know it today relies on the use of nuclear magnetic resonance
(NMR) spectrometry and mass spectrometry (MS).
NMR spectrometry takes advantage of the fact that the nucleus of all atoms is
charged and has a “spin” (I), a specific form of angular momentum. The value of I
depends on the atom and some atoms, such as 1H and 13C, have an I value of 1/2. When
a nucleus with I=1/2 is put into a magnetic field, it will align itself with the magnetic
field in a low energy state but can be forced to align itself against the magnetc field if
it absorbs enough energy. By pulsing radio waves through the sample in a magnetic
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field, the low energy nuclei flip to align against the field, and their relaxation back to
the low energy state can be measured as emitted radio waves. Because in a molecule
the atoms are also subject to the small magnetic effects of neighbouring electrons and
atoms as well as the magnetic field in the spectrometer, the nuclei will absorb energy
at slightly different frequencies than they would if it were just a single atom; this is
known as the chemical shift and is reflected in the radio waves detected during the
relaxation and can be plotted as intensity versus frequency. The resulting spectra vary
depending on what the nuclei with I=1/2 are surrounded by; if a nucleus is shielded
by many electrons then it will require a higher energy frequency to elevate it to a
high energy state, and if it is attached to a highly electronegative element it will be
less shielded and require less energy. By studying the chemical shifts it is possible
to determine the structure of a molecule and therefore identify it. For example when
using 1H NMR, each hydrogen nucleus will produce a peak in the spectrum at a slightly
different and frequency depending on what the hydrogen is bound to in the molecule,
and the pattern of peaks produced will be unique for each molecule. The intensity of
the signal is proportional to the number of hydrogen present, allowing quantification
when a standard of known concentration is included in the sample.
There are several benefits to using NMR; unlike MS it is a non destructive technique
so precious samples can be recovered for other analysis, and very little sample prepar-
ation is required. However it is not as sensitive as MS, and a larger sample volume is
required.
The first use of MS (which at the time was called a parabola spectrograph) was by
J.J. Thomson and his research assistant F.W. Aston at the University of Cambridge
in 1912. Thomson and Aston measured the deflection of neon ions travelling through
a magnetic and electrical field by capturing the deflected ions on photographic plates,
and observed two areas of the photographic plate had been hit by the neon ions. They
deduced that this was due to a difference in the mass-charge ratio of the ions and
reasoned that there must be two stable isotopes of neon (Thomson, 1913). Aston
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modified the parabola spectrograph to enable electromagnetic focusing (and discovered
many more isotopes), and A.J. Dempster further improved the design to what is more
recognisable as a mass spectrometer in 1918 (Dempster, 1918). The basic principles
of mass spectrometry are that once introduced the sample is ionised (electrons must
be removed from atoms in the sample to make positive ions. There are several ways
of ionising the sample, the most widely used of which are summarised in table 1.2 on
the next page) and passes into the vacuum of the mass analyser. The sample ions are
accelerated, so that they all have the same kinetic energy, and as they pass through
the magnetic field the positive ions get deflected. The lighter the ion, the greater the
deflection and also the more charged (positive) the ion, the greater the deflection. The
scattered ion beam hits an electronic detector and is transformed into a digital signal
for recording and analysis.
Figure 1.7: The components of a basic mass spectrometer.
In figure 1.7 the sample is ionised by Electron Ionistion or Electron Impact Ionisation
(EI); whereby electrons, which are released from the metal coil in the electric heater,
and are attracted to a positively charged electron trap, travelling through the gaseous
sample on their way and knocking electrons from the atoms in the sample. This creates
a reproducible collection of molecular ions and ionised molecular fragments for each
molecule which can be used to help deduce structure and also can be compared to
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libraries for identification, for analytes with a mass range under 1kDa. This method,
and all the variants on it, requires that either the sample is already a gas, or that it is
volatile and forms a gas when injected into the hot ionisation chamber.
In terms of metabolomics, MS became useful once it was coupled to chromato-
graphic techniques, such as gas chromatography (GC) which were already being used
to compare patterns of molecules in biological fluids of individuals (Pauling et al., 1971).
Chromatography techniques such as GC and liquid chromatography (LC) alone could
not produce the resolution or specificity necessary for accurate identification of the
metabolites, and MS alone was not useful for biological mixtures of lots of unknown
molecules. Today, different separation and ionisation techniques are used depending on
the nature of the analyte in order to capture as much information as possible. Some of
the most widely used configurations are described in table 1.2.
Table 1.2: Common separation, ionisation and de-
tection methods used in mass spectrometry
Gas chromatography
(GC)
Separation of
analytes
The sample is vaporised and forced along a
column in a carrier gas such as helium or ni-
trogen (the mobile phase). The column is
lined with a polymer (the stationary phase)
and as the analyte compounds interact with
the stationary phase they will ’stick’ in the
column for differing lengths of time, known as
the retention time. This method is suitable
for analysing both organic and inorganic mo-
lecules, although they must either be volatile
or able to be volatilised by derivitisation.
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Name Function Description
Liquid
chromatography (LC)
Separation of
analytes
The sample is dissolved in a liquid mobile
phase and drawn through a column contain-
ing particles of solid phase using gravity. As
with GC, components of the analyte mixture
will interact with the stationary phase for dif-
fering lengths of time depending on factors
such as polarity, resulting in different reten-
tion times. This method is suitable for ana-
lysing organic molecules and polymers.
High performance
liquid chromtography
(HPLC) or ultra-high
performance liquid
chromatography
(UHPLC)
Separation of
analytes
Similar to LC but with a high operating pres-
sure acting on the mobile phase, giving better
resolution during separation.
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Name Function Description
Electron spray
ionisation (ESI)
Ionisation The sample is dissoved in a volatile, polar
solvent and pumped through a stainless steel
capillary into the ionisation chamber of a
mass spectrometer. At the end of the capil-
lary a high voltage is applied, releasing the
sample as charged droplets which are carried
forward in a neubulising gas and the solvent
evaporates as a heated drying gas (usually ni-
trogen) is passed over it leaving just analyte
ions to enter the accelerator. Because the
evaporation of the polar solvent occurs in a
vacuum, each ion can gain multiple charges
which decreases the mass/charge (z) ratio
and makes it possible to get spectra for large
molecules. This form of ionisation is use-
ful for polar samples in the range <100Da -
100,000,000Da, so is often used when working
with un-denatured proteins. Both positive
and negative ions can be generated, with pos-
itive mode being used preferentially for pro-
teins and peptides and negative mode used
for saccharides and oligonucleotides.
Nanospray ionisation
(NI)
Ionisation Similar to ESI but uses a lower flow rate and
less sample is needed.
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Name Function Description
Electron impact
ionisation (EI)
Ionisation A gas phase sample is bombarded with elec-
trons which knock electrons from analyte
atoms creating ions. This is the most com-
mon method of ionisation in MS but is only
useful for analytes under 1kDa.
Chemical ionisation
(CI)
Ionisation This method first requires the EI of a reagent
gas such as methane or isobutane under high
pressure so that reagent ions are forced to re-
act with neutral reagent molecules and once
the sample is introduced the reagent ions re-
act with the sample, producing sample ions.
CI causes less fragmentation than EI so more
information can be gathered about the mass
of the molecule, again only for analytes with
a mass range under 1kDa.
Desorption chemical
ionisation (DCI)
Ionisation A variation on standard CI in which the
sample is loaded onto a filament which is
then heated very rapidly in the CI plasma,
the rapid ion formation reduces fragmenta-
tion still further, although requires very fast
scan speeds on the recorder.
Matrix assisted laser
desorption ionisation
(MALDI)
Ionisation The sample is mixed with a matrix before be-
ing exposed to a laser at 337nm. The mat-
rix absorbs the ultraviolet wavelengths and
some of it rapidly vapourises along with the
sample.
77
Name Function Description
Time of flight mass
spectrometry (TOF
MS)
Mass
spectrometry
Rather than measuring the electromagnetic
deflection of analyte ions, in TOF MS ex-
ploits the fact that the velocity of the
particles is dependent on the mass/charge ra-
tio (once they all have been given the same
kinetic energy in the acceleration stage) and
the accelerated ions are timed as they travel
to the detector. This has the advantage that
many more ions will be detected than in
other MS set ups where ions can be lost to
the walls of the instrument following deflec-
tion (although this “filtering” can be useful
too).
Tandem mass
spectrometry
(MS/MS)
Mass
spectrometry
Once ions of interest have been identified
in a first round of MS and have been frag-
mented by dissociation (i.e. they have col-
lided with an inert gas) they are filtered
through to a second mass spectrometer for
those fragments to be further separated by
their mass/charge ratio.
1.4.2 The use of metabolomics in biomarker discovery
Humans have been using the detection of small molecules to diagnose disease since
ancient times; as early as 1500-2000BC Chinese doctors used ants as a means of assaying
urine, with sweet urine (a result of the presence of glucose in the urine) attracting ants
used as a marker of diabetes. The more recent advances in NMR, GCMS and LCMS
have enabled the discovery of new biomarkers, for example elevated plasma levels of
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trimethylamine-N-oxide has been identified as a predictor of cardiovascular disease,
using LCMS (Wang et al., 2011b) and elevated levels of sarcosine in urine has been
described as a marker of prostate cancer (Sreekumar et al., 2009), although this finding
has not yet translated to the clinic. Advances in tandem mass spectroscopy have also
been essential in newborn screening, which requires just a dried drop of blood to identify
amino and fatty acids indicative of inherited metabolic disorders before symptoms begin
to show in the child, enabling faster treatment and a better patient outcome (Chace
et al., 2002).
More recently these technologies have also been applied to finding metabolites as-
sociated with ageing, which may give insights into the processes involved in age related
diseases. For example Cristina Menni and colleagues used metabolomic screening in
6055 humans, including twins, to identify a panel of 22 metabolites that correlate with
age and of which some specifically correlate with age related decline in health such as
bone density changes and lung function, and were associated also with birth weight.
The authors were also able to combine the metabolomics data with epigenetic studies
to link the metabolic profiles to methylation profiles, which is useful for studying mo-
lecular mechanisms that might be determined at a young age and what effect they have
on long term health and ageing (Menni et al., 2013).
1.4.2.1 Data handling
The large amount of data generated from metabolomics screens can also be used as
a source of information by other researchers looking for something different in the
metabolome, so researchers are encouraged to deposit data sets into databases such
as Metabolights (Haug et al., 2013) where they can be freely accessed. Moreover,
improved organisation and annotation is continuing to increase the usefulness of the
data, an example of this this the Husermet project which has documented the serum
metabolome profile of 1200 healthy UK individuals and annotated it according to meta
data such as sex, age, weight and whether the individual smokes. This resource gives a
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valuable example of baseline variation as a result of these common factors which may
impact other studies (Dunn et al., 2014).
1.5 Aims of this thesis
The primary aim of this work is to identify a novel biomarker for senescent fibroblasts
which is robust in regard to cell type and senescence induction mode, and which can
be measured non invasively.
In order to achieve this aim it is necessary to not only establish models of fibroblast
senescence but also models of transient growth arrest so that molecules associated with
growth arrest that will most likely be present in senescent cells but are not related
to the permanent cell cycle arrest characteristic of senescent cells, can be ruled out.
Furthermore, it will be necessary to model as far as possible the cellular stress that
can lead to senescence induction, but without inducing senescence, so that molecules
associated with the stress, which also will probably be present in senescent cells but
not involved specifically in permanent cell cycle arrest, can also be discounted (the
identification of induction type specific molecules will also help with this aim).
To capture candidates that are likely to be detectable in body fluids and therefore
amenable to a non invasive test, the search for a marker will be focused on the molecules
secreted into the tissue culture media, and to ensure as many candidates are identified
as possible a non targeted metabolomics approach will be used.
The secondary aim of the thesis is to use smaller scale targeted experiments to
validate candidates identified in the metabolomics screen, and identify transcriptional
and protein level changes that could explain the elevation of the marker.
If successful in these aims the data generated will provide a detailed and thorough
snapshot of the secreted metabolic phenotype of senescent fibroblasts that once up-
loaded to the database Metabolights will be available to other researchers to compare
with their data and mine for their own interests. We will have identified a robust,
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senescence specific secreted biomarker that is present in multiple senescence induction
models and in multiple tissue types but is not present in transient growth arrest, which
if validated in vivo could be extremely useful for the study of the role of senescence in
human ageing and disease and also provide a non invasive marker to assess the success
of treatments that aim to eliminate senescent cells.
Insights into why this marker is specifically elevated can potentially inform us of
what metabolic pathways are essential for senescence and this will improve our under-
standing of the complex senescence phenotype as well as providing potential targets for
the elimination of senescent cells or the activation of senescence in proliferating cells.
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Chapter 2
Validating the senescence models
2.1 Introduction
In order to identify biomarkers specific to senescence, therefore distinct from both
proliferating and transiently growth arrested cells but generic across replicative and
stress induced senescence, it was necessary to have in vitro models of all of these states
to make a comparison of their secreted metabolome. In this chapter I will describe the
senescence models used and the techniques used to validate their growth arrest status.
2.1.1 Models used in this study
Two models of senescence were used in this study; replicative senescence (PEsen) in-
duced by long term culturing under standard conditions, and irreparable DNA double
strand break stress induced senescence (IrrDSBsen), induced using 20Gy gamma irradi-
ation (Pitiyage et al., 2012). Both models were induced in fibroblasts from two different
tissues (IMR90 from lung and NHOF1 from the bottom lip of an adult) wherever pos-
sible, and in the original, untargeted screens more cells types were used, to increase the
likelihood of finding a genuinely generic senescence marker.
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2.1.2 Growth arrest controls
Although the senescence induction mechanisms used to generate the senescence models
are already established and we were confident the cells generated would be senescent, it
could not be assumed that everything detected in the metabolome of those cells would
be unique to senescent fibroblasts. It was predicted that there would be some shared
features between transiently growth arrested and senescent metabolomes, as well as
shared features between the metabolomes of cells with repairable and irreparable DNA
double strand breaks, because many of the same cellular processes would be occurring in
those situations. Therefore to be able to tease out events unique to senescence, controls
were produced to account for repairable DNA double strand breaks and transient growth
arrest.
2.1.2.1 Repairable DNA strand breaks
Previous work by Francis Rodier and colleagues had already established that a relatively
low dose of 0.5Gy gamma radiation does cause DNA damage, but to an extent which
can be resolved by the DDR (Rodier et al., 2009). As the IrrDSBsen model used in
this study is also induced by gamma radiation, 0.5Gy was a good control for both
the reversible DNA damage but also the experimental procedure of treating cells in
suspension with ionising radiation.
2.1.2.2 Transient growth arrest
Finding a suitable growth arrest control for replicative senescence was slightly more
difficult because there was no particular treatment that could be controlled for; the
cells were simply cultured under standard conditions for a long time. One method of
inducing a transient growth arrest, which has already been used in studies to elicit
transient growth arrest (Rosner et al., 2013), is to serum starve cells. By only adding
very small volumes of foetal calf serum to the culture media (0.1% vol/vol) the cells
are denied growth factors and mitogens so are not stimulated to divide, resulting in
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a growth arrest. The limitation of this technique is that the cellular metabolism is
affected by changes in concentrations of serum. Despite this limitation the model was
still considered useful as there were already studies published using that method. The
ideal control however, would share the same nutritional and stimulatory environment, so
that it would be reasonable to suppose that any differences in the metabolic phenotype
were likely due to a specific feature of senescence which is not present in transiently
growth arrested cells under the same conditions.
2.1.2.3 Confluence
When normal fibroblasts come into contact with other cells they undergo contact inhib-
ition of proliferation (Wieser et al., 1990), initiating a growth arrest that is reversible if
the interaction between cell surfaces is broken. This method of growth arrest allows the
use of the same growth media across the growing, growth arrested and PEsen groups
which is an advantage.
2.1.3 Identifying senescent cells
As explained in the previous chapter, the senescence phenotype is variable, so to ensure
the most robust results several markers were chosen to monitor the proliferation status
of the cells used in the experiments. Table 2.1 on the next page summarises some key
markers that can be used to assess the proliferation/growth arrest status of cells, and
more detail about the markers selected for use in this study is given in the following
subsections.
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Table 2.1: Markers of senescence. Although none of these markers alone is definitive
of senescence, using combinations of markers can be informative about the extent and
mechanism of growth arrest. 1 (Debacq-Chainiaux et al., 2009)2(Nakatsuru et al.,
1995)3(Rodier et al., 2011)4(Narita et al., 2003b)
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2.1.4 Markers used in this thesis
Because it is not practical to measure all of the possible markers of senescence, a
selection were chosen that cover the key phenotypic areas: growth arrest, morphological
changes, loss of replicative potential, signs of senescence inducing mechanism and cell
cycle inhibitors.
2.1.4.1 Growth arrest
Growth arrest was monitored by recording the doubling of cell populations, with the
prior knowledge that generally populations that have gone through over 45 doublings
are replicatively old and likely to contain an increasing population of senescent cells. If
the population was growing at a rate that would not enable one population doubling
within a month then the cells were considered growth arrested.
2.1.4.2 Morphological changes
An increase in cell size was observed but not measured in this study, although the
presence of enlarged lysosomes was ascertained using the SAβ-gal assay.
2.1.4.3 Loss of replicative potential
The presence of Ki67, which is associated with proliferation, and MCM7, which is
required for DNA replication, were monitored to establish whether growth arrested
cells had lost the potential to replicate.
2.1.4.4 Markers of the senescence induction mechanism
Both the PEsen and IrrDSBsen models used in this thesis were expected to senesce
via a DDR so markers of the SAHF and DNA-SCARS would be useful. In the present
study, an established model of DNA double strand break induction was used which had
already been validated using 53BP1 and GH2AX (Rodier et al., 2009), so 53BP1 foci
alone was deemed sufficient to monitor DNA double strand break induction.
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2.1.4.5 Cell cycle inhibitors
The cell cycle inhibitor p16INK4A was chosen because it often gradually accumulates
in senescence and should not be present in transiently growth arrested cells, unlike
p21WAF1 which can become elevated even in transient growth arrest by p53 as part of
the DDR (Robles and Adami, 1998).
2.1.5 Summary
Before the search for a senescence specific biomarker could begin, it was important to
characterise the senescent and control model’s phenotypes, so that the information could
be used to better understand the relevance of the metabolic phenotypes to senescent
growth arrest. This was done using several markers of senescence namely monitoring of
the population doubling rate, SAβ-gal staining, Ki67, MCM7, 53BP1 foci and p16INK4A
which, although individually not perfect, when considered together should give an ac-
curate picture of the level of senescence within a population and the extent of DNA
damage clearance.
To be able to tease out biomarkers specific to senescence later in the study, it was
important to find relevant controls that would account for the test conditions and also
transient growth arrest. The former was easily addressed by inclusion of relatively young
(in terms of population doublings) proliferating cells under the same culture conditions.
To control for the conditions of ionising radiation and DNA damage a low dose (0.5Gy)
of gamma radiation was applied to cells to induce recoverable DNA damage, and to
control for transient growth arrest both serum starved and confluent populations were
generated. Although both of these growth arrest control have confounds, taken together
they should provide a reasonable picture of transient growth arrest for the purposes of
excluding findings which are a feature of growth arrest but not specifically senescence,
later in the thesis.
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2.2 Materials and methods
2.2.1 Cell culture
In order to find a generic biomarker applicable to many tissue types, a range of
human cells were utilised. Normal human oral fibroblasts from an adult’s cheek (age
and sex unknown) (NHOF1) and lower lip (21 year old female) (NHOF5) were isolated
and cultured from healthy volunteers by Dr. Gayani Pityiage (Pitiyage et al., 2011),
normal new born human foreskin fibroblasts (HFF) were isolated and cultured by Dr.
June Munro (Munro et al., 2001). Normal human lung fibroblasts (16 weeks gestation
female) (IMR90) were purchased from the American Type Culture Collection (ATCC)
(ATCC-CCL-186), as were normal new born human skin fibroblasts (BJ) (ATCC CRL-
2522). Colon fibroblasts (Colon) were a generous gift from Professor Chris Paraskeva,
University of Bristol.
All of these cells were cultured under the same conditions: using DMEM (4.5g/L
glucose) supplied by Lonza (BE12-604F/12) supplemented with penicillin and strep-
tomycin antibiotics (Life Technologies 15070-063) to a final concentration of 50U/mL,
and L-glutamine (Life Technologies 25030-081) to a final concentration of 2mM, con-
taining 10% vol/vol HyClone Foetal Clone II foetal bovine serum (Thermo Scientific
SH30066.02), at 37°C in humid Eppendorf Galaxy S incubator with 10% CO2/90% air.
Flasks were kept at roughly 80% confluence, and medium was replenished every 3-4
days. Once cells became more than 80% confluent, or were needed for an experiment,
they were washed once with warm (37°C) PBS containing 0.02% weight/vol EDTA be-
fore being incubated for 5 minutes with PBS containing 0.1% weight/vol trypsin and
0.01% weight/vol EDTA (1mL/10cm2 dish). Following cell detachment the trypsin
was neutralised by the addition of serum containing media (3mL media for every 1mL
trypsin solution), and cells were counted manually using a haemocytometer to enable
calculation of the cumulative mean population doublings (cmpds). Cmpds were used
throughout the study as a measure of chronological age, and were calculated using the
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formula:
mpd = 3.32((log10cell number yield)-(log10cell number input)) (Munro et al., 2001)
2.2.2 DNA double strand break induction
To create irreparable DNA double strand breaks, in order to generate stress-induced
senescent cells, the cells were exposed to gamma radiation by Anthony Price and his
colleagues at the Wingate Institute, Whitechapel, London. Exposure to 0.5 and 20 Gray
(Gy) was performed at a dose rate of 1.4Gy per minute, with the cells in suspension in
4°C DMEM. Cells were re-plated and returned to the incubator as quickly as possible
following the treatment, and cultured for a total of 20 days under standard conditions.
2.2.3 “Collection”
Because the sample type collected in the final experiments was cell culture media,
conditioned over 24 hours (referred to in this thesis as the “collection period”), all cell
pellets were also collected and cells for immunohistochemistry fixed following the same
protocol as would be applied to collect the conditioned media.
2.2.3.1 Growth arrest control: Confluence
The protocol for collection of the media from the confluent cells, which were used as a
control for growth arrest, required slightly more time between plating of the cells and
the start of the collection period, to enable the cells to become properly confluent and
growth arrested. This protocol was optimised to get as many cells growth arrested (Ki67
negative) as possible whilst also not allowing irreparable DNA double strand breaks
to develop (the cells must also be negative for large 53BP1 foci), and the optimum
conditions were found to be plating the cells 4 days before collection was due, and
replenishing the media every day within that time. Media volume added to the flasks
during the collection period was increased to produce a cell number:volume ratio as
similar as possible to that found in the other flasks with cells growing at the usual
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density.
2.2.3.2 Growth arrest control: Serum starvation
Transient growth arrest induced by serum starvation in low serum media also required
optimisation to get as many growth arrested cells as possible without inducing irrepar-
able DNA double strand breaks. Cells were plated four days before collection was due,
24 hours after plating the cells were washed with 1xPBS and media was replaced with
DMEM containing additional glutamine and antibiotics as in the standard media but
containing only 0.1% vol/vol foetal calf serum.
2.2.4 Collection of cell pellets for western blot analysis
For PEsen experiments the PEsen and growing cells and in IrrDSBsen experiments all
cells were seeded at a density of 5x105cells per T75 flask approximately 24 hours before
the collection period was due to start. For PEsen experiment growth arrest controls
low serum or confluence experiments, cells were seeded 4 days before the collection
period was due to begin. At the start of the collection period media was replaced with
3mL freshly made media. Flasks were allowed to equilibrate to 10% CO2 before being
sealed with Parafilm to prevent evaporation. 24 hours later, after the removal of the
medium, the cells were washed with warm 1x PBS and incubated at room temperature
with 1mL trypsin/EDTA solution (as previously described) while the media was being
processed. Incubating the cells in the trypsin at room temperature rather than at 37°C
slowed the action of the trypsin slightly and allowed more time to process the media
before the cells detached fully. Following detachment the trypsin was neutralised by
addition of 3mL serum containing media and the cells were counted. The cell suspension
was then centrifuged at 800 rpm for 5 minutes to produce a cell pellet, which was re-
suspended in 1mL 1xPBS and transferred to an Eppendorf tube. A pellet was obtained
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by centrifuging the cell suspension at 13,000 rpm in a microfuge for 5 minutes and the
PBS was aspirated, then the pellet was snap frozen on ethanol/dry ice (EtOH/dry ice)
and stored at -80°C.
2.2.5 Immunocytochemistry
2.2.5.1 Preparation of cells for staining
Young growing cells were plated into 8 well chamber slides (LabTek II, Nunc, catalogue
number 154534) at a density of 2.8x103 cells/well (except for when confluence was
desired, then cells were plated at 1.66x104 cells/well), at the same time as the flasks
were seeded ready for the collection of media and pellets, and all media changes were
carried out in parallel. At the same time as media and pellets were collected from the
flasks, the media was removed from the chamber slides and the cells were washed once
with warm PBS, then fixed with 4% weight/vol formaldehyde at room temperature for
45 minutes. Following fixation the cells were washed twice with PBS and stored at 4°C
in PBS until staining.
2.2.5.2 Immunostaining
For both Ki67 (proliferation marker) and 53BP1 (DNA damage foci marker), the same
protocol applies. First the cells were permiablised for 20 minutes in PBS containing 1%
vol/vol Triton X-100, then the plastic chambers were removed so the slides could be
washed briefly in a Coplin Jar with PBS containing 0.1% vol/vol Tween 20 (PBS-T).
After washing, a solution of 0.1% weight/vol bovine serum albumin (BSA) in PBS-T
(blocking buffer) was applied to the slide for 30 minutes at room temperature to block
non specific reactive sites. Primary antibodies were diluted in blocking buffer (the
DAKO mouse monoclonal anti-Ki67 clone MIB-1, lot number 20003301, the Millepore
mouse kappa monoclonal anti 53BP1 MAb 3802 lot number 2279539, and the Abcam
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mouse kappa monoclonal MOPC-21 non specific IgG ab18443 lot number GR107754-3
were all used at a 1:1000 dilution), and 40μl was incubated on each well for 2 hours at
room temperature (care was always taken to dry the space between wells with a small
piece of tissue to avoid antibody solutions running onto the wrong wells), in a humidity
chamber consisting of damp tissue paper in the base of a slide box, with the slides
resting horizontally on the top directly under the close fitting lid. Next, the slides were
washed again in PBS-T and incubated with secondary antibody (Abcam Alexa Fluor
488 goat anti-mouse IgG (H+L) A11001 lot number 1219843) for 1 hour protected from
light in the humidity chamber. Following a last wash in PBS-T, coverslips were applied
using Vectashield Mounting Medium with DAPI (H-1200 Vector Laboratories) which is
a non-hardening mountant, so the coverslips were sealed with a border of nail varnish
before being stored at 4°C, protected from light.
2.2.5.3 Image acquisition
Images were obtained using the MetaMorph software package (MetaMorph Microscopy
Automation & Image Analysis Software, Molecular Devices LLC) on a Leica DM4000B
epi-fluorescence upright microscope with QIClick camera containing a Sony IC285 CCD
chip for image acquisition. Gain and exposure time were set using young proliferating
cells as positive control for Ki67, and senescent cells as a negative control for Ki67 and
vice versa as controls for 53BP1. A minimum of 3 12 bit images were taken in different
locations within each well, so that a minimum of 100 cells were imaged from different
areas of the well.
2.2.5.4 Ki67 image analysis
All scoring was carried out using the open source image analysis software ImageJ and
FIJI (Rasband, 1997; Schneider et al., 2012). The process described below has been
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scripted as a macro, with the help of Dr. Steven West at the University of Oxford,
which can be performed using either ImageJ or Fiji, in a semi-supervised manner (the
computer runs through the analysis itself, but the images are displayed on the screen
for the user to check in case the thresholding encountered any problems, as is sometimes
the case with completely negative images. If there were any problems noticed with a
particular image, the user has to go back and manually score that image). The DAPI
image was auto-thresholded using Otsu’s thresholding algorithm (OTSU) and dark
background settings. The ‘fill holes’ and ‘watershed’ tools were used to automatically
add a 1 pixel thick line to separate any touching nuclei. Nuclei were then defined
as regions of interest (ROI) using ‘analyse particles’ options, excluding any objects
touching the edges of the image, and including anything over 400 pixels in size to
be shown as an outline and added to the ROI manager. The corresponding Alexa
488 image was then opened, auto thresholded in the same way (although importantly
no “fill holes” or “watershed” was applied to these images) and the ‘analyse particles’
options were applied to show count masks of objects over 400 pixels in size, that have
circularity between 0-1 and exclude any objects on the edge. These measurements were
not added to the ROI manager. The ROI manager was then used to show the outlines
of the nuclei overlaid on the count masks from the Alexa 488 image, by selecting ‘show
all’, an example screen shot can be seen in figure 2.1. Using the ‘measure’ tool in the
ROI manager tool bar produces a table containing information on the size, shape, and
integrated density. Objects with 0 recorded for integrated density were recorded as
negative for Ki67, objects with a positive value for integrated density were recorded as
positive. The results were exported to an Excel spreadsheet, and the overall score was
recorded as number of positive nuclei as a percentage of total nuclei.
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Figure 2.1: Region of interest overlay on Ki67 staining. Screen shot showing
the region of interest (ROI), which has been defined by the thresholded DAPI image
depicting the nuclei, overlaid onto the thresholded Ki67 image in ImageJ. The black
arrow indicates a ROI containing positive Ki67 staining, the red arrow indicates a
nuclear outline ROI that is negative for Ki67, and the blue arrow indicates fluorescent
artefact in the 488 channel that does not fall inside a ROI and therefore will not be
counted.
2.2.5.5 53BP1 image analysis
As 53BP1 foci are also in the nucleus, first the ROI was defined as described for the
analysis of Ki67 staining in section 2.2.5.4 on page 92 , then using positive and negative
control cells (young proliferating as negative and previously verified senescent cells as
positive) a value of noise tolerance was defined in ‘find maxima’ tool such that any foci
that would manually be scored as large in the positive control are detected as maxima,
but any small foci in the negative control are not picked up. The value for noise
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tolerance was kept constant for all images, and ‘find maxima’ was used to report a foci
as a single point. The ROI were then overlaid and ‘measure’ from the ROI toolbar was
used to generate a table of measurements, including integrated density, of each nuclei.
The integrated density of one pixel (single point) is 255, so the integrated density of
each nucleus was divided by 255 to obtain the number of foci in each nucleus, and the
overall scoring reports the percentage of cells that scored positive (i.e. had at least one
large foci).
2.2.5.6 Senescence associated beta-galactosidase (SAβ-gal) staining
SAβ-gal staining was performed using a kit (Histochemical Senescence Detection Kit
(K320-250) from BioVision, Inc.). Cells were plated at a density of 8000 cells/well
in a 12 well tissue culture plate and the media was refreshed in the afternoon of the
following day at 5pm or later. 24 hours later, the media was removed and the cells
were washed with warm PBS before being fixed and incubated with staining solution
for 16 hours at 37°C in atmospheric ppCO2, protected from light, in accordance with
the kit instructions. The staining was achieved by hydrolysis of the colourless X-Gal
in the staining solution, by the SAβ-gal enzyme (now known to be lysosomal beta
galactosidase; senescent cells have larger lysosomes and much more of this enzyme
than non- senescent cells) which yields galactose and 5-bromo-4-chloro-3-hydroxyindole.
The latter then spontaneously forms a dimer which is oxidized to the insoluble blue
precipitate 5,5’-dibromo-4,4’-dichloro-indigo, which can be detected visually (Debacq-
Chainiaux et al., 2009).
After the staining solution had been removed, the cells were washed twice with PBS
and counter-stained using nuclear fast red (to make the nuclear fast red solution 5g of
aluminium sulfate (Sigma, Cat# 368458-500G) was dissolved in 100mL water in a glass
beaker, and the water level marked. 0.1g nuclear fast red (N8002 Sigma Aldrich) was
then added before slowly heating to the boil in a fume hood. After cooling the water
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level was topped back up to 100mL, the solution was centrifuged to 12000 rpm and
the supernatant filtered through a 0.45µm syringe filter to get rid of any precipitate).
500µl per well of staining solution was added and incubated for 15-20 minutes at room
temperature, the cells were then washed twice with PBS. Images of the stained cells
were taken at 100x magnification on a Nikon Eclipse TE2000-S inverted light microscope
with Nikon camera model LHM100C-1. A minimum of 6 images were taken (depending
how many cells are in view; ideally 100 cells in total at least) from different areas of the
well. Cells were scored manually and reported as positive cells as a percentage of total
cells.
2.2.6 Western blotting of p16INK4A and MCM7
Cell pellets collected as previously described in section 2.2.4 on page 90 were thawed
on wet ice and lysed in 50µl RIPA buffer (150 mM sodium chloride, 1.0% (vol/vol)
Triton X-100, 0.5% (weight/vol) sodium deoxycholate, 0.1% (weight/vol) sodium do-
decyl sulphate (SDS), 50mM Tris, pH 8.0, stored at -20°C in 10mL aliquots) containing
protease inhibitor cocktail (cOmplete EDTA free, Roche) according to manufacturer’s
instructions. The pellet was disrupted by pipetting, then centrifuged for 20 minutes at
12000rpm at 4°C to remove cell debris. The supernatant was transferred to a new tube
on ice and a protein standard curve was prepared using bovine serum albumin (BSA)
ranging in concentration from 0-2mg/mL. DC Protein Assay (Bio-Rad) reaction mix-
ture was added to samples and the standard curve in a clear, flat bottomed 96 well plate
(Primaria 353872, BD Falcon) and after 15 minutes incubation at room temperature
the light absorbance was measured at 750nm by plate reader (Fluostar Optima, BMG
Labtech). The concentration of protein in samples was calculated from the standard
curve and the original samples diluted to 2µg/µL in RIPA buffer and loading buffer (4X
Laemlli Sample Buffer #161-0747, Bio-Rad) and then boiled at 95°C for 5 minutes to
denature the protein. The prepared samples were then stored at -20°C until needed.
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The proteins in the cell lysate were separated by molecular weight using sodium
dodecyl sulphate poly acrylamide gel electrophoresis (SDS-PAGE) with the NuPage
Mini Cell system and pre-cast gels (Novex Protein NuPAGE Mini Gels, 4-12% Bis-
Tris) and using 1X NuPage running buffer (NuPAGE MOPS SDS Running Buffer (20X)
NP0001). A molecular weight marker was run on at least one end of the gel (BioRad
Precision Plus dual colour ladder #161-0374) as a reference for the size of the protein
bands. Gels were run for 120 minutes at 90V before the proteins were transferred from
the gel to a membrane for detection. Immediately prior to exposure to the gel, the
nitrocellulose membrane (with a pore size 0.45µm) was incubated in transfer buffer
(Tris-glycine buffer: 25mM Tris, 192mM glycine, 10% vol/vol methanol), then carefully
arranged on top of the gel in the middle of a sandwich of filter paper and sponges, all
soaked in cold transfer buffer. The transfer was performed at 4°C (in a cold room) in
transfer buffer for 90 minutes, at 30V.
Once the proteins had been transferred from the gel to the membrane, the mem-
brane was incubated in blocking buffer consisting of Tris buffered saline containing 0.1%
vol/vol Tween 20 (TBS-T) with 5% weight/vol milk (Marvel Original dried Skimmed
Milk) for 1 hour at room temperature under gentle agitation, to block reactive sites.
Using the molecular weight marker as a guide, the membranes were cut horizontally
at a molecular weight between that of the protein of interest (either p16INK4A at 16KDa
or MCM7 at 81KDa) and the loading control (β-actin at 46KDa), to allow primary
antibodies for different targets to be incubated with the membranes in parallel. The
primary antibody targeting p16INK4A(Anti-CDKN2A/p16INK4a EP4353Y(3) ab81278
from Abcam, UK) was diluted 1:2000 in blocking buffer, the primary antibody targeting
MCM7 (Anti-MCM7 EP1974Y ab52489 from Abcam, UK) was diluted to 1:2000, the
primary antibody targeting β-actin was diluted 1:20,000 in blocking buffer and incub-
ated with the membrane overnight at 4°C, under gentle agitation. The next day the
membranes were washed three times in TBS-T, 5 minutes per wash on a medium speed
rocker, prior to incubation with secondary antibody (horse radish peroxidase (HRP)
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conjugated goat anti rabbit, from Thermo Fisher Scientific, USA) 1 hour at room tem-
perature with gentle agitation. A final set of washes in TBS-T were performed and the
protein bands were visualised using an enhanced chemiluminescent substrate of HRP
(Pierce ECL Western Blotting Substrate). Membranes were incubated with substrate
solution containing luminol and peroxide for 2 minutes, then excess liquid was dabbed
off and the membrane was exposed to light sensitive film (Amersham Hyperfilm ECL
28906837, GE Healthcare) in a dark room. The film was developed using the Xograph
Film Autoprocessor 5.7 and scanned using a Cannon LiDE 210 scanner so that the
protein bands could be analysed using the densitometry feature of ImageJ.
2.3 Results
In order to identify a metabolic marker specific to senescence it was necessary to control
for features of transient growth arrest and the radiation treatment as well as prolifera-
tion. As explained in the chapter introduction, serum starvation and confluence were
chosen as growth arrest control conditions for PEsen, and 0.5Gy gamma radiation was
chosen as a control for the radiation treatment used to generate IrrDSBsen cells. These
groups were characterised using markers of growth arrest and DNA damage induction,
and these results are discussed below.
2.3.1 Generation of PEsen fibroblasts
2.3.1.1 Growth arrest
A slow rate of population doubling was observed in PEsen cells relative to growing
controls; a representative example showing the rate of doubling over 4 days in young
and old fibroblasts can be seen in figure 2.2.
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Figure 2.2: Mean population doublings (mpd) achieved by “young” and “old”
IMR90 and NHOF1 fibroblasts over a period of 4 days. The number in brackets
above the bars represents the cumulative mean population doublings (cmpd) for that
particular population.
2.3.1.2 Morphological changes
Phase contrast images of fixed cells that had been exposed to X-gal (see figure 2.3) show
both morphological changes (larger, flatter cell shape, in some cases multi-nucleated)
and increased β-galactosidase activity (as evidenced by accumulation of blue pigment)
in populations of fibroblasts which had gone through over 50 population doublings and
had failed to complete one population doubling in a month.
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Figure 2.3: SAβ-gal staining of PEsen and growth arrest controls. Top panels
show representative images of growing, serum starved, confluent and PEsen IMR90
(A) and NHOF1 (C) cells treated with X-gal; blue pigment has accumulated in cells
with high beta galactosidase activity. Scale bars represent 50μm. Bottom panels show
average % cells staining positive for SAβ-gal in IMR90 (B) and NHOF1 (D). n=3 NS:
not significant ***p<0.01 with 1 way ANOVA, Tukey’s post hoc analysis
2.3.1.3 Replicative potential
Replicative potential was assessed by both Ki67 (figure 2.4) and MCM7 protein level
(figure 2.5).
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Figure 2.4: Ki67 staining in PEsen NHOF1 and growth arrest controls A Rep-
resentative DAPI (blue) and Ki67 (green) staining in young, confluent, serum starved
and PEsen cells (left and middle columns of images). The right hand column shows
ImageJ thresholded image overlays, depicting which nuclei in the image were positive
for Ki67. Scale bars represent 50µm. Bar charts B and C show the mean score for each
group across three repeats. Error bars represent standard deviation from the mean.
n=3 NS = not significant with 1 way ANOVA.
As figure 2.4 shows, the thresholding method identified fewer Ki67 positive nuclei
in serum starved, confluent and PEsen populations compared to the young growing
population however the trend was not significant when a 1 way ANOVA was applied.
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Figure 2.5: MCM7 protein level in PEsen fibroblasts. A and C are representative
western blots of MCM7 protein levels in PEsen, growing (Gr), serum starved (LS) and
confluent (Con) controls with β-actin loading control, in IMR90 and NHOF1 respect-
ively. B and D show average MCM7 protein levels in PEsen and growth arrest controls
already described in A and C. n=3 error bars represent standard deviation from the
mean NS= not significant with a 1 way ANOVA.
Figure2.5 shows MCM7 levels decreased in both IMR90 and NHOF1 PEsen com-
pared to growing cells but the trend was not statistically significant. The large error
bars on the growth arrest control cells show there is a high level of variability in the
confluent and serum starved cells, although in general they appear to retain higher
levels of MCM7 than PEsen cells.
2.3.1.4 Senescence inducing mechanism (DDR)
53BP1 foci are indicative of a DDR, and large foci accumulate when there is irreparable
DNA damage.
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Figure 2.6: 53BP1 staining in PEsen and growth arrest controls. A ImageJ nuc-
lear outline overlays (magenta dotted lines) on 53BP1 foci staining (green) in growing,
serum starved, confluent and PEsen NHOF1 cells. Yellow arrows point to 53BP1 foci,
which can only be seen in the nuclei of PEsen cells. Scale bar represents 50µm. B the
mean percentage of cells positive for 53BP1 foci for each group across three repeats.
n=3 Error bars represent standard deviation from the mean. NS = not significant
*p<0.05 **p<0.01 ***p<0.001 with 1 way ANOVA using Tukey’s post hoc analysis.
Figure 2.6 shows that PEsen cells have many more 53BP1 foci than the other groups
and this trend was found to be statistically significant with a 1 way ANOVA and Tukey’s
post hock analysis, while the growing and growth arrest control cells did not show a
statistical difference in the number of 53BP1 foci.
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2.3.1.5 Cell cycle inhibition
To confirm that senescence had not been induced in the growth arrest control cells
western blots were performed to assess the levels of p16INK4A, a CDK inhibitor. As can
be seen in figure 2.7 there was a statistically significant increase in p16INK4Aexpression in
PEsen IMR90 cells compared to growth arrested and growing controls, however NHOF1
PEsen cells did not show any detectable p16INK4A protein (figure 2.8).
Figure 2.7: p16INK4A protein level in PEsen IMR90 and growth arrest con-
trols. A. Representative western blot of p16INK4A protein levels in PEsen IMR90 cells
as well as growing (Gr), serum starved (LS) and confluent (Con) controls, with β-actin
loading control. B. Average p16INK4A protein levels in PEsen IMR90 and controls as in
A, quantified relative to HeLa. Error bars represent standard deviation from the mean,
n=3 ***p<0.001 with 1 way ANOVA and Tukey’s post hoc analysis.
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Figure 2.8: p16INK4A protein level in PEsen NHOF1 and growth arrest con-
trols. Representative western blot of p16INK4A protein levels in PEsen NHOF1 cells
as well as growing (Gr), serum starved (LS) and confluent (Con) controls, with β-actin
loading control. No signal for p16INK4A was detected in any of the NHOF1 lysates, so
no quantification was performed.
2.3.2 Generation of DNA double strand break stress induced
senescent fibroblasts
The same approach was used to characterise the IrrDSBsen fibroblasts
2.3.2.1 Growth arrest
In the 18 days after irradiation with 20Gy gamma, both NHOF1 and IMR90 IrrDSBsen
populations did not proliferate, where as the 0Gy control cells continued to complete
multiple population doublings in that time. An example is shown in figure 2.9.
Figure 2.9: Mean population doublings (mpd) achieved by IMR90 and
NHOF1 fibroblasts that had been subject to 20Gy gamma or 0Gy gamma
radiation, over a period of 18 days. The number in brackets above the bars repres-
ents the cumulative mean population doublings (cmpd) for that particular population.
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2.3.2.2 Morphological changes
SAβ-gal levels were increased after 20 days in cells that were exposed to 20Gy gamma
compared to growing cells and cells that had been exposed to 0.5Gy gamma in both
IMR90 (figure 2.10) and NHOF1 (figure 2.11).
Figure 2.10: A Representative SAβ-gal staining of 0Gy 0.5Gy and 20Gy treated IMR90
at 5, 10 and 20 days after treatment. Scale bar represents 50μm. B Average % SAβ-Gal
scores 0Gy 0.5Gy and 20Gy treated IMR90 at 5, 10 and 20 days after treatment. Scale
bars represent standard deviation from the mean. N=3 NS = non significant, **p<0.01
***p<0.001 with 1 way ANOVA and Tukey’s post hoc analysis.
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Figure 2.11: A Representative SAβ-gal staining of 0Gy 0.5Gy and 20Gy treated NHOF1
at 5, 10 and 20 days after treatment. Scale bar represents 50μm. B Average % SAβ-Gal
scores 0Gy 0.5Gy and 20Gy treated NHOF1 at 5, 10 and 20 days after treatment. Scale
bars represent standard deviation from the mean. N=3 NS = non significant, *p<0.05
1 with 1 way ANOVA and Tukey’s post hoc analysis.
2.3.2.3 Replicative potential
The levels of the proliferation marker Ki67 declined over time in both IMR90 and
NHOF1, and in NHOF1 the effect of 20Gy irradiation caused a statistically significant
decrease compared to controls as early as 5 days after treatment (see figure 2.13) al-
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though interestingly in IMR90 the decline in Ki67 following 20Gy was not significantly
different to the decline in controls until the 20Gy time point (figure 2.12).
Figure 2.12: A Thresholded Ki67 staining with nuclear regions of interest (identified
using DAPI) shown as magenta outlines, in IMR90 cells 5, 10 and 20 days after a 0,
0.5 and 20Gy dose ionising radiation. Scale bar represents 50µm. B Mean Ki67 scores
for each group across three repeats. Error bars represent standard deviation from the
mean. NS = not significant *p<0.05, 2 way ANOVA with Tukey’s post hoc analysis.
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Figure 2.13: A Thresholded Ki67 staining of NHOF1 cells 5, 10 and 20 days after
exposure to 0Gy, 0.5Gy and 20Gy, showing nuclear regions of interest (identified using
DAPI) shown as magenta outlines. B Average percentage Ki67 positive NHOF1 cells 5,
10 and 20 days after exposure to 0Gy, 0.5Gy and 20Gy. Error bars represent standard
deviation from the mean, n=3 NS= not significant ***p<0.001 with 2 way ANOVA
using Tukey’s post hoc analysis.
Further assessment of replicative potential was made using the marker MCM7, show-
ing that in IMR90 the decline in MCM7 following 20Gy gamma radiation is statistically
significant at just 5 days (figure 2.14) and a similar pattern is seen in NHOF1 although
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it was not statistically significant (figure 2.15).
Figure 2.14: MCM7 protein levels in IrrDSBsen IMR90 A western blot showing
MCM7 protein levels in IMR90 cells treated with 0Gy, 0.5Gy and 20Gy on days 5,
10 and 20 after treatment. B Average MCM7 protein levels in IMR90 cells treated
with 0Gy, 0.5Gy and 20Gy on days 5, 10 and 20 after treatment. Error bars represent
standard deviation from the mean. For day 10 0Gy and 0.5Gy n= 2, for all other points
n=3. NS = not significant ***p<0.001 **p<0.01 with a 1 way ANOVA and Tukey’s
post hoc analysis (on 5 day and 20 day data points only)
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Figure 2.15: MCM7 protein levels in IrrDSBsen NHOF1 A Representative west-
ern blot showing MCM7 protein levels in NHOF1 cells treated with 0Gy, 0.5Gy and
20Gy on days 5, 10 and 20 after treatment. B Average MCM7 protein levels in NHOF1
cells treated with 0Gy, 0.5Gy and 20Gy on days 5, 10 and 20 after treatment. Error
bars represent standard deviation from the mean, n=3. NS= not significant with a 2
way ANOVA with Tukey’s post hoc analysis
2.3.2.4 Senescence inducing mechanism (DDR)
53BP1 staining shows an induction of DNA double strand breaks by day 5 that are
sustained for the 20 day time period in the 20Gy treatment group but not in the 0Gy
or 0.5Gy populations in both IMR90 and NHOF1, a trend which was not statistically
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significant in IMR90 (figure 2.16) but was highly statistically significant in NHOF1
(figure 2.17).
Figure 2.16: 53BP1 staining in IrrDSBsen IMR90 A ImageJ nuclear overlays
(magenta dotted lines) on 53BP1 foci (green, highlighted by yellow arrows) in IMR90
after 0, 0.5 or 20Gy ionising radiation on 5, 10 and 20 day time points. Scale bar
represents 50µm. B shows the mean score for each group across three repeats. Error
bars represent standard deviation from the mean, n=3 in 5 and 10 day groups, n=2 in
day 20 group due to damage on the slide. NS = not significant with 1 way ANOVA.
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Figure 2.17: 53BP1 staining in IrrDSBsen NHOF1 A ImageJ nuclear overlays
(magenta dotted lines) on 53BP1 foci (green, highlighted by yellow arrows) in NHOF1
after 0, 0.5 or 20Gy ionising radiation on 5, 10 and 20 day time points. Scale bar
represents 50µm. B shows the mean score for each group across three repeats. Error
bars represent standard deviation from the mean. NS = not significant ***p<0.001, 2
way ANOVA with Tukey’s post hoc analysis.
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2.3.2.5 Cell cycle inhibition
Protein levels of the cell cycle inhibitor p16INK4A were measured using western blot.
p16INK4A levels did appear to increase in IMR90 cells following irradiation with 20Gy
however the trend was weak and not statistically significant (figure 2.18) and p16INK4A
was undetectable in NHOF1 (figure 2.19).
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Figure 2.18: p16INK4A protein levels in IrrDSBsen IMR90 A. Representative
western blot of IMR90 lysate showing a slight increase in p16INK4A levels over time and
with 20Gy gamma irradiation, and the loading control β-actin. B shows densitometry
analysis of 3 biological repeats of the same treatment, relative to the same HeLa lysate
on each blot and corrected for loading against beta actin. Error bars represent standard
deviation from the mean. n=3 NS = not significant with 2 way ANOVA.
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Figure 2.19: p16INK4A protein levels in IrrDSBsen NHOF1. Representative
western blot of p16INK4Aprotein levels in IrrDSBsen NHOF1 cells. No signal was detec-
ted from any of the NHOF1 lysates so no quantification has been carried out. n=3.
2.4 Discussion
This chapter set out to characterise the models of senescence used in this thesis, to
ensure that information gained in later experiments regarding the metabolome can be
interpreted as accurately as possible. By employing the growth arrest controls con-
fluence and serum starvation, as well as the irradiation exposure control 0.5Gy, all of
which have been shown in this chapter to show markers of growth arrest but not DNA
double strand breaks or senescence, greater confidence can be placed in the outcomes
of the experiments in the remainder of the thesis.
2.4.1 Differences in the population doubling rate and SAβ-gal
activity between both senescence induction modes and
cell lines
Firstly, it was observed that both the PEsen and IrrDSBsen cells had an extremely slow
doubling rate compared to young and unirradiated controls. The growth of the IrrDSB-
sen cells was slower than the PEsen cells, as can be seen when comparing figure 2.2
on page 99 with figure 2.9 on page 105. This could be because the PEsen population
is likely to be a heterogeneous mix of cells ranging from some which are still dividing,
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some which are just entering senescence and some which are fully senescent, whereas
the IrrDSBsen population of cells all received the same strong, senescence inducing
stimulus at the same time so the growth arrest is much more synchronous. This may
be an important observation to consider later when comparing the metabolomes of the
two models.
Next we considered the morphology of the PEsen and IrrDSBsen populations, by
looking at phase contrast images of cells stained for SAβ-gal activity. In both IMR90
and NHOF1 cells the PEsen population comprised cells with a larger cell size and a
statistically significantly higher percentage positive for SAβ-gal activity whereas the
growth arrest controls retained their normal size and did not have significantly elevated
levels of SAβ-gal activity compared to growing controls (see figure 2.3 on page 100).
There is a difference between the cell lines in terms of intensity of staining and total
percentage of cells that stained positive; the young growing IMR90 population had
an average of just under 10% of cells positive for SAβ-gal activity, whereas the young
growing NHOF1 population had 0%, which was increased with PEsen to over 90%
positive in IMR90 compared to 25% positive in NHOF1. This observation could reflect
a difference in the lysosome compartment of the cells generally or it could suggest the
IMR90 cells are more senescent generally. Further insight into this observation can
be gained by looking at figures 2.10 on page 106 and 2.11 on page 107, which show
the SAβ-gal staining of IrrDSBsen IMR90 and NHOF1 and the 0.5Gy reversible strand
break control compared to growing cells. Both cell lines have a significant increase in
SAβ-gal activity following 20Gy gamma which is evident after 10 days but is at its
highest after 20 days. As with the PEsen model, IMR90 cells have a higher baseline
SAβ-gal activity than NHOF1, and interestingly the IrrDSBsen NHOF1 cells averaged
over 60% positive for SAβ-gal activity compared to just 25% in the PEsen population
suggesting that the IrrDSBsen NHOF1 population is generally more senescent than
the PEsen population. This supports the theory that the rate of growth was even
slower in IrrDSBsen cells than in PEsen cells because a larger proportion of the cells
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are fully senescent. Comparing the two cell lines it is also evident that there are some
underlying differences between IMR90 and NHOF1 in terms of rate of doubling and
SAβ-gal activity. These observations taken together suggest that the IMR90 population
may be physiologically older than the NHOF1 population, or may be more sensitive to
senescence inducing stimuli. Importantly, the growth arrest controls for both PEsen
and IrrDSBsen in both IMR90 and NHOF1 were found to be not significantly different
to the growing controls, regardless of the baseline SAβ-gal activity.
2.4.2 Proliferative potential
Ki67 staining was used to assess the percentage of cells in cycle. Unfortunately Ki67
data on PEsen was only obtained for NHOF1, so we cannot compare PEsen Ki67 levels
between the two cell lines, or between the two induction mechanisms for IMR90. In
NHOF1 Ki67 decreased more drastically at 20 days after 20Gy (IrrDSBsen) than in the
equivalent senescent model PEsen, as we would expect based on the relative growth
rates and SAβ-gal activity of the populations. Despite the decrease in Ki67 in PEsen
NHOF1 not being statistically significant relative to growing controls, there is a clear
trend and importantly there was also a decline in Ki67 levels in both the confluence and
serum starved growth arrest controls, indicating that the conditions used are creating
populations of cells more phenotypically similar to senescent cells than growing cells.
The IrrDSBsen model in NHOF1 appears to give a more robust decrease in Ki67 staining
across all time points which was statistically significant and also importantly there was
no statistical difference in the Ki67 levels in the 0Gy growing control and the 0.5Gy
irradiation/repairable DNA double strand break control indicating that the damage is
indeed reversible and does not induce senescence.
The Ki67 score in the IrrDSBsen IMR90 cells was not significantly different to 0Gy or
0.5Gy controls until the 20 day time point, unlike in NHOF1 cells. This maintenance
of Ki67 in IrrDSBsen IMR90 relative to controls is quite puzzling, as the cells were
exhibiting several other signs of being senescent from a much earlier point. As the
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presence of Ki67 only tells us the cells are not in G0 it is possible that more of the cells
had arrested at some other point in the cycle. Another factor that certainly influenced
this result, is the fact that the percentage of cells positive for Ki67 in the 0Gy and 0.5Gy
control groups is lower on days 5 and 10 than on day 20, so the perceived decrease in
Ki67 in 20Gy treated cells after 20 days is more attributable to an increase in Ki67 in the
0Gy control rather than a large decrease in the 20Gy group, although the experiment
was repeated 3 times and at days 5 and 20 there is little variation between the data
from the repeats suggesting that this pattern is not a result of experiment variation.
As we have already seen from the population growth rate and SAβ-gal, IMR90 cell
populations likely have a higher proportion of senescent cells, so the observation that
the 0Gy and 0.5gy have generally lower levels of Ki67 than the equivalent NHOF1 cell
populations is not surprising.
MCM7 protein levels are also an indicator of proliferative potential as it is a protein
required for replication fork formation, and should be independent of which phase cells
have arrested in. MCM7 protein levels should therefore help to ascertain whether there
are indeed more growth arrested cells in the control populations of IMR90 cells, in
which case the MCM7 levels in those controls would be low relative to a positive control
(HeLa) and relative to NHOF1. Indeed for PEsen, figure 2.5 on page 102 demonstrates
that IMR90 growing cells have roughly half the level of MCM7 protein expression seen
in NHOF1, when both are compared to HeLa. Both lines show the same trend for
decrease of MCM7 in PEsen relative to growing cells, although the relationship was not
statistically significant in either cell line. In IMR90 both growth arrest controls retained
higher levels of MCM7 on average than the PEsen group, indicating that they have not
lost the potential to proliferate despite being growth arrested. In NHOF1 the serum
starved cells retained high levels of MCM7 however on average the confluent cells did
exhibit a reduction in MCM7 protein levels similar to those seen in the PEsen group.
It is probable that the variability is due to the dynamic nature of transient growth
arrest; although much effort was given to optimising the conditions so that cells were
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just growth arrested, but not engaging senescence entry mechanisms, it is very difficult
to get populations of cells consistently within the narrow phenotype requirements when
externally they look practically identical to growing cells. The variability would almost
certainly reduce with a larger sample size, however under the time constraints it wasn’t
possible to achieve.
The decline in MCM7 levels in 20Gy but not 0.5Gy relative to 0Gy in the IrrDSBsen
model was more obvious, and in the case of IMR90 was statistically significant (see
figure 2.14 on page 110). There was considerable variation in the NHOF1 MCM7
protein levels and as a result the 20Gy specific decline in MCM7 was not statistically
significant but the trend is still clear.
So far the data suggests that the senescence induction methods have been successful
in causing an increase in the number of growth arrested cells in the population which
have lost the potential to replicate, and that the growth arrest control conditions serum
starvation and confluence have also caused a growth arrest, but one that is not perman-
ent as the cells retained markers of proliferative potential. Next we looked at whether
there was evidence of a DDR occurring in our PEsen an IrrDSBsen populations as well
as their associated controls.
2.4.3 Evidence of a DDR
The DNA damage repair protein 53BP1 is recruited to sites of DNA damage so im-
munostaining of this protein was used to assess DNA damage response foci. Again
unfortunately data on 53BP1 in PEsen was only collected for NHOF1, so we can only
make the comparison between PEsen and IrrDSBsen in that cell line. In PEsen NHOF1
it was clearly demonstrated that the DDR was being engaged, as there was a statist-
ically significant increase in the percentage of the population that contained 53BP1
foci in PEsen compared to growing controls and crucially both growth arrest controls
contained very similar levels of 53BP1 positive cells to the growing control, confirming
that the mild stress used to growth arrest them was not causing damage that could
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lead to senescence engagement via DDR (figure 2.6 on page 103).
In NHOF1 IrrDSBsen there was a slight elevation in the number of cells treated with
0.5Gy engaging the DDR, although the number was highly statistically significantly
different from cells treated with 20Gy, which had much higher levels of DDR positive
cells even from day 5. This is consistent with the findings of researchers that much of the
DNA damage induced by even 1Gy ionising radiation is resolved within 24 hours(Schultz
et al., 2000) and confirms that the 0.5Gy dose is a good control for repairable strand
breaks and the irradiation treatment. The sustained elevation in 53BP1 over 20 days
strongly suggests that senescence is being induced via a DDR in this model, as we would
expect. IMR90 cells subjected to 20Gy and 0.5Gy show the same trend as NHOF1,
with an increase in 53BP1 in 20Gy cells from 5 days that is maintained to 20 days
compared to 0Gy and a slight increase in 53BP1 in 0.5Gy treated cells compared to
0Gy, however the results were not statistically significant. We can see that the baseline
level of 53BP1 in IMR90 is a little higher than in NHOF1, suggesting that the overall
slower rate of growth and increased level of SAβ-gal staining could be due to on-going
low levels of DNA damage in this cell line.
2.4.4 p16INK4A protein levels
IMR90 PEsen cells showed a large increase in the level of p16INK4A protein expression
compared to growing controls; further evidence that the PEsen IMR90 population is
largely fully senescent. As expected the growth arrest controls did not cause a signific-
ant increase in p16INK4A protein level, demonstrating that the growth arrest induced in
these cells is transient and not engaging senescence pathways. In PEsen NHOF1 how-
ever no p16INK4A protein could be detected. The presence of a protein band in HeLa
demonstrates that there was not a technical issue with the blot or antibody, so the lack
of p16INK4A could suggest that PEsen NHOF1 are not fully senescent, although if this
were the case we would still expect to some signal in the PEsen population, it could
also suggest that NHOF1 are senescing via a p16INK4A independent mechanism. Inter-
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estingly a previous student had identified individual p16INK4A positive NHOF1 cells in a
less senescent population and additionally it has been informally observed that NHOF1
cell growth rate slows at around 45mpds increasing again until the population under-
goes senescence at around 65mpds. One explanation for this could be that a subset of
the NHOF1 population is p16INK4A positive; these cells senesce around 45mpds due to
elevation of p16INK4A and are outgrown by a p16INK4A negative population which then
goes on to senesce through a different mechanism after further population doubling.
Unfortunately there was not time to investigate this result further.
No p16INK4A was detected in IrrDSBsen NHOF1 either, and even in IMR90 which
are known to have constituently high levels of p16INK4A the build up of p16INK4A was
not very substantial, as can be seen from figure 2.18. Again this result cannot be put
down to any problems with the blot or antibody, because the HeLa lysate repeatedly
gave good signal as shown in the representative blots in figures 2.18 and 2.19, therefore
it appears likely that the IrrDSBsen induction mechanism does not require elevation of
p16INK4A.
2.4.5 Summary
The aims of this chapter were to characterise the phenotype of the models used in
this thesis and verify that the controls showed signs of reversible growth arrest. These
aims were largely met; both PEsen and IrrDSBsen models showed signs of permanent
growth arrest induced via DNA double strand breaks, while the growth arrest con-
trols serum starvation and confluence showed signs of a transient growth arrest that
was not engaging the DDR. The control for irradiation treatment and repairable DNA
damage, 0.5Gy gamma radiation, also seems appropriate as there was no long lasting
DNA damage response and the populations did not become growth arrested. Some
observations were made that will be useful later when comparing the metabolomes of
the two senescence models and cell lines, such as the observation that the IMR90 cell
populations appear to be harbouring low levels of DNA damage, are slower growing
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and senesce via p16INK4A in PEsen but possibly not IrrDSBsen conditions. NHOF1 on
the other hand appear to have less senescent cells in the young population, which have
lower levels of DNA damage than IMR90, and possibly do not up-regulate p16INK4A
in PEsen or IrrDSBsen conditions. Overall in both lines a more robust phenotype was
seen in the IrrDSBsen populations compared to the PEsen and this has been attrib-
uted to the heterogeneous nature of the PEsen population compared to the IrrDSBsen
population. Going forward it will be interesting to see if these differences are reflected
in the secreted metabolome.
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Chapter 3
The metabolome of senescent
fibroblasts
3.1 Introduction
3.1.1 The study of small molecules
The metabolome
Within each cell, every single process is underpinned by chemical reactions in which
molecules are precursors, reactants, intermediates, waste products, catalysts and inhib-
itors; leaving behind a metabolic footprint known as the metabolome. The study of
this biochemical signature of cellular processes is called metabolomics.
What the metabolome can uniquely tell us
While genomics has uncovered a wealth of markers that predispose to disease, and
transcriptomics and proteomics give us insight into the structure and function of cellular
components, it is the addition of information on the metabolome which can ultimately
tell us what processes have actually been occurring within the cell. In addition, the use
of mass spectrometry coupled to liquid and gas chromatography allows high throughput,
accurate identification and quantification of metabolites in small volumes of biological
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fluids that can be taken repeatedly from the same subject (for example blood, urine,
saliva, and cell culture media), making metabolomics the ideal method to study dynamic
biological systems.
Metabolon
Some of the techniques commonly used in the field of metabolomics were outlined
in Chapter 1; each technique has its strengths and weaknesses that make it better
for detecting certain types of molecule, so when performing untargeted exploratory
screens to identify novel biomarkers it is preferable to use multiple platforms to capture
as many components of the metabolome as possible. To gather comprehensive and
reliable metabolomic profiles of senescent versus growing fibroblasts we sent conditioned
media samples to Metabolon, the industry leading commercial metabolomic screening
service that uses a proprietary platform called DiscoveryHD4. Using a library of over
4500 known metabolites built from pure reference standards to identify metabolites
detected with a combination of GCMS and UHPLC MS/MS in positive and negative
detection modes allows rapid, accurate and reproducible metabolite identification, with
verification performed by specialist chemical spectral analysts. The aim of using a
commercial screening service was to identify the strongest candidates for biomarkers
of senescence which could then be followed up on smaller scale using the technology
available locally.
3.1.2 Summary
In this chapter the methods used to assess the secreted metabolome of the senescence
and growth arrest models described in the previous chapter will be explained, from
the untargeted screen performed by Metabolon which was used to identify candidate
markers and highlight altered metabolic pathways, to the search for a more local and
affordable targeted method of following up these findings.
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3.2 Materials and methods
3.2.1 Collection of conditioned media
3.2.1.1 General protocol
On the 18th day following irradiation for IrrDSBsen, or once cells were deemed replicat-
ively senescent for PEsen, cells were counted and re-plated at a density of 5x105 cells per
T75 flask (Thermo Fisher), in 12mL culture media. The following day (except in the
case of the confluent and low serum experiments, the conditions for these collections are
detailed below) the media in the flasks was replaced with freshly made DMEM (made
as described earlier), with the reduced volume of 3mL per T75 flask. A 3mL aliquot
of this freshly prepared media, that had not been exposed to cells, was centrifuged
and frozen in exactly the same manner as outlined below for the samples, to act as a
control for the baseline media constituents. The flasks were allowed to equilibrate to
10% CO2 /90% air in the 37°C incubator before being sealed with Parafilm to prevent
evaporation. The flasks were then incubated for 24 hours to allow the media to become
conditioned, before the media were collected into 30mL tubes and centrifuged at 800xg
for 2 minutes to remove any dead cells or other debris. The media were then split
between 3 or more Eppendorf tubes as 1mL aliquots and centrifuged again at 13,000
rpm in a microfuge. The media was then transferred to fresh Eppendorf tubes and snap
frozen in a bath of EtOH/dry ice for at least 15 minutes before being transferred to a
-80°C freezer for storage.
3.2.1.2 Growth arrest control: Confluence
The protocol for collection of the media from the confluent cells, which were used as a
control for growth arrest, required slightly more time between plating of the cells and
the start of the collection period, to enable the cells to become properly confluent and
growth arrested. This protocol was optimised to get as many cells growth arrested (Ki67
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negative) as possible whilst also not allowing irreparable DNA double strand breaks
to develop (the cells must also be negative for large 53BP1 foci), and the optimum
conditions were found to be plating the cells 4 days before collection was due, and
replenishing the media every day within that time. Media volume added to the flasks
during the collection period was increased to produce a cell number:volume ratio as
similar as possible to that found in the other flasks with cells growing at the usual
density.
3.2.1.3 Growth arrest control: Serum starvation
Transient growth arrest induced by serum starvation in low serum media also required
optimisation to get as many growth arrested cells as possible without inducing irrepar-
able DNA double strand breaks. Cells were plated four days before collection was due,
24 hours after plating the cells were washed with 1xPBS and media was replaced with
DMEM containing additional glutamine and antibiotics as in the standard media but
containing only 0.1% vol/vol foetal calf serum.
3.2.2 Collection of cell pellets
Cell pellets were always collected at the same time as the conditioned media, or under
identical conditions. Cells were seeded at a density of 5x105 cells per T75 flask and
the following day the media was replaced with 3mL freshly made media. Flasks were
allowed to equilibrate to 10% CO2/90% air before being sealed with Parafilm to prevent
evaporation. 24 hours later, after the removal of the medium, the cells were washed with
warm 1x PBS and incubated at room temperature with 1mL trypsin/EDTA solution
(as previously described) while the media was being processed. Incubating the cells in
the trypsin at room temperature rather than at 37°C slowed the action of the trypsin
slightly and allowed more time to process the media before the cells detached fully.
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Following detachment the trypsin was neutralised by addition of 3mL serum containing
media and the cells were counted. The cell suspension was then centrifuged at 800
rpm for 5 minutes to produce a cell pellet, which was re-suspended in 1mL 1xPBS
and transferred to an Eppendorf tube. A pellet was obtained by centrifuging the cell
suspension at 13,000 rpm in a microfuge for 5 minutes and the PBS was aspirated, then
the pellet was snap frozen on EtOH/dry ice and stored at -80°C.
3.2.3 Metabolon’s analysis platforms
Metabolon is a leading commercial metabolomics phenotyping company based in the
USA with proprietary analysis platforms and informatics systems that offer the most
comprehensive metabolomics platform for screening biological samples available. The
protocols used to prepare and analyse the samples we sent are as follows (adapted from
descriptions provided by Metabolon):
3.2.3.1 Sample Preparation
Samples were thawed and a recovery standard was added prior to protein removal by
precipitation with methanol of a 100μl (this process was performed using the auto-
mated MicroLab STAR® system from Hamilton Company). The resulting extract was
divided into four fractions: one for analysis by UPLC/MS/MS (positive mode), one for
UPLC/MS/MS (negative mode), one for GCMS, and one for backup. Samples were
placed briefly on a TurboVap (Zymark) to remove the organic solvent. Each sample was
then frozen and dried under vacuum. Samples were then prepared for the appropriate
instrument, either UPLC/MS/MS or GC/MS.
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3.2.3.2 UPLC/MS/MS
The LC/MS portion of the platform was based on a Waters ACQUITY ultra-performance
liquid chromatography (UPLC) and a Thermo-Finnigan linear trap quadrupole mass
spectrometer, which consisted of an ESI source and linear ion-trap mass analyser. The
sample extract was reconstituted in acidic or basic LC-compatible solvents, each of
which contained 8 or more injection standards at fixed concentrations to ensure injec-
tion and chromatographic consistency. One aliquot was analysed using acidic positive
ion optimized conditions and the other using basic negative ion optimized conditions in
two independent injections using separate dedicated columns. Extracts reconstituted
in acidic conditions were gradient eluted using water and methanol containing 0.1%
vol/vol formic acid, while the basic extracts, which also used water/methanol, con-
tained 6.5mM ammonium bicarbonate. The MS analysis alternated between MS and
data-dependent MS/MS scans using dynamic exclusion.
3.2.3.3 GCMS
The samples for GCMS analysis were re-dried under vacuum desiccation for a minimum
of 24 hours prior to being derivatised under dried nitrogen using bistrimethyl-silyl-
triflouroacetamide. The GC column was 5% phenyl and the temperature ramp was from
40° to 300° C in a 16 minute period. Samples were analysed on a Thermo-Finnigan
Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact
ionization. The instrument was tuned and calibrated for mass resolution and mass
accuracy on a daily basis.
3.2.3.4 Quality assurance
Additional samples were included with each day’s analysis. These samples included
extracts of a pool created from a small aliquot of the experimental samples and process
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blanks. Quality control (QC) samples were spaced evenly among the injections and all
experimental samples were randomly distributed throughout the run. A selection of
QC compounds was added to every sample for chromatographic alignment, including
those under test. These compounds were carefully chosen so as not to interfere with
the measurement of the endogenous compounds.
3.2.3.5 Data extraction and compound identification
Raw data was extracted, peak-identified and QC processed using Metabolon’s hardware
and software. These systems are built on a web-service platform utilizing Microsoft’s
.NET technologies, which run on high-performance application servers and fibre-channel
storage arrays in clusters to provide active failover and load-balancing. Compounds were
identified by comparison to library entries of purified standards.
3.2.3.6 Data analysis
The profile of a sample of unconditioned media (collected at the beginning of the media
conditioning period) was subtracted from the profile of conditioned media samples,
to give an indication of whether metabolites were being secreted or depleted in the
conditioned media. The scaled intensity values for each metabolite were then normalised
to the average cell count over the collection time period.
Principal components analysis
The un-targeted metabolomic screens performed by Metabolon provided a huge amount
of data; turning this overwhelmingly large collection of numbers into a wealth of in-
formation was made possible using multivariate analysis. The primary method used was
Principal Components Analysis (PCA), which is a dimension reduction technique that
transforms correlations in the data into new variables (latent variables, or components)
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and lists them in descending order based on how much of the total variance in the data
is represented by that component. PCA aims to reduce the number of variables by
creating components that explain as much of the variance as possible. Often, 80-90%
of the variance in a data set can be explained by the first 4 or 5 components, which are
referred to as the “principal components”. By looking at what original variables caused
the separation of these components (which variables loaded onto which components,
described by the loading scores) it is possible to identify which metabolites were differ-
ent between the control groups and the senescent groups. This analysis was performed
by Metabolon.
Random forests analysis
Random forests is a supervised machine learning technique that uses a subset of the
available data, which has identifying true class information associated with it, to con-
struct a “training tree” that the remaining data, known as the “out-of-bag” (OOB)
variables, are passed down to obtain a class prediction for each variable (in this thesis
the variables are levels of metabolites, and the classes are the cell groups i.e. senescent
versus growing). This process is repeated thousands of times, using all of the data but
never passing data used to create a tree down that particular tree, to produce the forest.
The final classification of each sample is determined by computing the class prediction
frequency (“votes”) for the OOB variables over the whole forest. For example, if the
random forest consists of 50,000 trees; 25,000 of which had been used to make a pre-
diction for sample 1, and of the 25,000, 15,000 trees classified the sample as belonging
to Group A and the remaining 10,000 classified it as belonging to Group B, then the
votes are 0.6 for Group A and 0.4 for Group B, so the final classification will be Group
A. This method is unbiased, because the prediction for each sample is based on trees
built from a subset of samples that do not include that sample. When the full forest
is grown, the class predictions are compared to the true classes, generating the “OOB
error rate” as a measure of prediction accuracy. The prediction accuracy can therefore
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be used as an unbiased estimate of how well sample class can be predicted in a new
data set.
To determine which metabolites make the largest contribution to the classification,
a “variable importance” measure is calculated. Metabolon used the “Mean Decrease
Accuracy” (MDA) as this metric. The MDA is determined by randomly altering a vari-
able, running the observed values through the trees, and then reassessing the prediction
accuracy. If a variable is not important, then this procedure will have little change in
the accuracy of the class prediction (permuting random noise will give random noise).
By contrast, if a variable is important to the classification, the prediction accuracy will
drop if that variable is changed, and this is recorded as the MDA. The result is an
“importance” rank ordering of biochemicals; typically the top 30 biochemicals are given
as the output of the analysis, forming a list of metabolites that are potentially worthy
of further investigation.
3.2.4 Enzymatic quantification of lactate
Extracellular lactate was quantified using an enzymatic assay from BioAssay Sys-
tems (Enzychrom L-Lactate Assay Kit ECLC-100). Frozen aliquots of conditioned
media as well as the blank media controls were thawed on ice, and kept on ice at all
times. A standard curve of L-Lactate at concentrations ranging from 0 to 1mM was
prepared in serum free DMEM. Media samples were diluted in distilled water 4 or 8
times. Corresponding diluted media and serum free media controls were also used.
Initial testing showed that endogenous enzyme activity in the media was negligible/
non-existent. Diluted media samples were added to clear, flat bottomed 96 well plates
(Primaria 353872, BD Falcon) in triplicate. A reaction mix containing Assay Buffer,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), NAD, and an en-
zyme mix was then added, and a time zero (T0) measurement at 565nm was taken using
a plate reader (Fluostar Optima, BMG Labtech). After 20 minutes incubation at room
temperature a second measurement was taken at 565nm. The T0 measurement was sub-
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tracted from final measurement, and relevant media controls subtracted from sample
measurements before the results were multiplied by relevant dilution factors and ori-
ginal concentrations derived from the equation of the line of the standard curve. Values
were corrected for cell number.
3.2.5 Quantification of citrate
3.2.5.1 Enzymatic assays
The Citrate Colorimetric/Fluorometric Assay Kit was obtained from BioVision
(K655-100). For the colorimetric assay, conditioned and unconditioned media were
diluted 1:10, 1:50 and 1:100 in Assay Buffer and a standard curve of 0 to 10nmol/ well
prepared. All were added to a clear flat bottomed 96 well plate (Primaria 353872, BD
Falcon) in triplicate and a reaction mix containing buffer, enzyme mix, developer and
probe was then added. The plate was protected from light for the incubation period of
30 minutes at room temperature. Absorbance was measured at 570nm (Fluostar Op-
tima, BMG Labtech), and the concentration of citrate in the samples was determined
from the standard curve. The blank media values were subtracted from all conditioned
media values before being corrected for cell number. For the fluorescent assay, samples
were not diluted and a slightly different range of standard curve of citrate, ranging in
concentration from 0 to 1nmol/well, was used. The samples were added to a black 96
well plate (Nunclon Delta Black microwell S1), and the reaction mix was then made
and added in the same way as for the colorimetric assay. The plate was protected from
light and incubated at room temperature for 30 minutes before being read in a fluores-
cence plate reader (Fluostar Optima, BMG Labtech) at excitation wavelength 535nm,
emission 587nm. The concentration of citrate in the conditioned media samples was
determined from the standard curve, and again unconditioned blank media values were
subtracted from conditioned media values and finally the values were corrected for cell
number.
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3.2.5.2 Precipitation of citrate
Citrate has been successfully quantified in urine using a precipitation method, so
we decided to see if it would be sensitive enough to work with culture media using
a method described by Lewis (Lewis, 1990). A standard curve was made using so-
dium citrate dehydrate (Sigma) ranging from 0 to 4.5mM in unconditioned cell culture
medium. To each 4mL sample of conditioned cell culture medium 100µl 25% vol/vol
NH4OH (Sigma) was added, the samples were mixed by vortexing before addition of
900µl 0.2M MgCl2 and then centrifuged at 4000xg for 10 minutes to remove phosphates.
The supernatant was transferred to a fresh tube and the pH was adjusted to 2.0 with
HCl. Then, 250µl 18mM FeCl3 was added and the tubes were mixed by vortexing,
before 200µl was transferred to a clear, flat bottomed, 96 well plate and the absorb-
ance was immediately read at 390nm (Fluostar Optima, BMG Labtech). The citrate
concentration was determined from the standard curve.
3.2.5.3 Proton Nuclear Magnetic Resonance (1H NMR)
1H NMR uses the nuclear magnetic resonance of hydrogen -1 nuclei (the absorption
and re-emission of a pulse of electromagnetic radiation by the hydrogen nuclei) to
generate a spectrum of peaks that vary depending on the electron environment of each
hydrogen in a molecule. From these spectral signatures molecules can be identified, and,
because the intensity of the peaks are proportional to the number of hydrogens present,
the number of molecules can be quantified when a standard of known concentration
is run. Here 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) was chosen because it is
highly water soluble and its extremely low electronegativity means its peak occurs at
much lower chemical shift than any naturally occurring molecules, so is not overlapped
by anything in the samples. Because the resonance frequency of the 1H nucleus (or
indeed any nucleus) is proportional to the magnetic field strength, it is vital that the
field strength remains stable and to facilitate this deuterium oxide (D2O) was added
to the samples. D2O resonance can be continuously detected in a different channel to
the 1H resonance because the resonance frequencies are very different, and this signal is
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used by the spectrometer to inform a feedback loop that adjusts the current accordingly
to maintain a stable field strength during the acquisition of the 1H resonance.
600µl of sample medium was added to a NMR tube with 10% vol/vol D2O (151882
lot#STB04343V, Sigma Aldrich) and 10% weight/vol DSS (DLM-32-1 lot# I-15653
Cambridge Isotope Laboratories, Inc.). Tubes were taken on wet ice directly to the
NMR facility in the Joseph Priestley Building, School of Biological and Chemical Sci-
ences, Queen Mary University of London. Data were acquired by Dr. Harold Toms with
Bruker AV600; 600 MHz using 5mm inverse/BB auto-tuning probe with Z gradient, us-
ing the software package TopSpin. The signal from the water in the media, which was
the main constituent of the samples, was suppressed, the signals Fourier transformed,
and the base line and phase were corrected, using TopSpin. Peaks were identified in
MNova Lite by comparing blank media to media containing sodium citrate, and con-
firmed by comparing to reference peaks in the human metabolome database (HMDB)
(Wishart et al., 2013).
3.2.5.4 Targeted GCMS
A collaboration was set up with the laboratory of Dr Jake Bundy at Imperial College
London. There I was shown how to derivitise the samples by Dr Sarah Davies, and a
detection method was developed with Mr. Mark Bennett.
GCMS requires the molecule(s) of interest to be volatile, thermally stable, and to
not have functional groups that can be adsorbed onto the injector. For this reason
the sample needed to be derivatised (chemically altered) to ensure reproducible peak
heights and shapes for citrate. Two derivitising agents were chosen; methoxyamine
hydrochloride, which reacts with carbonyl groups to form an oxime derivative, and n-
methyl-n-(trimethylsilyl) trifluoroacetamide (MSTFA), which replaces active hydrogens
on OH, NH or SH groups with a silyl group. In order for the MSTFA to be effective
at derivitising the molecules of interest all the water needed to be removed from the
sample, otherwise the abundance of active hydrogens in the water would make the
derivatisation of anything else very inefficient. In addition, to prevent unnecessary
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clogging of the injector, proteins also needed to be removed from the samples which
was done by precipitation with methanol. Just as with NMR, an internal standard
of known concentration (deuterated citrate at 0.1mM final concentration) was added
to each sample at the beginning of the sample preparation process so that any loss of
the sample due to problems during the sample preparation or GCMS itself could be
accounted for. To make the assay quantitative, a calibration curve of 0mM, 0.01mM,
0.05mM, 0.1mM, 0.2mM, 0.4mM, 0.6mM 0.8mM and 1mM citrate was prepared in
unconditioned culture media using sodium citrate and extracted, dried, derivatised and
run alongside the samples.
Firstly, samples were defrosted on wet ice, randomised, and then mixed by vortexing.
25μl of sample was added to an Eppendorf containing 2.5μl internal standard (1mM
d4citrate), before protein was extracted from the solution by addition of 50μl -20°C
methanol. The tubes were vortexed again and then centrifuged at 4°C for 10 minutes
at 14,000rpm and the precipitated protein pellet was discarded. The supernatants
were then transferred to deactivated glass vials (from Agilent, catalogue number 5183-
4432) and the samples were either freeze dried over night (this method was used in
early experiments until the freeze drier broke) or dried in a SpeedVac (much easier and
faster, this method was quickly adopted after the breakdown of the freeze drier) for
30 minutes at 40°C. 20μl 20mg/mL methoxyamine hydrochloride in anhydrous pyridine
was added (under a fume hood as pyridine is harmful if inhaled, swallowed, or absorbed
through the skin) and the vials were vortexed to mix, briefly centrifuged, then incubated
at 30°C for 90 minutes under 1400 rpm agitation in an Eppendorf Thermo Mixer.
After another brief centrifugation, 80μl MSTFA + 1% (vol/vol) TMCS in anhydrous
pyridine was added to each vial (again in the fume hood), the vials were vortexed and
centrifuged again and then incubated at 37°C for 30 minutes under 1400 rpm agitation
in the Eppendorf Thermo Mixer. The sample was collected in the bottom of the vial
with another brief centrifugation, then using a glass Pasteur pipette each sample was
transferred to a deactivated glass insert (Agilent catalog number 5183-2088) which was
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then replaced in the vial, so that the injector needle could reach the small sample
volume. The samples were then centrifuged once more, and carefully checked for the
presence of any precipitate, which could clog the GCMS sample injector. If there
was precipitate in the insert, the supernatant was transferred to a new insert without
disturbing the precipitate pellet at the bottom.
The GCMS was carried out in pulsed splitless mode on a Hewlett Packard HP6890
series GC system with Agilent 6890 series injector and a 30m long 250μm dimeter capil-
lary column (Agilent, model number 19091s-433HP5MS) using a flow rate of 1mL/minute,
and a Hewlett Packard 5973 Mass selective detector. The acquisition was done in either
full scan (for example in the optimisation of the method for detecting citrate, and to
trouble shoot when the spectra derived looked abnormal) or selective ion monitoring
mode (SIM). When in SIM mode the ion masses detected were: 273.0, 350.0, 465.0,
276.0, 375.0, 469.0, 347.0, and 378.0 and the dwell time for all of these ions was 50ms.
Once the spectra had been obtained, the ratio of the 4 peak heights from the most
abundant ions of citrate (at 273, 347, 375 and 465) to the corresponding ions from
deuterated citrate (at 276, 350, 378 and 469) was taken, to normalise across samples.
The concentration of citrate in the samples was calculated from the equation of the line
obtained from plotting the calibration curve.
3.2.6 Treatment of cells with lactate, 3OHB and citrate
Young growing IMR90 and NHOF1 cells were plated at a density of 5000 cells/well
in a 12 well tissue culture plate in standard DMEM containing 10% vol/vol foetal calf
serum as previously described. 24 hours later the medium was replaced with 2mL of
a mixture of DMEM and Ham’s F12 (1:1 mix), with antibiotics, glutamine and serum
added as normal, containing either 1mM citrate, 10mM lactate, 10mM 3OHB or no
treatment. The treatments were applied to triplicate wells and cells were cultured for
one month, constantly exposed to the treatments. Once one well became confluent, all
the wells were trypsinised, counted, and replated at 5000 cells/well in standard DMEM
before having the treatment re-applied 24 hours later. The cumulative mean population
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doublings were averaged across the three wells for each repeat of the experiment due to
the variable nature of manual cell counts, and plotted over time for each treatment to
compare rate of growth.
3.3 Results
3.3.1 Untargeted metabolomics screens identified candidate
biomarkers of senescence
In total, as part of this project four metabolomic screens have been performed by
Metabolon, and with each screen the quality of the data improved as the protocols were
refined. For example it became apparent that it was important to keep the cell density
to media volume ratio consistent between flasks, and that scaling down the experiments
(using flasks with an area smaller than 75cm2) led to more variable results. It was also
noticeable that in the earlier screens some of the senescent groups were not as old as
others, making it more difficult to pull out differences in the metabolome. Despite
this, even in the early experiments with lower quality data, it was evident that several
areas of cellular metabolism were altered in senescence, as shown in the random forest
analysis in figure 3.1, which was generated by Metabolon using data from PEsen and
growing NHOF1, NHOF5, Colon, BJ and IMR90 fibroblast lines.
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Figure 3.1: Random forests analysis of PEsen versus growing fibroblasts (pro-
duced by Metabolon). The y axis lists metabolites in order of importance for the
predictive model built in the ’forest’ to differentiate between conditioned media from
senescent and growing cells. The confusion matrix shows how good the predictions
made by the forest were; a 77% predictive accuracy is more than would be expected
by chance (50%)The red star and arrow highlight citrate, a metabolite in the “energy”
pathway group which ranked 5th in importance to separation of senescent and growing
extracellular profiles.
The random forest lists the metabolites in order of importance for the predictive
model built in the ’forest’ to differentiate between conditioned media from senescent
and growing cells. The confusion matrix shows how good the predictions made by the
forest were; a 77% predictive accuracy is more than would be expected by chance (50%)
so we can be reasonably confident that the metabolites selected by the random forest
are truly important in the metabolic pathways that are different in PEsen and growing
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cells.
The majority of highly important molecules suggested in this model are peptides,
lipids and amino acids, although the TCA cycle intermediate (“energy” metabolite)
citrate is also listed as highly important. However this experiment did not include the
growth arrest controls, so it’s difficult to tell if the changes detected are specific for
senescence compared to transient growth arrest.
In another screen, which focused on one cell line (NHOF1) but included the growth
arrest controls validated in the previous chapter, Metabolon used another multivari-
ate analysis technique to identify differences between experimental groups; principal
components analysis (PCA). The PCA plot Metabolon produced is shown in figure 3.2.
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Figure 3.2: Principal component analysis of metabolomic data from PEsen (labelled
senescent) growing, confluent and serum starved (labelled quiescent) NHOF1 condi-
tioned culture media. The x, y and z axis show the 1st 2nd and 3rd components The
number in square brackets represents the percentage of the total variance explained by
that component.
The PCA plot shows there is clear separation of the groups, except for the 0.1%
vol/vol serum blank and serum starved growth arrest control, which appear to be closely
related. It also appears that the confluent growth arrest control profile is the closest
to the senescent cell profile. To see if this separation was related to the molecules
identified as important across multiple fibroblast lines in the random forest analysis,
direct comparisons were made between the levels of metabolites in the groups previously
identified: peptides, lipids, amino acids and energy metabolism.
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3.3.1.1 Peptide metabolism in PEsen
The particular peptide molecules identified in the random forest were not found to be
specifically altered in the study using the growth arrest controls but other metabolites
in the same pathway were either significantly depleted or elevated (figure 3.3 and figure
3.4).
Figure 3.3: Extracellular dipeptide levels in PEsen NHOF1 and growth arrest
controls. Several dipeptides were specifically depleted in PEsen (Sen) NHOF1 relative
to growing (Gro), serum starved (Qui) and confluent (Conf) cells. The y axis on all
the graphs represents the net scaled intensity of each metabolite normalized to 1 Ö
105 cells/mL, error bars represent standard deviation from the mean. n = 3 *p<0.05,
**p<0.01 with 1 way ANOVA and Tukey’s post hoc analysis.
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Figure 3.4: Extracellular amino acid levels in PEsen NHOF1 and growth
arrest controls. Several amino acids were specifically elevated or depleted in PEsen
(Sen) NHOF1 relative to growing (Gro), serum starved (Qui) and confluent (Conf)
cells. The y axis on all the graphs represents the net scaled intensity of each metabolite
normalized to 1 Ö 105 cells/mL, error bars represent standard deviation from the mean.
n = 3 *p<0.05, **p<0.01 with 1 way ANOVA and Tukey’s post hoc analysis.
3.3.1.2 Lipid metabolism in PEsen
As with the peptides, the particular lipids highlighted by the random forest were not
found to be specifically modulated in the screen using the growth arrest controls, but
metabolites in the same pathways were specifically elevated or depleted in PEsen relative
to growth arrest controls. Figure 3.5 shows some essential fatty acids and figure 3.6
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shows some phospholipids that were specifically modulated.
Figure 3.5: Extracellular essential fatty acid levels in PEsen NHOF1 and
growth arrest controls. Several essential fatty acids were either specifically depleted
or specifically elevated in PEsen (Sen) NHOF1 relative to growing (Gro), serum starved
(Qui) and confluent (Conf) cells. The y axis on all the graphs represents the net
scaled intensity of each metabolite normalized to 1 Ö 105 cells/mL, error bars represent
standard deviation from the mean. n = 3 *p<0.05, **p<0.01 ***p<0.001 with 1 way
ANOVA and Tukey’s post hoc analysis.
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Figure 3.6: Extracellular phospholipid levels in PEsen NHOF1 and growth ar-
rest controls. Several phospholipids were specifically elevated in PEsen (Sen) NHOF1
relative to growing (Gro), serum starved (Qui) and confluent (Conf) cells. The y axis
on all the graphs represents the net scaled intensity of each metabolite normalized to 1
Ö 105 cells/mL, error bars represent standard deviation from the mean. n = 3 *p<0.05,
**p<0.01 ***p<0.001 with 1 way ANOVA and Tukey’s post hoc analysis.
3.3.1.3 Energy metabolism in PEsen
Several biochemicals involved in the central energy metabolism pathways were elevated
or depleted in the conditioned media of PEsen NHOF1 relative to growth arrest controls,
and once again a significant change in the level of citrate was detected (figure 3.7).
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Figure 3.7: Extracellular energy metabolite levels in PEsen NHOF1 and
growth arrest controls. Several energy metabolites were either specifically depleted
or specifically elevated (including citrate) in PEsen (Sen) NHOF1 relative to growing
(Gro), serum starved (Qui) and confluent (Conf) cells. The y axis on all the graphs
represents the net scaled intensity of each metabolite normalized to 1 Ö 105 cells/mL,
error bars represent standard deviation from the mean. n = 3 *p<0.05, **p<0.01
***p<0.001 with 1 way ANOVA and Tukey’s post hoc analysis.
For further insight into the metabolic state of the cells, intracellular levels of meta-
bolites involved in three key energy metabolism pathways were examined. As shown in
figures 3.8 and 3.9, intracellular levels of several metabolites of glycolysis and the PPP
were elevated compared to growing and growth arrested controls, while TCA metabol-
ites were generally depleted.
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Figure 3.8: Intracellular energy metabolite levels from the TCA cycle, glyco-
lysis and gluconeogenesis in PEsen NHOF1 and growth arrest controls. A
Intracellular levels of TCA metabolites B Glycolytic metabolites in PEsen NHOF1 and
growth arrest controls. The y axis on both graphs represents the net scaled intensity of
each metabolite normalised to 1x105 cells/mL, error bars represent standard deviation
from the mean. n = 3 ns = not significant *p<0.05, **p<0.01 ***p<0.001 with 1 way
ANOVA and Tukey’s post hoc analysis.
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Figure 3.9: Intracellular energy metabolite levels from the PPP in PEsen
NHOF1 and growth arrest controls. The y axis represents the net scaled intensity
of each metabolite normalised to 1x105 cells/mL, error bars represent standard deviation
from the mean. n = 3 ns = not significant *p<0.05, **p<0.01 ***p<0.001 with 1 way
ANOVA and Tukey’s post hoc analysis.
Adding further insight into the metabolic state of the cells, levels of intracellular
ADP were also detected (figure 3.10). Although not statistically significant, there was
a clear trend for depletion of this molecule in senescent NHOF1 compared to growth
arrest controls.
Figure 3.10: Intracellular levels of adenosine di-phosphate (ADP) in PEsen
NHOF1 and growth arrest controls. n=3 error bars represent standard deviation
from the mean NS = not significant with 1 way ANOVA.
Intracellular levels of AMP were also measured and were significantly depleted in
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PEsen cells compared to growing controls (figure 3.11).
Figure 3.11: Intracellular levels of adenosine mono-phosphate (AMP) in
PEsen NHOF1 and growth arrest controls normalised to cell number. n=3
error bars represent standard deviation from the mean NS= not significant ***p<0.001
with a 1 way ANOVA and Tukey’s post hoc analysis.
Intracellular levels of acetyl Co-A were elevated in PEsen NHOF1 and growth arrest
controls compared to growing controls, a relationship which was statistically significant
in PEsen and serum starved cells (figure 3.12).
Figure 3.12: Intracellular levels of acetyl Co-A in PEsen NHOF1 and growth
arrest controls normalised to cell number. n=3 error bars represent standard
deviation from the mean NS= not significant **p<0.01 with a 1 way ANOVA and
Tukey’s post hoc analysis
Co factors are essential for metabolic pathways to function, as they facilitate the
transfer of electrons from one molecule to the next. The intracellular levels of three key
co factors are shown in figure 3.13.
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Figure 3.13: Intracellular levels of NAD+, NADH and NADPH in PEsen
NHOF1 and growth arrest controls. A Average intracellular levels of NAD+ and
NADH in PEsen as well as serum starved and confluent growth arrest controls and
growing control NHOF1, normalised to protein. n=3 error bars represent standard
deviation from the mean. B Ratio of intracellular NAD+ to NADH measured in PEsen
as well as serum starved and confluent growth arrest controls and growing control
NHOF1, normalised to protein. n=3 error bars represent standard deviation from the
mean. NS = not significant, *p<0.05, **p<0.01 with a 1 way ANOVA and Tukey’s
post hoc analysis. C Average intracellular levels of NADPH in PEsen as well as serum
starved and confluent growth arrest controls and growing control NHOF1, normalised to
protein. n=3 error bars represent standard deviation from the mean NS= not significant
with a 1 way ANOVA.
3.3.1.4 Citrate
Because citrate was specifically picked up in repeated screens, and is involved in energy
metabolism which is known to be altered but is not yet well understood in senescence
(see section 1.2.4 on page 56) it was decided that citrate would be a good candidate
marker to focus on.
Looking at the data for citrate across multiple PEsen fibroblast cell lines there
was indeed a clear trend for citrate elevation in the PEsen cells, although it was not
statistically significant for all lines (see figure 3.14). Overall if all the lines are considered
together the increase in citrate in PEsen cells was statistically significant (figure 3.15),
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and as already shown in figure 3.7 on page 146, citrate was not elevated in transient
growth arrest.
Figure 3.14: Extracellular citrate in PEsen cells from five fibroblast lines com-
pared to growing controls. GCMS performed by Metabolon. Error bars represent
standard deviation from the mean, n=3 NS= not significant,**p<0.01 with a Student’s
T test
Figure 3.15: Average extracellular citrate in PEsen cells from five fibroblast
lines compared to growing controls. GCMS performed by Metabolon. n= 5 error
bars represent standard error of the mean, **p<0.01 Student’s T test.
An elevation of citrate was found in another untargeted metabolomics screen of
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multiple cell lines, this time in IrrDSBsen fibroblasts (figure 3.16).
Figure 3.16: Extracellular citrate in IrrDSBsen (20Gy) cells from four fibroblast
lines compared to growing controls (0Gy). GCMS performed by Metabolon. Error bars
represent standard deviation from the mean, n=3 per group. **p<0.01, ***p<0.001
with Student’s T-test.
Furthermore, citrate was not found to be elevated in cells that received 0.5Gy gamma
radiation, the control used for repairable DNA damage, as shown in figure 3.17.
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Figure 3.17: Extracellular citrate measured in IrrDSBsen NHOF1 cells with
0Gy and 0.5Gy controls. GCMS performed by Metabolon. n=3, error bars represent
standard deviation from the mean, NS= not significant, ***p<0.001 with 1 way ANOVA
and Tukey’s post hoc analysis.
3.3.1.5 Lactate
In addition to citrate, lactate was of interest as it had been reported in the literature
that it is released from senescent cells present in the tumour stroma and acts as a
metabolic fuel for cancer cells (Bonuccelli et al., 2010; Whitaker-Menezes et al., 2011).
Figure 3.18 shows the relative levels of extracellular lactate in five PEsen fibroblast
lines, and only one line (Colon fibroblasts) showed an elevation in lactate following
PEsen. When all the cell lines are combined there is no significant elevation of lactate
(figure 3.19).
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Figure 3.18: Extracellular lactate in five PEsen fibroblast lines. GCMS per-
formed by Metabolon. Error bars represent standard deviation from the mean, n=3
NS= not significant, **p<0.01 with Student’s T test.
Figure 3.19: Average extracellular lactate in 5 PEsen fibroblast lines. GCMS per-
formed by Metabolon. Error bars represent standard error of the mean, n=5 NS= not
significant with Student’s T test.
This result was confirmed in another screen of PEsen using the growth arrest controls
(shown in figure 3.20).
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Figure 3.20: Extracellular lactate in PEsen NHOF1 cells and growing, serum
starved and confluent controls. GCMS performed by Metabolon. Error bars rep-
resent standard deviation from the mean, n=3 NS= not significant, *p<0.05 with a 1
way ANOVA and Tukey’s post hock analysis.
In IrrDSBsen fibroblasts however there was an increase in extracellular lactate fol-
lowing senescence, except in NHOF1, as shown in figure 3.21, and overall across all of
the cell lines the increase was statistically significant (figure 3.22).
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Figure 3.21: Extracellular lactate measured in four IrrDSBsen (20Gy) and
growing control (0Gy) fibroblast lines. GCMS performed by Metabolon. n=3
NS= not significant, **p<0.01 ***p<0.001 with Student’s T test.
Figure 3.22: Average extracellular lactate in four IrrDSBsen fibroblast lines.
GCMS performed by Metabolon. n=12 **p<0.01 with Student’s T test
The screen that covered the 0.5Gy control for IrrDSBsen was carried out in NHOF1
only, and in accordance with the previous result there was no elevation of lactate seen
in this experiment (figure 3.23).
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Figure 3.23: Extracellular lactate measured in IrrDSBsen NHOF1 cells with
0Gy and 0.5Gy controls. GCMS performed by Metabolon. n=3, error bars represent
standard deviation from the mean NS = not significant *p<0.05 with 1 way ANOVA
and Tukey’s post hoc analysis.
3.3.1.6 Reduction-oxidation (redox) homeostasis
The untargeted screens also detected that several metabolites related to redox homeo-
stasis were specifically elevated in PEsen compared to the other groups (figure 3.24)
and while none are suitable as biomarkers of senescence, because redox homeostasis is
often affected in many pathologies, this finding could give insight into the regulation
and maintenance of the senescence phenotype.
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Figure 3.24: Gamma glutamyl redox homeostasis pathway and related meta-
bolites detected in the conditioned media of PEsen (Sen.) NHOF1 and serum
starved (Qui.) and confluent (Conf.) growth arrest controls compared to growing (Gro.)
controls. The graphs show net scaled intensity normalised to 1x105cells/mL, n=3, error
bars represent standard deviation from the mean. *p<0.05, **p<0.01, ***p<0.001 with
unpaired two ample T Test. GGT: gamma glutamyl transferase; ROS: reactive oxygen
species. Figure taken from James et al., 2015.
3.3.2 The secretome is not a product of increased biomass
The decision to normalise extracellular metabolite levels to cell number rather than
total protein content was made because the primary aim of the work was to identify a
secreted biomarker that could potentially be used to detect the presence of increased
numbers of senescent cells in an individual simply from the metabolite levels detected
in their blood serum. In that scenario, the desired result is the accurate detection
of an increased population of senescent cells, and as an increased cell size is part of
the senescence phenotype the effect the increased size has on the levels of metabolites
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secreted is irrelevant. Nevertheless, ascertaining whether the increase in extracellular
citrate is a product simply of increased overall protein content and therefore an up-
scaled citrate production, in which case the fold increase in citrate would be expected
to be similar to the fold increase in total protein, or whether it is a specific increase in
citrate independent of the increase in total protein, is usefull information for deducing
the source of increased extracellular citrate. Graph A in figure 3.25 on the following
page shows that the ratio of citrate normalised by cell number to citrate normalised by
protein in growing, serum starved and confluent cells is around 1 for both intracellular
and extracellular citrate, meaning there is hardly a difference between the levels of
citrate recorded using normalisation with either method. In PEsen cells however both
intracellular and extracellular citrate had a ratio of around 3, meaning that normalising
to cell number was giving a reading of citrate 3 times higher than if it were normalised
to protein. This effect must be due to the increased biomass of the senescent cells,
however it does not completely explain the scale of the elevation in extracellular citrate.
As shown in graph B in figure 3.25 on the next page, while the PEsen citrate scaled
intensity value when normalised to cell number is roughly 3 times greater than when
normalised to protein, it is more than 8 times greater than the scaled intensity values
of citrate in growing and growth arrested cells. The increase in extracellular citrate is
not proportional to the increase in protein content of the senescent cells. Furthermore,
when normalised to protein the levels of extracellular citrate detected were still higher
in PEsen than in growing, serum starved or confluent cells.
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Figure 3.25: Normalisation of citrate to cell number compared with normalisa-
tion to protein. A The ratio of both intracellular citrate (blue bars) and extracellular
citrate (red) citrate normalised by cell number to citrate normalised by protein. B The
scaled intensity values of extracellular citrate normalised to cell number (blue bars) and
normalised to protein (red bars) n=3 error bars represent standard deviation from the
mean.
Interestingly intracellular levels of citrate decrease in PEsen relative to controls if
citrate is normalised to protein, and appears unchanged if normalised to cell number,
as figure 3.26 on the following page shows. Whichever method is used, citrate is not
elevated inside the cell despite its accumulation outside the cell.
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Figure 3.26: Intracellular citrate levels in PEsen NHOF1 and growth arrest
controls. A Intracellular citrate normalised to protein B Intracellular citrate normal-
ised to cell number. N=3 error bar represent standard deviation from the mean NS =
not significant **p<0.01 with a 1 way ANOVA and Tukey’s post hoc analysis.
3.3.3 Targeted methods used to support findings from untar-
geted screens
Attempts to confirm the result from the Metabolon screen using an enzymatic assay
to quantify the extracellular lactate produced the opposite finding than had been seen
in the untargeted screens: lactate was elevated in PEsen but not in IrrDSBsen. There
was a trend for increased extracellular lactate in PEsen compared to young growing
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cells although the relationship was not statistically significant as shown in figure 3.27,
however when all lines were considered together lactate was significantly elevated in
PEsen (figure 3.28).
Figure 3.27: Extracellular lactate measured in four PEsen fibroblast lines
using an enzymatic assay. Error bars represent standard deviation from the mean
n= 3 NS = not significant with a Student’s T test.
Figure 3.28: Average extracellular lactate measured in four PEsen fibroblast
lines using an enzymatic assay. Error bars represent standard error of the mean
n= 4 *p<0.05 with a Student’s T test.
However the increase in extracellular lactate measured in IrrDSBsen IMR90 cells
was not statistically significant (figure 3.29 on the next page).
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Figure 3.29: Extracellular lactate in IrrDSBsen IMR90 measured by en-
zymatic assay. Error bars represent standard deviation from the mean, n=3 NS=
not significant with Student’s T test.
Attempts to use an enzymatic assay to quantify citrate were not successful. The
assay worked as demonstrated by the production of a standard curve in figure 3.30
A, however no citrate was detectable in any tests of conditioned media, and once the
background (determined from blank media) had been subtracted values were usually
negative, the opposite result to the Metabolon screen. An example of results from one
of the pilot experiments is shown in figure 3.30 B.
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Figure 3.30: Extracellular citrate in IrrDSBsen IMR90 measured using en-
zymatic assay A Standard curve from the pilot test of enzymatic citrate quantific-
ation, showing linear relationship between increasing concentration of citrate in cell
culture media and absorbance at 570nm B Pilot experiment showing extracellular cit-
rate measured in IrrDSBsen IMR90. n=1.
Attempts to detect citrate by precipitating it out of solution were also unsuccessful,
as shown in figure 3.31. In standard cell culture media that many samples had already
been collected in, the phenol red interfered with the assay and the standard curve
was not very linear (A). Removal of phenol red from the media improved the linearity
slightly (B) however the presence of lactate in the media reduced the linearity (C-D).
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Figure 3.31: Quantification of precipitated citrate A standard curve of precipit-
ated citrate in DMEM 10% (vol/vol) foetal calf serum (FCS). B a standard curve of
precipitated citrate in DMEM 10% (vol/vol) FCS without phenol red (kit recommend-
ation). C standard curve of precipitated citrate in DMEM 10% (vol/vol) FCS without
phenol red but with 4mM lactate added. D standard curve of precipitated citrate in
DMEM 10% (vol/vol) FCS without phenol red but with 30mM lactate added.
NMR initially appeared promising for detection of citrate in the conditioned media,
with a spiked in citrate standard giving peaks in an area of the spectrum not occupied
by other peaks present in unconditioned media (see figure 3.32 on the following page)
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Figure 3.32: Detection of citrate in DMEM using NMR. NMR spectra as shown
in MNova Lite from A unconditioned DMEM, red box shows where peaks from citrate
would be expected B unconditioned DMEM containing 0.1mM citrate, red box shows
the area where peaks from citrate would be expected C magnified area of spectrum
(unconditioned DMEM on the left, DMEM containing 0.1mM citrate on the right)
where peaks from citrate would be expected.
However citrate was undetectable in media from IrrDSBsen NHOF1 and IrrDSBsen
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IMR90 (example data shown in figure 3.33).
Figure 3.33: NMR of IrrDSBsen NHOF1 conditioned media. NMR spectra
as shown in MNova Lite from A unconditioned DMEM B conditioned DMEM from
IrrDSBsen NHOF1 C magnified area of spectrum where citrate would be seen.
Citrate was successfully measured using GCMS with the help of Mark Bennett and
Sarah Davies at Imperial College London. The spectra of the ions used to measure
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citrate have been plotted in figure 3.34.
Figure 3.34: Detection of citrate using GCMS. Example spectra of the ions used
to identify citrate in DMEM using GCMS.
Figure 3.35: Extracellular citrate measured in PEsen fibroblasts using GCMS.
Concentration of extracellular citrate from NHOF1 and IMR90 fibroblasts that are
senescent due to proliferative exhaustion (PEsen) compared to growing controls, and
normalised to cell number n=3 per group *p<0.05 **p<0.01 with a Student’s T Test.
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Figure 3.36: Extracellular citrate measured in IrrDSBsen fibroblasts using
GCMS. A Extracellular citrate in NHOF1 5, 10 and 20 days after irradiation with 0,
0.5Gy and 20Gy gamma. n=3 error bars represent standard deviation from the mean
NS = not significant *p<0.5 with a 1 way ANOVA and Tukey’s post hoc analysis. B
Extracellular citrate in IMR90 5, 10 and 20 days after irradiation with 0, 0.5Gy and
20Gy gamma. n=3 except for day 10 0Gy and 0.5Gy where n=2. error bars represent
standard deviation from the mean NS = not significant *p<0.5 with a 1 way ANOVA
and Tukey’s post hoc analysis
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Lactate and the ketone 3OHB had previously been reported to act as a metabolic
fuel for cancer cells (Capparelli et al., 2012); to see if these molecules or citrate had
any effect on normal fibroblast growth rates young NHOF1 cells were cultured in media
containing either lactate, citrate or 3OHB for approximately 1 month and their growth
rate was monitored. There was very little effect on growth as figure 3.37 shows.
Figure 3.37: The effect of lactate, citrate and 3OHB on cell population doub-
ling rates in NHOF1 measured by manual cell counts over approximately 30 days.
n=3.
3.4 Discussion
In this chapter we examined the secreted metabolome of senescent fibroblasts with the
aim of finding a secreted biomarker of senescence. The untargeted screens gave an
overview of the general metabolic phenotype of the different cell groups, allowing com-
parisons to be made between the profile of the senescent cells with the profiles of growing
and growth arrest controls. The untargeted screens highlighted key pathways that were
altered in the senescent models including peptide metabolism, lipid metabolism, redox
homeostasis and energy metabolism. Importantly, one molecule was consistently elev-
ated specifically in senescence (it was not elevated in the growth arrest or irradiation
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controls) over multiple screens; citrate. In order to use citrate as a marker of senes-
cence in experiments that aimed to manipulate the senescent phenotype and deduce the
mechanism behind its elevation, it was necessary to find a targeted method that was
sensitive, accurate and affordable. In this section the findings of the untargeted screens
will be examined and the methods of targeted citrate analysis tested will be discussed.
3.4.1 Comparison of growth arrest controls
While both serum starved and confluent cells were very useful for teasing out which
changes were specific for senescence rather than common to both senescence and tran-
sient growth arrest, the PCA plot in figure 3.2 on page 141 shows that the detected
profile of confluent cells was more similar to that of PEsen cells than any other group.
This suggests that confluence may be a more suitable control for PEsen than serum
starvation. The profile of serum starved cells was very similar to the unconditioned
0.1% vol/vol serum media, which could suggest the serum starved cells had very low
metabolic activity over the 24 hour collection period as it would appear that there were
not many changes in the the metabolite levels. Senescent cells however are known to
remain metabolically active, and this is supported by figure 3.2 which shows the profile
of PEsen NHOF1 cells is separate from the unconditioned 10% vol/vol DMEM.
3.4.2 Metabolomic screens confirm that several metabolic path-
ways are altered in senescence
The untargeted metabolomic screens highlighted several altered metabolic pathways
in senescent cells, as over multiple screens different molecules belonging to the same
pathway were either significantly elevated or depleted.
3.4.2.1 Peptide metabolism
The finding that multiple dipeptides, all of which are products of incomplete catabolism
of proteins, are depleted (figure 3.3 on page 142) in the conditioned media of senescent
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cells suggests that dipeptides are being taken up from the media which is interesting be-
cause it has been demonstrated that senescent cells have impaired proteosome activity,
so are unable to effectively break down proteins that have sustained severe oxidative
damage (Sitte et al., 2000). Instead of recycling or releasing energy from proteins from
within the cells, perhaps senescent cells rely on uptake of dipeptides to serve their en-
ergy needs. Although according to the Human Metabolome Database (HMDB) the
dipeptides that were elevated in this study have no known biological function other
than to be further broken down, it is possible that these dipeptides are beneficial to the
cells in other ways that have not yet been discovered, as was found for the dipeptide
carnosine. Carnosine has been shown to delay senescence through its ability to promote
protein turnover (McFarland and Holliday, 1994).
Some amino acids were elevated in the media of senescent cells, including kynurenine
(figure 3.4 on page 143). Kynurenine is a product of tryptophan metabolism and has
been associated with age related neurodegenerative diseases such as Alzheimer’s disease
(Schwarcz et al., 2012). A relationship between senescence in the brain, for example
astrocyte senescence, and neurodegeneration has been previously observed (Bhat et al.,
2012) but is not well understood. The observation that extracellular kynurenine is spe-
cifically elevated in senescence, if replicated in astrocytes could offer further mechanistic
insight into the link between senescence, ageing and neurodegenerative disease.
Overall it would appear that senescent cells have impaired proteosome activity, as
already reported (Sitte et al., 2000) but are taking up and breaking down exogenous
dipeptides, causing the observed increase in extracellular amino acids. Alternatively,
these findings could be explained by the specific secretion of protease enzymes from
senescent cells, as part of the SASP, which has been reported in the literature (Coppe´
et al., 2010a). External breakdown of the dipeptides would account for both their
depletion and the increase in amino acids, although further investigation would be
required before any conclusions could be made regarding this observation.
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3.4.2.2 Lipid metabolism
The observed elevation of glycerophoshorylcholine (GPC) in senescent cells (figure 3.6
on page 145) is in agreement with data from a study of senescent cells using NMR (Gey
and Seeger, 2013). GPC is formed from the breakdown of phosphatidylcholine and is a
major form of choline storage, so its elevation in senescence suggests choline metabolism
and phospholipid degradation is important in senescence. Overall the depletion of
essential fatty acids such as the membrane lipid linoleate combined with the apparent
degradation of phospholipids suggests there is extensive membrane catabolism occurring
in senescent cells.
Interestingly, one of the phospholipids that was specifically elevated in senescent
fibroblasts was malonate, which is a known inhibitor of succinate dehydrogenase. Suc-
cinate dehydrogenase is an enzyme involved in both the TCA cycle and complex II
of the electron transport chain, and inhibition of this enzyme could impact dramatic-
ally on the cells ability to utilise those methods of energy generation, giving weight to
the theory that senescent cells have compromised mitochondrial function and favour
glycolysis over the TCA cycle.
3.4.2.3 Redox homeostasis
The increase in gamma-glutamyl amino acids and other gamma-glutamyl pathway inter-
mediates in senescent cells (figure 3.24 on page 158) suggests that the gamma-glutamyl
pathway is active in senescence. The gamma-glutamyl pathway plays a crucial role in
redox homeostasis within cells as it is a mechanism of regenerating reduced glutathione
(GSH), a tripeptide formed of cysteine, glutamate and glycine that reduces peroxides
and mops up radicals which would otherwise cause damage to proteins, lipids and DNA.
Oxidative stress is reported to be high in senescent cells (Hubackova et al., 2012)
and is thought to be linked to mitochondrial dysfunction, which can induce senescence
(Wiley et al., 2016). It is therefore not surprising to find that oxidative defence path-
ways appear to be active. Furthermore, the senescence effector protein p53 plays an
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important role in redox homeostasis independently of senescence. At high levels p53 is
able to increase ROS by suppressing antioxidant genes such as manganese superoxide
dismutase at the promoter level (Drane et al., 2001), or by trans-activating ROS gen-
erating enzymes for example quinone oxidoreductase (Polyak et al., 1997). Conversely,
p53 can also trans-activate and up-regulate antioxidant enzymes such as glutathione
peroxidase 1 (Sablina et al., 2005). It has been proposed that by manipulating the
balance of ROS p53 is able to regulate cell fate, causing apoptosis, autophagy and
senescence (Liu et al., 2008).
The observation that the gamma-glutamyl pathway is active is in agreement with
there being high levels of ROS in the senescence models used, because it suggests there
is a demand for the reducing agent GSH. High levels of ROS could be indicative of
either low levels of p53, consistent with loss of the p53 induction and activation of
antioxidant enzymes, or high levels of p53 consistent with suppression of antioxidant
genes. Of these two options, the most likely is that there are low levels of p53 in the
senescent cells, because the levels of ROS induced in the presence of high levels of p53
often induces apoptosis, not senescence (Liu et al., 2008), and it has been established
that during the course of senescence induction and stabilisation an initial increase in
p53 activation is followed by an increase in p21WAF1 and subsequent decline in p53,
with the senescent state usually being maintained by p16INK4A (Stein et al., 1999).
3.4.2.4 Energy metabolism
One measure of the energy status of the cells is the relative level of ATP to ADP or
AMP. Although intracellular ATP was not detected in the metabolomic screen, intra-
cellular ADP levels were measured (see figure 3.10 on page 148) and did not increase in
PEsen, although they did show a slight elevation in the growth arrest controls (which
was not statistically significant). This is important because if ATP is considered the
“cellular energy currency”, ADP is effectively evidence of spent ATP (the breaking of
a phosphate bond in ATP releases energy, leaving ADP which can be recycled back to
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ATP). Having more ADP than ATP is a sign of metabolic imbalance; the cell is using
up ATP faster than it can generate it. While the ratio of ATP:ADP could not be cal-
culated here, it is reasonable to assume that as the intracellular levels of ADP in PEsen
NHOF1 were not higher than in growing controls, it is unlikely that there is a meta-
bolic imbalance in those cells. Furthermore, AMP was significantly depleted in PEsen
NHOF1 but not growth arrest controls (figure 3.11 on page 149) which contradicts
findings by Zwerschke and colleagues, who reported that senescent cells have elevated
AMP (Zwerschke et al., 2003). Both ADP and AMP activate AMP-activated protein
kinase (AMPK) when elevated, which has multiple effects on cell metabolism. AMPK
has been shown to increase glucose transport into the cell, promoting glycolysis, as well
as increasing fatty acid oxidation, mitochondrial biogenesis and autophagy, all of which
should increase ATP production to restore the balance of energy (reviewed in (Choud-
hary et al., 2014). The fact that AMP and ADP are low in PEsen cells suggests that
either adequate ATP is being generated in senescent cells or that senescent cells are not
utilising ATP. Given that the PCA analysis showed a clear separation between PEsen
and unconditioned media (figure 3.2 on page 141) it must be assumed that PEsen cells
are metabolically active, so the latter explanation can be rejected. Therefore PEsen
cells must be generating ATP, either through glycolysis coupled to the TCA cycle and
oxidative phosphorylation, or alternatively by glycolysis.
The observation that senescent cells have increased glycolytic activity but an im-
paired TCA cycle has also been recorded in a study of dermal fibroblasts. The authors
described an increase in glycolytic activity that was not matched by TCA activity com-
bined with decreased activity in the malate - aspartate shuttle, resulting in a metabolic
imbalance and a depletion of ATP (and therefore accumulation of ADP). ATP deple-
tion is known to activate nutrient sensors and promote the transcription of glycolytic
enzymes, which exacerbates the phenotype (Zwerschke et al., 2003). However, as fig-
ure 3.10 on page 148 shows, we did not find an accumulation of intracellular ADP in
senescence, in fact the opposite was observed. The growth arrest controls however did
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display an increase in intracellular ADP (figure 3.10 on page 148), indicating that while
cellular stress does induce a metabolic imbalance and a build up of ADP results, the
scenario is not not the same in established senescence.
The accumulation of the TCA cycle intermediates citrate and fumarate in the con-
ditioned media of senescent fibroblasts could support the theory that the TCA cycle
remains active in senescence. In addition the depletion of pyruvate from the media,
which is converted to acetyl Co-A before entering the TCA cycle, could be due to a
reduced level of glycolysis, because pyruvate is a product of glycolysis and its depletion
from the media indicates that more is being consumed than produced. Acetyl Co-A is
not only used in the TCA cycle however, it is also required for acetylation of proteins,
so acetyl-Co-A produced from breakdown of pyruvate is not necessarily all going into
the TCA cycle. In addition the accumulation of acetyl Co-A seen in PEsen and growth
arrested NHOF1 (figure 3.12 on page 149) could be an indication that the TCA cycle
is not functioning optimally. Another way of assessing the activity of the TCA cycle
is to look at the NAD+/NADH ratio. As figure 1.6 on page 58 illustrates, the TCA
cycle generates NADH from NAD+. and in growing cells there is a relative abundance
of NADH compared to NAD+ however in growth arrested and senescent cells NADH
levels fall, while NAD+ levels are maintained (figure 3.13 on page 150). This could also
support the case that the activity of the TCA cycle is reduced in senescence.
In contrast to the suggestion that the senescent cells could be exhibiting reduced
glycolytic activity, when data from IrrDSBsen conditioned media is taken into account
an increase in extracellular lactate is observed. Lactate is also a product of glycolysis,
and its elevation is generally associated with a glycolytic phenotype. As demonstrated in
Chapter 2, it seems likely that the phenotype exhibited by IrrDSBsen is stronger because
a higher percentage of the cells are fully senescent at the time of measurement whereas
in the PEsen experiments the percentage was much lower. It is possible therefore that
there is a gradual shift in metabolism over time as the senescent phenotype develops.
A shift away from the TCA cycle towards a more glycolytic metabolism may be due to
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declining mitochondrial function in senescence. Several studies have already shown that
mitochondrial dysfunction can induce senescence (Passos et al., 2007; Moiseeva et al.,
2009; Velarde et al., 2012; Wiley et al., 2016) and recent work by Clara Correia-Melo
and colleagues has demonstrated that mitochondrial biogenesis is necessary for much
of the senescence phenotype (Correia-Melo et al., 2016).
The data on intracellular metabolites in PEsen NHOF1 also show an increase in
several metabolites associated with PPP activity (see figure 3.8 on page 147). The
PPP (a schematic of which is shown in figure 3.38 on the following page) is a pathway
that breaks down glucose and produces ribose-5-phospahte (in the oxidative arm of the
pathway) which can be used in nucleotide metabolism, or recycled back to glucose-6-
phosphate (in the non-oxidative arm of the pathway) and re-enter the oxidative arm
of the pathway. The oxidative arm of the PPP also generates NADPH, a reducing
equivalent used in lipid synthesis as well as forming a vital part of the cells oxidative
defence by facilitating the reduction of oxidised glutathione (Winkler et al., 1986).
Interestingly, intracellular NADPH was elevated in PEsen and growth arrest controls
(see figure 3.13 on page 150) although the increase wasn’t found to be statistically
significant. When considered together with the elevation of several PPP metabolites
it does suggest that PPP activity is increased in growth arrest and particularly in
senescence. The observation that PPP activity is increased in senescent cells supports
previous suggestions that senescent cells have an active oxidative stress response.
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Figure 3.38: The pentose phosphate pathway (PPP) Blue boxes represent en-
zymes, blue text represents the intermediates in the oxidative arm of the PPP and
orange text represents intermediates in the non-oxidative arm of the PPP. Solid arrows
represent the direction of reaction and dotted arrows show where the product of one
reaction is involved at a different section of the pathway. NADP+ = nicotinamide
adenine dinucleotide phosphate NADPH = reduced nicotinamide adenine dinucleotide
phosphate
3.4.3 Extracellular citrate is specifically elevated in senescence
As well as forming part of the general energy metabolism signature of senescent cells,
citrate was the only molecule to be elevated across all of the screens with statistical
significance. It was significantly elevated relative to growth arrest controls in PEsen
NHOF1 fibroblasts (figure 3.7 on page 146), as well as being significantly elevated in
PEsen cells from other tissues relative to growing controls (figure 3.14 on page 151),
and was also significantly elevated in IrrDSBsen cells from multiple lines relative to 0Gy
controls (figure 3.16 on page 152), and in IrrDSBsen NHOF1 relative to 0.5Gy radiation
controls (figure 3.17 on page 153). Interestingly, intracellular citrate was not elevated
(figure 3.26 on page 161). This is important because citrate is known to directly inhibit
glycolysis via inhibition of phosphofructokinase (Newsholme et al., 1977), however in
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PEsen NHOF1 cells at least, intracellular citrate is not elevated compared to growing
cells (see figure 3.26 on page 161) so would not be expected to have any increased
inhibitory effect on glycolysis.
Attempts to replicate this result using enzymatic kits and precipitation were not
successful, due to interference from other molecules present in the media. NMR was
also unsuccessful, most likely due to the low total amount of citrate present in the
media as we were able to identify peaks corresponding to citrate when it was spiked
into the media, so there was not a problem with the method used. Targeted GCMS
was successfully used to detect elevated citrate in IrrDSBsen compared to 0.5Gy and
0Gy controls (figure 3.36 on page 169) and PEsen (figure 3.35 on page 168) although
the data was more variable than that acquired by Metabolon. This is probably due
to the extra variation introduced during preparation and derivitisation of the samples
as Metabolon used an automated system to extract and derivitise the samples, which
is a technically demanding process involving small volumes of liquid. Any inaccuracy
in the volumes pipetted both before drying and during the derivitisation impacts on
the calculation of the original concentration in the sample. In the targeted analysis
I manually pipetted each sample individually at all of the steps, so small errors were
more likely than in the original screens. Despite the increased variation, the method
was successful in quantifying extracellular citrate.
Citrate therefore appears to be a strong candidate for a secreted marker of senes-
cence. Indeed, a search of the literature revealed that citrate plays a role in several cell
processes reported be altered in senescence (Lee et al., 2015), and has even been linked
to ageing in humans (Menni et al., 2013).
3.4.3.1 Role of citrate in cell biology
Citrate is a tricarboxylate produced from acetyl Co-A by the enzyme citrate synthase
(CS) in the mitochondria. It is then either broken down by aconitase 2 (ACO2) in the
TCA cycle to form isocitrate, or exported from the mitochondria into the cytoplasm
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by the selective transporter SLC25A, where it can be broken down to isocitrate by
aconitase 1 (ACO1) or used by ATP citrate lyase (ACLY) to generate acetyl Co-A and
NADPH which are important for fatty acid metabolism and acetylation of proteins,
and NAD+ which is necessary for glycolysis. More citrate can be transported into the
cytoplasm from outside the cell if needed through SLC13 transporter family members
NaDC1, NaDC3 and NaCT (Gopal et al., 2007; Mycielska et al., 2009)(see figure 3.39).
Figure 3.39: Fate of citrate within the cell. Citrate is produced in mitochondria
by citrate synthase, it then either remains in the mitochondria and enters the TCA
cycle where it is broken down by aconitase 2 to isocitrate, or is transported across the
mitochondrial membrane into the cytoplasm by the SLC25A citrate carrier. Once in
the cytoplasm citrate can inhibit glycolysis via phosphofructokinase, can be converted
to isocitrate by aconitase 1, or to acetyl Co-A by ATP citrate lyase. Additional citrate
can be transported across the plasma membrane through the SLC13 family members
NaDC1, NaDC3 and NaCT (reviewed in Mycielska et al., 2009).
Citrate is present in the blood usually at around 0.1mM (Costello and Franklin,
1991), although there is not much literature on where this citrate comes from, Gopal
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suggests that it comes mainly from dietary intake, with the possibility that some cit-
rate is released from cells by an unknown mechanism (Gopal et al., 2007). In prostate
luminal epithelium however there is a known mechanism for citrate transport across
the plasma membrane from the cytoplasm to the extracellular space; an isoform of the
mitochondrial citrate transporter SLC25A which is translocated to the plasma mem-
brane (Mazurek et al., 2010). Unlike other tissues, the prostate produces large amounts
of citrate and releases it in the expressed prostatic secretion at concentrations up to
150mM, with final concentration in the seminal fluid of up to 50mM (Kavanagh, 1994).
It has been observed that incubating spermatozoa in 10mM citrate (and 10mM lactate)
increases ATP production (Medrano et al., 2006), so it is likely that these high concen-
trations of citrate act as metabolic fuel for the spermatozoa. Given that intracellular
citrate levels in senescent cells are not elevated, it seems reasonable to assume that the
extracellular elevation is due to an active process of transport across the plasma mem-
brane, possibly in the same way citrate is transported across the plasma membrane of
prostate epithelium. Although currently the only data on intracellular citrate in senes-
cent cells are part of an untargeted screen that was not quantitative, the relative levels
of intracellular citrate in senescent cells to growing cells compared with the relative level
of extracellular citrate in senescent cells to growing cells suggest that senescent cells
are not only exporting citrate while the growing cells are not but are either producing
more citrate or not breaking down citrate as readily as growing cells.
While the concentrations detected in this thesis were not as high as recorded in
the prostatic secretions, it is not known what the local concentrations surrounding
senescent cells in vivo might be. To see if lower levels of citrate or lactate were capable
of promoting proliferation in normal fibroblasts we incubated cells in media containing
either 10mM lactate, 1mM citrate or 10mM 3OHB (a molecule also previously reported
to be used as a metabolic fuel (Bonuccelli et al., 2010)) and measured the population
doubling rate. The addition of these molecules did not have a positive effect on the
growth rate of the cells, however the effect on the metabolism of the cells was not
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investigated.
3.4.4 Summary
In this chapter citrate was identified as a strong candidate for a secreted biomarker of
senescence in fibroblasts; fulfilling the primary aim of this project. The metabolomic
screens also showed that energy, lipid and protein metabolism were altered in senescent
cells as well as redox homeostasis pathways, which give insight into the overall metabolic
status of senescent cells. Taken together the data suggest that senescent cells have
increased glycolytic and PPP activity, whereas the TCA cycle appears to be less active.
This shift in metabolism may be in response to oxidative stress, as several metabolites
involved in redox homeostasis were also elevated. These data are also consistent with
reports in the literature that senescent cells have dysfunctional mitochondria (Hutter
et al., 2004; Passos et al., 2007; Ghneim and Al-Sheikh, 2010; Wiley et al., 2016), as
functioning mitochondria are necessary for the TCA cycle and OXPHOS to occur and
moreover dysfunctional mitochondria are are ineffective at neutralising ROS (Balaban
et al., 2005). In the next chapter we will discuss the experiments which were undertaken
to try and understand more about what is regulating these changes and how citrate is
involved.
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Chapter 4
Regulation of the metabolome in
senescence
4.1 Introduction
In the previous chapter the TCA cycle intermediate citrate was identified as a spe-
cific secreted marker of senescence. Several metabolic pathways were also identified as
altered in both PEsen and IrrDSBsen. In this chapter we will look more closely at
proteins that may be involved in the regulation of those pathways and therefore could
directly or indirectly influence the levels of extracellular citrate.
4.1.1 Proteins involved in glucose metabolism
Firstly, as citrate is an intermediate in the TCA cycle, and the untargeted screens
identified energy metabolism as a pathway generally altered in senescence, qPCR was
used to investigate any changes at the transcriptional level of proteins involved in the
TCA cycle and the closely related pathways glycolysis and the PPP. Enzymes directly
involved in the generation (citrate synthase (CS)) and breakdown (ACLY, ACO1 and
ACO2) of citrate were also assessed at the transcriptional level and the results confirmed
at the protein level using western blots.
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4.1.2 Proteins involved in oxidative stress response
Redox homeostasis was another pathway identified as important in differentiating between
senescent cells and growing or growth arrested controls. The metabolic pathways active
in a cell can be affected by the levels of ROS present, and furthermore ROS is known
to induce senescence. For this reason transcriptional regulation of proteins involved in
cellular oxidative stress response was examined, and levels of ROS were measured.
4.1.3 Senescence effector proteins
To determine the importance of the senescence effector proteins p16INK4A, p21WAF1 and
p53, conditioned culture media was analysed from fibroblasts lacking these proteins.
Preliminary data has also been gathered on the relationship between telomere length
and extracellular citrate levels.
4.1.4 Summary
This chapter will address the second aim of the thesis; to elucidate the mechanism
behind the elevation of citrate in senescent cells, using a combination of molecular
techniques (qPCR and western blot) and cell biology (knockout of senescence effector
proteins).
4.2 Materials and methods
4.2.1 Cell culture
Routine culture was performed using the same reagents and techniques as described in
previous chapters, although some different cell lines were used for this work. Normal
human lung fibroblasts (Loxo26) along with isogenic knockout of p53 (Loxo26 p53-/-)
and p21WAF1 (Loxo26 p21-/-) were a kind gift from John Sedivy at Brown University
USA. Gordon Peters at the Cancer Research UK London Research Institute kindly
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gave us human dermal fibroblasts homozygous for a 19 base pair deletion in exon 2 of
the CDKN2A gene that encodes p16INK4A, and so are p16INK4A-/-(Leiden) (Stott et al.,
1998).
NHOF1 cells were immortalised by Professor Ken Parkinson (Queen Mary Univer-
sity of London) by expression of TERT. To distinguish between the telomere lengthening
and non canonical functions of TERT, TERT-HA was used (TERT-HA is TERT with
a c- terminal haemaglutinin (HA) tag. TERT-HA is catalytically active but does not
lengthen telomeres (Counter et al., 1998)), and the vector control NHOF1 pBabe Puro
was also created. The vectors were provided by Professor Robert Weinberg (Massachu-
setts Institute of Technology).
4.2.2 Measurement of reactive oxygen species (ROS)
1x105 adherent cells were incubated for 1 hour with 1μM H2DCFDA (2’,7’-dichlorofluoroscin
diacetate, catalog number 287810 from Calbiochem) in DMEM containing 10% vol/vol
FBS. After trypsinisation as described previously, the cell suspension was centrifuged at
1000rpm for 5 minutes. The cell pellet then was re-suspended in 500μl 1xPBS at 37°C
and the suspension was transferred to FACS tubes with 1µl of DAPI added to enable cell
viability counts. With the help of Dr Gary Warnes at the Blizard Flow Cytometry Core
Facility, a Beckton Dickinson BD LSRII flow cytometer was used to detect cells that
had sufficient ROS to oxidise the non-fluorescent product of H2DCFDA to the fluores-
cent 2’, 7’ –dichlorofluorescein (DCF). DCF has excitation and emission spectra of 495
nm and 529 nm respectively. As a positive control, cells treated with 1mM Tert-butyl-
hydroperoxide (Luperox TBHP solution, 458139 lot#BCBG4467V Sigma Aldrich) for
2 hours were used, with or without recovery time prior to the assay and as a negative
control, cells treated with the antioxidant PBN (N-tert-butyl-α-phenylnitrone B7263,
Sigma Aldrich) at 1mM in DMEM containing 10% vol/vol FBS for 1 or 2 hours before
assay were used. Non-viable cells as determined by DAPI staining were excluded from
the counts, and cells within the gates of viable and positive for DCF were compared to
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cells within the gates of viable but negative for DCF.
4.2.3 qPCR of transcripts involved in energy metabolism and
oxidative stress response
4.2.3.1 RNA extraction
RNA was extracted using the RNeasy Mini Kit (Qiagen catalog number 74104).
The cell pellet of approximately 5x105 – 1x106 cells was thawed on wet ice, lysed as per
Qiagen recommendations in 350µl RLT buffer containing 1% vol/vol β-Mercaptoethanol,
and homogenised using a QIAshredder spin column (Qiagen catalog number 79654).
Total RNA was extracted using ethanol precipitation onto columns followed by elution
in 30µl RNAse free water. Eluted material was re-incubated for 1 minute on the column
before being spun off, to maximise the RNA yield.
4.2.3.2 RNA quantification and quality assessment
RNA was diluted 1:4 in Tris-EDTA (TE) pH 8.0 (5µl RNA + 15µl TE) and using
a Nanodrop 1000 UV with a blank of 5µl RNAse free water + 15µl TE pH 8.0, the
absorbance values at 260nm, 230nm and 280nm were recorded. The 260/280nm ratio
and 260/230nm ratios were recorded to make sure that both values were close to 2.0
and that there was a single peak at 260nm., to ensure that the RNA was not contam-
inated with proteins, chaotropic salts or phenol. The Nanodrop 1000 calculated the
concentration of RNA from the absorbance of UV light using the Beer- Lambert Law.
4.2.3.3 Complimentary DNA (cDNA) generation
cDNA was generated from mRNA using the RT2 First Strand Kit (from Qiagen,
catalog number 330401) with on column DNAse digestion for 20 minutes at room tem-
perature (RNAse free DNAse Set, Qiagen catalog number 79254). 400ng RNA was used
per reverse transcription reaction, as per kit instructions. The reactions were carried
out in duplicate or triplicate at 42°C for 15 minutes, and to stop the reaction the tem-
perature was increased to 95°C for 5 minutes before the tubes were removed and put
directly onto ice. All of the incubations were carried out in a PCR block (Venti 96 well
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Thermal Cycler, Applied Biosystems).
4.2.3.4 qPCR arrays
384 (4 x 96) well array plates containing 4 replicate primer assays for each of 84
pathway-focused genes (Human Glucose Metabolism PAHS-006Z, SA Biosciences and
Human Oxidative Stress PAHS-065Z, SA Biosciences) were used as well as 4 replicate
primer assays for each of 5 housekeeping genes, 4 wells containing genomic DNA con-
trols, 12 wells containing reverse-transcription controls, and 12 wells containing positive
PCR controls. cDNA was mixed with Sybr Green Mastermix (Roche) and added to the
plates using EZLoad covers; cDNA from senescent and matching young control cells
from both IMR90 and NHOF1 were run together on each plate. Real Time PCR was
carried out using the Roche LightCycler 480; 1 cycle of 10 minutes at 95°C to activate
HotStart DNA polymerase, with 45 cycles of 15 seconds at 95°C and 1 minute at 60°C
for data acquisition. Quantification of threshold crossing (CT) was done using the Light
Cycler 480 Second Derivative Max. Analysis of the fold up or down regulation of genes
was performed using the Excel-based PCR Array Data Analysis Templates for 384-well
arrays (available for download from www.SABiosciences.com/pcrarraydataanalysis.php.),
using the most stable housekeeping genes for normalisation (minimum of 2 used). 3 bio-
logical repeats were quantified in this way. A full list of genes for the Human Glucose
Metabolism array and Human oxidative stress array along with a brief description of
their functions can be seen in appendix A on page 270 and appendix B on page 285
respectively.
4.2.3.5 Western blot of PDK4, ACO1, ACO2 and ACLY.
Western blots were performed as described previously in Chapter 3 section 2.2.6 on
page 96. The primary antibody targeting PDK4 (mouse monoclonal [ICBG5] ab110336
from Abcam UK), ACO1 (rabbit monoclonal [EPR7225] ab126595 from Abcam, UK),
ACO2 (rabbit polyclonal ab71440 from Abcam, UK) or ACLY (rabbit polyclonal #4332
from Cell Signalling) was diluted 1:1000 in blocking buffer, and incubated with the
membrane overnight at 4°C, under gentle agitation. The next day the membranes were
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washed three times in TBS-T, 5 minutes per wash on a medium speed rocker, prior to
incubation with secondary antibody (goat polyclonal anti-mouse IgG HRP conjugated
ab6789 from Abcam UK, at a dilution of 1:5000, or goat polyclonal anti-rabbit IgG
HRP conjugated, from Thermo Fisher Scientific, USA and 1:10,000) for 1 hour at room
temperature with gentle agitation. A final set of washes in TBS-T were performed
and the protein bands were visualised using an enhanced chemiluminescent substrate
of HRP (Pierce ECL Western Blotting Substrate) as previously described. In the case
of PDK4, which has a molecular weight of 47kDa very similar to that of β-actin, the
membrane had to be stripped using mild stripping buffer (15g glycine, 1g SDS, 10mL
Tween-20 adjusted to pH2.2 and brought to 1L with ultrapure water). Membranes
were incubated in stripping buffer for 10 minutes with gentle agitation before being
washed twice with PBS for 10 minutes each, then twice with TBS-T for 10 minutes
each. The success of the stripping process was checked by applying HRP substrate
and exposing the membrane to film for longer than the longest exposure time used to
detect the first primary antibody, and developing it. If bands were visible the stripping
process was repeated. If no bands were visible the membranes were then incubated in
blocking buffer for 30 minutes before addition of primary rabbit anti-β-actin antibody
as previously described in section 2.2.6 on page 96.
4.3 Results
4.3.1 Glucose metabolism
As some of the data from the metabolomic screen regarding the TCA metabolites was
difficult to interpret (the elevation of citrate and fumarate in the media suggested the
TCA cycle was active however intracellularly the levels of these metabolites was not
elevated) a qPCR array was used to interrogate the mRNA levels of transcripts relevant
to energy metabolism pathways. A list of all the genes assessed in the array and can
be seen in appendix A.
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Many genes coding proteins that had a role in glycolysis were significantly elevated
in PEsen fibroblasts relative to growing controls, however in some cases there were quite
dramatic cell type specific differences (see figure 4.1). For example the transcript for
phosphoenolpyruvate carboxykinase 2 (PCK2) was down-regulated in PEsen NHOF1
but up-regulated in PEsen IMR90.
Figure 4.1: Fold up/down regulation of genes involved in glycolysis regulation
in PEsen fibroblasts. Bars represent fold up/down regulation of genes in PEsen
fibroblasts that were identified as being statistically significant from growing controls
using a Student’s T Test. n=3 error bars represent standard deviation from the mean.
Similarly, there were a number of genes relating to the TCA cycle that were signi-
ficantly up-regulated in PEsen, although again in some cases the opposite result was
seen in NHOF1 and IMR90 (figure 4.2).
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Figure 4.2: Fold up/down regulation of genes involved in TCA cycle regulation
in PEsen fibroblasts. Bars represent fold up/down regulation of genes in PEsen
fibroblasts that were identified as being statistically significant from growing controls
using a Student’s T Test. n=3 error bars represent standard deviation from the mean.
Some genes involved in the PPP were also significantly altered in PEsen fibroblasts,
although only phosphoribosyl pyrophosphate synthetase 1 (PRPS1) in IMR90 showed
a fold change larger than 2 (figure 4.3).
Figure 4.3: Fold up/down regulation of genes involved in PPP regulation
in PEsen fibroblasts. Bars represent fold up/down regulation of genes in PEsen
fibroblasts that were identified as being statistically significant from growing controls
using a Student’s T Test. n=3 error bars represent standard deviation from the mean.
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As previous chapters have demonstrated, the IrrDSBsen model of senescence rep-
resents a more extreme phenotype than PEsen, so a more dramatic set of changes were
expected at the transcriptional level in IrrDSBsen cells. In fact the difference was not
very dramatic, except in the case of PDK4 which in IrrDSBsen was up-regulated by
nearly 60 fold in IMR90 (figure 4.4) compared to an up-regulation of around 5 fold
in PEsen. Generally the trend for up or down regulation of a certain gene was the
same in both PEsen and IrrDSBsen, with a few exceptions in the genes associated with
glycolysis; for example hexokinase 2 (HK2) was down-regulated in PEsen IMR90 but
up-regulated in IrrDSBsen IMR90, although in PEsen the down-regulation was less
than 2 fold, so not very substantial. In some cases fold up/down regulation of specific
genes was not available for one or other of the senescence models because the quality
of the data was not good enough, so some of the genes shown in the PEsen graphs are
not found in the IrrDSBsen graphs for the same pathway and vice versa.
Figure 4.4: Fold up/down regulation of genes involved in glycolysis regulation
in IrrDSBsen fibroblasts. Bars represent fold up/down regulation of genes in PEsen
fibroblasts that were identified as being statistically significant from growing controls
using a Student’s T Test. n=3 error bars represent standard deviation from the mean.
The fold up/down regulation of genes involved in the TCA cycle was not remarkable
even in IrrDSBsen (figure 4.5), and there were no contradictions regarding whether a
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gene was up or down regulated between IrrDSBsen and PEsen.
Figure 4.5: Fold up/down regulation of genes involved in TCA cycle regulation
in IrrDSBsen fibroblasts. Bars represent fold up/down regulation of genes in PEsen
fibroblasts that were identified as being statistically significant from growing controls
using a Student’s T Test. n=3 error bars represent standard deviation from the mean.
The PPP also did not show large fold changes in IrrDSBsen fibroblasts (figure 4.6)
and many of the fold changes that were statistically significant were in the opposite
direction to those shown in PEsen.
Figure 4.6: Fold up/down regulation of genes involved in PPP regulation in
IrrDSBsen fibroblasts. Bars represent fold up/down regulation of genes in PEsen
fibroblasts that were identified as being statistically significant from growing controls
using a Student’s T Test. n=3 error bars represent standard deviation from the mean.
When considering only genes with an up or down regulation of 2 fold or more in
either IMR90 or NHOF1 fibroblasts, it becomes clear that at the transcriptional level
senescence has no measurable effect on genes relating to the TCA cycle, but there are
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several genes involved in glycolysis that are altered at the transcriptional level in both
PEsen and IrrDSBsen senescence, as shown in figure 4.7.
Figure 4.7: Total number of detected transcriptional changes in glycolysis compared to
TCA cycle, in both IrrDSBsen and PEsen. Genes up or down regulated by 2 fold or
more in either NHOF1, IMR90 or both lines were counted. n=3 per gene per cell line
per senescence group. Statistical significance determined using a Student’s T Test.
The gene with the largest fold change was PDK4. To see if this up regulation at
the transcriptional level resulted in an increase at the protein level, and also to include
growth arrest controls that it was not possible to run the qPCR, a western blot was
performed on the lysates of growing, PEsen and growth arrested NHOF1 (figure 4.8) and
IMR90 (figure 4.9). PDK4 protein was not elevated in PEsen in either line, although
in IMR90 it was significantly elevated in confluent controls.
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Figure 4.8: PDK4 protein levels in PEsen NHOF1 and growth arrest con-
trols. A Representative western blot of PDK4 protein in PEsen NHOF1 cells as well
as growing (Gr), serum starved (LS) and confluent (Con) controls, with β-actin loading
control. B Average PDK4 protein level in PEsen NHOF1 and controls as in A, quan-
tified relative to HeLa. Error bars represent standard deviation from the mean, n=3
NS= not significant with a 1 way ANOVA and Tukey’s post hoc analysis.
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Figure 4.9: PDK4 protein levels in PEsen IMR90 and growth arrest controls.
A Representative western blot of PDK4 protein in PEsen IMR90 cells as well as growing
(Gr), serum starved (LS) and confluent (Con) controls, with β-actin loading control. B
Average PDK4 protein level in PEsen IMR90 and controls as in A, quantified relative
to HeLa. Error bars represent standard deviation from the mean, n=3 *p<0.05 with a
1 way ANOVA and Tukey’s post hoc analysis.
In IrrDSBsen NHOF1 PDK4 was not detected, however in IrrDSBsen IMR90 there
was a trend for PDK4 elevation that was not statistically significant (see figure 4.10).
In NHOF1 it appears there could have been protein degradation in the 20Gy samples
across all time points, or a miss calculation of protein content leading to under-loading
of the gel for those groups.
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Figure 4.10: PDK4 protein levels in IrrDSBsen NHOF1 and IMR90. A rep-
resentative western blot of PDK4 protein in NHOF1 and IMR90 fibroblasts 5, 10 and
20 days following 0Gy, 0.5Gy and 20Gy gamma radiation, with β-actin loading control.
Because PDK4 and β-actin have the same molecular weight, the membrane was stripped
to remove primary and secondary antibodies in between probing for each protein. The
membrane was incubated with HRP substrate and exposed for to film for 15 minutes
(post strip membrane) to ensure the strip was successful before the next primary (which
was a different species to the first primary) to make sure that the signal detected with
the second antbody was not contaminated by residual binding from the first primary
antibody. B Average PDK4 protein levels in IrrDSBsen (20Gy) IMR90 and 0Gy and
0.5Gy controls 5, 10 and 20 days after gamma radiation relative to HeLa. n=3 error
bars represent stadar deviation from the mean, NS = not significant with a 1 way AN-
OVA. No PDK4 was reliably detected in NHOF1 cell so densitometric analysis was not
done.
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4.3.2 Regulation of citrate
To assess the transcriptional regulation of enzymes that could potentially affect the
accumulation of citrate observed in the previous chapter qPCR was used to measure
the fold up or down regulation of genes coding for the enzymes ACLY, ACO1, ACO2
and CS. None of the genes had a fold change over 2 (figure 4.11).
Figure 4.11: Fold up/ down regulation of genes directly involved in citrate
metabolism (ACLY, ACO1, ACO2 and CS) in IrrDSBsen and PEsen NHOF1 and
IMR90 fibroblasts relative to growing controls. n= 3. Green line marks 2 fold up/down
regulation threshold, less than 2 fold change is considered not changed.
In case there was a post transcriptional modification that could cause there to be a
difference in citrate related enzymes at the protein level in senescent fibroblasts, western
blots were performed. In both NHOF1 and IMR90 there was no significant change in
protein level of ACLY, ACO1 or ACO2 (figures 4.12 and 4.13).
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Figure 4.12: ACLY protein levels in PEsen NHOF1 and IMR90 as well as
growing and growth arrest controls. A Representative western blot of ACLY
protein in PEsen NHOF1 and IMR90 cells as well as growing (Gr), serum starved (LS)
and confluent (Con) controls, with β-actin loading control. B Average ACLY protein
level in PEsen NHOF1 and IMR90 and controls as in A, quantified relative to HeLa.
Error bars represent standard deviation from the mean, n=3 NS= not significant with
a 1 way ANOVA.
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Figure 4.13: Aconitase 1 (ACO1) and aconitase 2 (ACO2) protein levels in
PEsen NHOF1 and IMR90 as well as growing and growth arrest controls. A
Representative western blot of ACO1 protein in PEsen NHOF1 and IMR90 cells as well
as growing (Gr), serum starved (LS) and confluent (Con) controls, with β-actin loading
control. B Average ACO1 protein level in PEsen NHOF1 and IMR90 and controls as in
A, quantified relative to HeLa. Error bars represent standard deviation from the mean,
n=3 NS= not significant with a 1 way ANOVA. C Representative western blot of ACO2
protein in PEsen NHOF1 and IMR90 cells as well as growing (Gr), serum starved (LS)
and confluent (Con) controls, with β-actin loading control. D Average ACO1 protein
level in PEsen NHOF1 and IMR90 and controls as in C, quantified relative to HeLa.
Error bars represent standard deviation from the mean, n=3 NS= not significant with
a 1 way ANOVA.
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In IrrDSBsen there was also not a significant difference in the levels of ACLY for
NHOF1 or IMR90, however IMR90 had more ACLY relative to HeLa than NHOF1 did
after 20 days regardless of treatment (figure 4.14).
Figure 4.14: ACLY protein levels in NHOF1 and IMR90 5, 10 and 20 days
after exposure to 0Gy, 0.5Gy and 20Gy gamma radiation. A Representative
western blot of ACLY protein in IrrDSBsen (20Gy) NHOF1 and IMR90 cells as well
growing (0Gy) and repairable DNA damage (0.5Gy) controls, 5, 10 and 20 days after
radiation, with β-actin loading control. B Average ACLY protein level in IrrDSBsen
NHOF1 and IMR90 and controls as in A, quantified relative to HeLa. Error bars
represent standard deviation from the mean, n=3 except in the case of IMR90 day 10
0Gy and 0.5Gy which are n=2
Similarly IrrDSBsen NHOF1 and IMR90 did not elevate ACO1 or ACO2 protein
levels relative to 0Gy controls, but the protein level of ACO1 in IMR90 was higher
relative to NHOF1, regardless of treatment (figures 4.15 and 4.16).
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Figure 4.15: Aconitase 1 (ACO1) protein levels in NHOF1 and IMR90 5, 10
and 20 days after exposure to 0Gy, 0.5Gy and 20Gy gamma radiation. A
Representative western blots of ACO1 protein in IrrDSBsen (20Gy) NHOF1 and IMR90
cells as well growing (0Gy) and repairable DNA damage (0.5Gy) controls, 5, 10 and
20 days after radiation, with β-actin loading control. B Average ACO1 protein level
in PEsen NHOF1 and IMR90 and controls as in A, quantified relative to HeLa. Error
bars represent standard deviation from the mean, n=3 except in the case of IMR90 day
10 0Gy and 0.5Gy which are n=2.
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Figure 4.16: Aconitase 2 (ACO2) protein levels in NHOF1 and IMR90 5, 10
and 20 days after exposure to 0Gy, 0.5Gy and 20Gy gamma radiation. A
Representative western blots of ACO2 protein in IrrDSBsen (20Gy) NHOF1 and IMR90
cells as well growing (0Gy) and repairable DNA damage (0.5Gy) controls, 5, 10 and
20 days after radiation, with β-actin loading control. B Average ACO2 protein level
in PEsen NHOF1 and IMR90 and controls as in A, quantified relative to HeLa. Error
bars represent standard deviation from the mean, n=3 except in the case of IMR90 day
10 0Gy and 0.5Gy which are n=2.
4.3.2.1 p53 restrains extracellular citrate
To see if p53 or the down stream senescence effector p21WAF1 are involved in the regula-
tion of citrate production or release from senescent cells, extracellular citrate levels were
measured using targeted GCMS of the conditioned media from isogenic lung fibroblasts
with knock out of p53 and p21WAF1. The cells lacking p53 show elevated extracellu-
lar citrate, although none of the cells expressed an increased senescence phenotype as
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demonstrated by SAβ-gal staining (figure 4.17). There was no significant difference
between extracellular citrate in p16INK4A-/- cells and controls (figure 4.18).
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Figure 4.17: Extracellular citrate in Loxo26 fibroblasts and isogenic p53-/- and
p21WAF1-/- controls. A Extracellular citrate in Loxo26 fibroblasts and isogenic p53-/-
and p21WAF1-/- controls measured using targeted GCMS and normalised to cell count.
N=3, error bars represent standard deviation from the mean, NS = not significant,
*p<0.05, **p<0.01 with a 1 way ANOVA and Tukey’s post hoc analysis. B SAβ-
gal scores for Loxo26 and the isogenic p53-/-, p21WAF1-/- populations used for citrate
quantification. IMR90 49.6mpd is a PEsen positive control for the SAβ-gal assay. n=3,
error bars represent standard deviation from the mean, NS = not significant with a 1
way ANOVA.
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Figure 4.18: Extracellular citrate in dermal fibroblasts lacking
p16INK4A(Leiden) and dermal normal fibroblasts (HFF) measured using GCMS.
n=3 error bars represent standard deviation from the mean NS= not significant with
a Student’s t Test.
4.3.3 Oxidative stress response
Because redox homeostasis pathways are closely associated with senescence and the
metabolomic screens suggested there was an oxidative stress response active in the sen-
escent cells, and also because p53 (which restrains citrate (figure 4.17)) is known to
regulate ROS (Liu et al., 2008), a qPCR array was used to assess the transcriptional
regulation of some key oxidative stress response genes in PEsen and IrrDSBsen. All
of the fold changes that were statistically significant were in the direction of up regu-
lation, and NOX5, PNRP, PTGS1, PTGS2, SFTPD and SOD3 were all consistently
up-regulated in both lines in both PEsen and IrrDSBsen (figure 4.19).
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Figure 4.19: Fold up/down regulation of genes involved in oxidative stress
response in PEsen and IrrDSBsen fibroblasts. A Fold up/down regulation of
genes involved in oxidative stress response in PEsen NHOF1 and IMR90 fibroblasts that
were identified as being statistically significant from growing controls using a Student’s
T Test. n=3 error bars represent standard deviation from the mean. B Fold up/down
regulation of genes involved in oxidative stress response in IrrDSBsen NHOF1 and
IMR90 fibroblasts that were identified as being statistically significant from growing
controls using a Student’s T Test. n=3 error bars represent standard deviation from
the mean.
A breakdown of the types of proteins affected most by these transcriptional changes
can be seen in figure 4.20 on the next page.
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Figure 4.20: Total number of detected transcriptional changes in genes for
proteins involved in reducing reactive oxygen species in PEsen and IrrDSB-
sen fibroblasts. Total number of detected transcriptional changes in genes for proteins
involved in reducing reactive oxygen species damage in mitochondria, the cytosol, spe-
cifically in the glutathione pathway, in lipids and membranes and which are secreted
from the cell in A PEsen and B IrrDSBsen. Genes up or down regulated by 2 fold or
more in senescent compared to growing controls in either NHOF1, IMR90 or both lines
were counted. n=3 per gene per cell line per senescence group. Statistical significance
determined using a Student’s T Test.
A DCF assay demonstrated that the levels of hydrogen peroxide in PEsen NHOF1
were elevated compared to growing controls however in IMR90 that was not the case,
as shown in figure 4.21.
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Figure 4.21: Reactive oxygen species levels in PEsen and IrrDSBsen NHOF1
and IMR90 fibroblasts determined by DCF intensity using a flow cytometer. n = 2.
To see if there was a link between senescence effector proteins and ROS the DCF
assay was applied to fibroblasts lacking either p16INK4A, p53 or p21WAF1 along with
matched controls. The assay revealed that cells lacking p16INK4A or p53 had elevated
levels of ROS compared to controls, but that loss of p21WAF1 did not have a significant
effect on ROS levels (figure 4.22).
Figure 4.22: Reactive oxygen species levels in fibroblasts lacking senescence
effector proteins p16INK4A(Leiden p16-/-), p21WAF1 (Loxo26 p21-/-) and p53
(Loxo26 p53-/-), compared with either tissue matched controls (BJ dermal fibroblasts
as a control for Leiden dermal fibroblasts) or isogenic controls (Loxo26 lung fibroblasts
as a control for p21WAF1 and p53 knockout lung fibroblasts) determined by DCF in-
tensity using a flow cytometer. n = 3, error bars represent standard deviation from the
mean NS = not significant, **p<0.01 ***p<0.001 with a Student’s T Test.
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To examine the role of telomere length on the level of extracellular citrate, targeted
GCMS was used to measure the extracellular citrate present in the conditioned media
from NHOF1 cells expressing enzymatically active telomerase (NHOF1 TERT), or ex-
pressing telomerase lacking a key function necessary for lengthening telomeres (NHOF1
TERT HA), compared to the extracellular citrate in NHOF1 containing the vector con-
trol (NHOF1 puro). Collections of conditioned media were made after NHOF1 TERT
HA and NHOF1 puro cell populations showed signs of PEsen. Preliminary results
shown in figure 4.23 suggest that cells expressing TERT but not TERT HA do not have
elevated extracellular citrate despite completing more population doublings than TERT
HA and vector control cells were able to complete before ceasing to divide.
Figure 4.23: Extracellular citrate in telomerised NHOF1 fibroblasts with te-
lomerase (NHOF1 TERT) at +55.3mpd, telomerase lacking telomere lengthening activ-
ity (TERT HA) at +17.8mpd compared to vector control (NHOF1 puro) at +9.9mpd
measured using targeted GCMS n=1. The graph on the right shows the corresponding
SAβ-gal scores for the cell populations used for citrate quantification. n=3 error bars
represent standard deviation from the mean, NS= not significant, **p<0.01 with a 1
way ANOVA and Tukey’s post hoc analysis.
4.4 Discussion
The aim of this chapter was to shed light on the mechanisms behind the elevation of
citrate in the conditioned media of senescent cells and add further detail to the general
metabolic state of senescent cells which was described in the previous chapter.
Firstly the transcriptional regulation of glucose metabolism (one of the pathways
implicated in the metabolomic screen) was assessed using qPCR, this included enzymes
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that directly regulate citrate, and key results were confirmed at the protein level using
western blots. The impact of p53, p21WAF1 and p16INK4A on levels of extracellular citrate
were investigated using knock-out fibroblasts lines. The transcriptional regulation of
redox homeostasis pathways (another of the pathways implicated in the metabolomic
screen) was also assessed using qPCR and the levels of ROS in senescent cells were
measured. Finally telomerised cells were used to assess the importance of telomere
attrition to the accumulation of extracellular citrate in senescence.
The data described in this chapter helped to clarify the findings from the metabolo-
mic screen and were also informative regarding the route of citrate elevation, although
further work is required to determine the mechanism.
4.4.1 Regulation of energy metabolism in senescent fibroblasts
Firstly, transcriptional regulation of the pathways involved in energy metabolism was
assessed because citrate is an intermediate in the TCA cycle, so its elevation might
be explained by an increase or decrease in transcription of vital proteins in the TCA
cycle or associated pathways. Furthermore the intracellular metabolic profile of NHOF1
suggested that senescent cells are glycolytic, an aspect of the phenotype that may be
regulated at the transcriptional level.
qPCR analysis of a panel of transcripts of genes coding proteins involved in glyco-
lysis, the TCA cycle and the PPP revealed that most of the transcriptional changes in
energy metabolism during senescence were occurring in glycolytic enzymes. As figure 4.7
on page 193 shows, there were no fold up or down regulation changes in TCA cycle genes
that were greater than two fold, whereas there were several statistically significant up
and down regulations over 2 fold in glycolytic enzymes. The number of genes with a fold
up regulation in glycolytic enzymes was still quite low (5 genes), but the one with the
largest up regulation was pyruvate dehydrogenase kinase 4 (PDK4), a key gatekeeper
enzyme. PDK4 is induced by metabolic stress such as starvation or glucose depriva-
tion (Wu et al., 2000) and fatty acid flux (Abbot et al., 2005; Nahle´ et al., 2008), and
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regulates TCA cycle activity by inhibiting the pyruvate dehydrogenase complex (PDH)
(Sugden and Holness, 2003), therefore preventing the conversion of pyruvate to acetyl
co-A and lowering flux through the TCA cycle. An increase in this enzyme suggests
that metabolism is being diverted away from the TCA cycle, supporting the intracellu-
lar metabolomic screen data which found increased glycolytic and PPP intermediates
(figure 3.8 on page 147).
When PDK4 protein levels were investigated using western blot however, there was
not a significant increase in PDK4 protein in PEsen or IrrDSBsen (figures 4.8, 4.9
and 4.10), although there was a non significant increase in IrrDSBsen IMR90 cells.
Interestingly there was a significant increase in PDK4 protein in confluent IMR90,
which could suggest that elevation in PDK4 and possibly diversion of metabolic flux
away from the TCA cycle is more strongly associated with the cell dealing with the stress
that induces the senescence rather than the actual senescence growth arrest itself.
Nevertheless, there did appear to be a glycolytic phenotype when considering the
untargeted metabolomic screen data, that was distinct from the metabolic phenotype of
the growth arrest controls, the fact that this difference in profiles is not fully explained
by changes at the transcriptional level means there must be an involvement of post
transcriptional changes.
A more detailed picture of the extent to which senescent cells use glycolysis, the
TCA cycle and the PPP could be achieved with flux experiments. By replacing some
of the glucose (or other substrates such as pyruvate or glutamine) in the culture media
with glucose containing a stable heavy carbon isotope (13C) and taking samples of cells
for metabolite extraction at multiple time points starting immediately after addition of
the media, the uptake and breakdown of the labelled glucose could be tracked along with
the fate of the heavy carbon. The accumulation of heavy carbon in a particular pool of
metabolites would enable the identification of the most active metabolic pathways.
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4.4.2 Transcriptional regulation of enzymes directly involved
in citrate metabolism
As an increase in extracellular citrate had been observed in senescent cells, it was ex-
pected that there would either be an increase in the production of citrate or a reduction
in its breakdown. It had been previously reported in the literature that CS activity
declines in senescence (Ghneim and Al-Sheikh, 2010), so a decrease in the enzymes that
break down citrate (ACO1, ACO2 and ACLY) seemed most likely. It was surprising
to find that there were no changes at the transcriptional level of the enzymes ACO1,
ACO2 or ACLY (figure 4.11 on page 197), and no detectable changes in their protein
levels either (figures 4.12 on page 198, 4.13 on page 199, 4.14 on page 200 and 4.15 on
page 201).
These observations do not rule out the possibility that the enzyme activity is af-
fected, and attempts were made to measure the activity of both ACO1 (in the cyto-
plasm) and ACO2 (in the mitochondria) in senescent fibroblasts. Unfortunately these
attempts were not successful, due to incomplete separation of the mitochondrial and
cytoplasmic cell fractions prior to running the assay. The protocol required a large
number of cells and it was not possible to optimise the experiment in the time frame
of this project. ACLYlyase, the other enzyme investigated that breaks down citrate,
has previously been linked to senescence. Knock-down of ACLY has been shown to
induce senescence, and in rat and human dermal fibroblast (HDF) cells ACLY protein
levels were shown to be reduced (Lee et al., 2015), contrary to findings in this thesis.
Unfortunately there was no time to measure ACLY activity, which can be measured
indirectly by measuring the optical density change caused by oxaloacetate (a product of
the reaction catalysed by ACLY in which citrate is broken down) reaction with NADH
in the presence of excess malate dehydrogenase (Srere, 1959).
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4.4.3 Post translational modification of enzyme activity
Attempts were also made to find evidence of post-translational modifications that could
cause a reduction in enzymatic activity. 4-hydroxynonenal (4HNE) residues can form
on proteins and affect their function following oxidative damage to lipids (Uchida and
Stadtman, 1992), so an antibody targeting 4HNE was used on western blot membranes
in an attempt to compare total 4HNE levels in senescent and growing fibroblasts, how-
ever this avenue of investigation was not pursued because the signal was extremely
variable and a suitable positive control had not been characterised.
Although there was not time to properly optimise the measurement of ACO1 and
ACO2 activity in this thesis, it has been reported that human prostate, the only tissue
known to produce citrate in large volumes and export it out of the cell, has a reduced
capacity to oxidise citrate due to rate limiting ACO2 (mitochondrial aconitase) activity,
despite the protein levels remaining normal. This has been attributed to inhibition
by zinc, which is present in high concentrations in prostate mitochondria (Costello
and Franklin, 1981). Zinc accumulation in prostate is known to be due to hormonal
regulation (Costello and Franklin, 1994), so it would be surprising if the in vitro results
reported in this thesis were also due to specific inhibition of ACO2 by zinc. Nevertheless,
inhibition of ACO2 by ROS (Yan et al., 1997) or fumarate (Ternette et al., 2013) as
potential source of elevated citrate appears to be worth further investigation, in addition
to ACLY.
4.4.4 The role of senescence effector proteins in extracellular
citrate accumulation
The generous gifts of knockout p53, p21WAF1 and p16INK4A made it possible to test the
probable role of these proteins in the accumulation of extracellular citrate. While stable
knockout ensured that there was a complete loss of the proteins of interest and enabled
their stable culture, long term effects of the knockout and therefore the induction of
compensatory mechanisms cannot be ruled out especially in the case of p53, which is
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involved in numerous cellular processes. With this in mind ideally the results obtained
using these cells will be confirmed using transient knock-down of the proteins, however
there was not time to do this during the project.
4.4.4.1 p16INK4A
Conditioned media collected from cells lacking p53, p21WAF1 and p16INK4A were analysed
using targeted GCMS. Cells lacking p16INK4A did not show any significant change in
extracellular citrate relative to control cells (the control cells were not ideal as they
were not isogenic, however they were from the same tissue type), so p16INK4A is not
likely to be closely involved in citrate regulation. Given that the two cell lines most
studied in this thesis had completely different expression levels of p16INK4A (NHOF1
did not have detectable levels of p16INK4A whereas IMR90 had low levels of p16INK4A in
growing cells and elevated p16INK4A in senescence), yet both had elevated extracellular
citrate in senescence, it was expected that p16INK4A probably did not play a key role
in the extracellular accumulation of citrate. However, this still remains to be properly
tested directly.
4.4.4.2 p53 and p21WAF1
p53-/- fibroblasts showed a significant increase in extracellular citrate. This elevation
was not related to senescence as an SAβ-gal assay showed the cells were negative for
the characteristic blue stain (figure 4.17 on page 204), and suggests that p53 normally
functions to restrain citrate. p53 could be either restraining citrate production, citrate
export from the cells, or both but the fact that knockout of p21WAF1 had no effect on
citrate levels shows that the mechanism p53 is involved in to elevate citrate does not
include the transcriptional activation of p21WAF1.
The evidence that loss of p53 leads to an increase in extracellular citrate fits with the
prior knowledge that established senescence is associated with low levels of p53. There
are several ways in which the levels of p53 could be influencing the level of citrate and
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metabolism in general in senescence.
4.4.4.3 Potential direct effects of p53
p53 is known to directly interact with several metabolic enzymes and transcriptionally
regulate both metabolic enzymes and transporters of metabolic fuels.
Metabolic enzymes
Malic enzyme 1 (ME1) and malic enzyme 2 (ME2) convert malate to pyruvate and in
doing so regenerate NADPH from NADP+. NADPH is required for reductive biosyn-
thesis of lipids, and over expression of ME1 and ME2 results in increased total lipids.
p53 has been shown to repress expression of ME1 and 2, as demonstrated by the eleva-
tion of both malic enzymes and subsequent increase in lipid levels in TP53-/- cells (Jiang
et al., 2013). The phenotype observed in the previous chapter included the specific ac-
cumulation of multiple phospholipids in senescence (figure 3.6 on page 145) which might
be explained by de-repression at the transcriptional level of ME1 and ME2 following a
decline in p53 protein levels in established senescence. Furthermore PGM, a glycolytic
enzyme, is inhibited by p53 (Kondoh et al., 2005) and TIGAR inhibits the glycolytic
enzyme PFK1) by degrading fructose-2,6-bisphosphate which acts to stimulate PFK1
(Bensaad et al., 2006). Low p53 activity would therefore suggest that the inhibition of
glycolysis via these routes would be alleviated.
As well as inhibiting glycolysis p53 acts to promote oxidative phosphorylation through
transcriptional regulation of proteins necessary for mitochondrial respiration such as
synthesis of cytochrome oxidase 2 (SCO2) which is critical to the formation of complex
IV in the electron transport chain (Matoba et al., 2006).
NFkB
The transcription factors NFkB play several roles in senescence induction and mainten-
ance, but it is also involved in some of the metabolic functions of p53.
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p53 is necessary for the anti-glycolytic, pro-OXPHOS activities of NFkB, as demon-
strated by Claudio Mauro and colleagues, who showed that inhibition of NFkB subunit
RelA resulted in an increase in lactate production and a decrease in oxygen consump-
tion, signs that the cells had become glycolytic. Expression of p53 in these cells reduced
lactate production and increased oxygen consumption (Mauro et al., 2011). Further-
more, p53 inhibits the NFkB driven expression of GLUT3, a glucose transporter that
increases glucose transport into the cell to fuel glycolysis (Kawauchi et al., 2008). Low
levels of p53 activation would therefore be expected to result in repression of the anti-
glycolytic activities of NFkB and an increase in the expression of GLUT3 and therefore
glucose transport into the cell, supporting a glycolytic phenotype. These assumptions
are yet to be tested.
Transport of metabolic fuel
As already mentioned p53 represses the expression of GLUT3 via NFkB, but p53
is also known to repress GLUT1 and GLUT4 which are also glucose transporters
(Schwartzenberg-Bar-Yoseph et al., 2004). The product of glycolysis is lactate, and
if cells are heavily reliant on glycolysis the build up of lactate can reduce the intra-
cellular pH which inhibits glycolysis. in order to maintain a glycolytic metabolism
the surplus lactate needs to be transported out of the cell via members of the mono-
carboxylate transporter family (Halestrap and Price, 1999). We have some evidence of
increased extracellular lactate in senescence (see figure 3.22) suggesting that there may
be increased transporter activity. MCT1 is repressed by p53 (Boidot et al., 2011), again
suggesting that in late senescence with low levels of p53 activation glycolysis increases.
ROS
p53 also has a complex relationship with ROS regulation and depending on the context
p53 can induce or repress ROS (Liu et al., 2008); in the case of substantially decreased
p53 activity ROS has been shown to go up due to lack of transcription of several
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antioxidant p53 target genes (Sablina et al., 2005). Redox homeostasis pathways were
another aspect of the senescent phenotype studied in this chapter based on findings in
the metabolomic screen, discussed in the next section.
4.4.5 Oxidative stress response
There is evidence that at the transcriptional level senescent cells launched an oxidative
stress response including up-regulation of SOD3 ( 4.19 on page 206); an enzyme that
catalyses the conversion of superoxide to to hydrogen peroxide (H2O2) and water and
has been shown to reduce cellular oxidative stress (Serra et al., 2003). Interestingly
several genes known to increase cellular oxidative stress were elevated in senescent cells
as shown in figure 4.19 including the NADPH oxidases DUOX1 and 2 and NOX5. These
proteins generate H2O2 and maintain the DDR (Fulton, 2009; Ameziane-El-Hassani
et al., 2015) and their increased transcription would suggest that senescent cells have
elevated levels of ROS. Indeed data from a DCF assay measuring intracellular H2O2
showed elevated ROS levels in PEsen fibroblasts (see figure 4.21). Elevated levels of ROS
is generally associated with dysfunctional mitochondria (Wang et al., 2013), so it is likely
that oxidative metabolism would be impaired in these cells, which is a possible reason
for the observed glycolytic phenotype. If there had been more time this hypothesis
could have been tested by measuring the membrane potential and respiration rate of
the mitochondria in senescent cells (Brand and Nicholls, 2011) however unfortunately
it was not possible to achieve in the time frame.
While the loss of of p53 in Loxo26 p53-/- did result in increased levels of ROS, as
expected according to the literature (Sablina et al., 2005), interestingly the p16INK4A
negative Leiden cells showed relatively higher levels of ROS (see figure 4.22) compared
to both control cells and the Loxo26 p53-/-, but did not show elevated levels of citrate
(figure 4.18) suggesting that elevated citrate is not closely related to higher levels of
ROS in senescent cells. However, this requires direct testing.
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4.4.6 Telomerase
NHOF1 cells with added telomerase did not senesce despite undergoing more population
doublings than were necessary to cause senescence in NHOF1 cells lacking telomerase,
and preliminary citrate measurements show that citrate does not accumulate in the me-
dia of telomerised cells following long term culture (figure 4.23 on page 209), as would
be expected when considering the knowledge that telomerase enables immortalisation
by lengthening and maintaining telomeres (Vaziri and Benchimol, 1998). Unfortunately
the citrate measurement data shown for telomerised cells only represents an n of one,
due to technical issues with the GCMS which meant that the subsequent experimental
samples could not be analysed in time for this thesis. If the pattern of the result remains
the same when the final data points are added, the increase in extracellular citrate fol-
lowing PEsen in NHOF1 cells expressing telomerase with the HA tag which prevents it
from lengthening or maintaining telomeres, immortalising cells, or avoiding replication
crisis in cells (Counter et al., 1998), suggests that non-canonical functions of telomerase
retained by TERT HA are not sufficient to prevent accumulation of citrate. If that
is the case then citrate elevation is probably not due to DNA damage alone, because
one of the non-canonical functions of telomerase is enhanced DNA damage response
and resolution, not just at the telomere (Masutomi et al., 2005), although the extent of
DDR/DNA damage in these cells was not examined here so this assumption remains to
be tested. Another non-canonical function of telomerase is protection of mitochondrial
DNA and improved mitochondrial function with less mitochondrial ROS generation
(Ahmed et al., 2008). It was not possible to determine from the NHOF1 TERT data
whether the lack of citrate accumulation was due to the telomere lengthening activity of
telomerase or if all or part of the effect was due to the non-canonical functions such as
the ability to protect mitochondria. The TERT HA expressing cells have the potential
to answer this question; if the tagged telomerase is fully capable of localising to the
mitochondria in the same way as TERT, then mitochondrial dysfunction is unlikely
to be the cause of elevated citrate, as we would expect mitochondrial dysfunction to
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be corrected in TERT HA expressing cells (which still senesce and show elevated cit-
rate) however there is no evidence to demonstrate the HA tagged protein’s ability to
enter the mitochondria. Further investigations are necessary to establish the extent of
mitochondrial damage in senescent cells expressing TERT HA.
4.4.7 Summary
Following the metabolomics study which identified citrate as a potential secreted bio-
marker of senescence, a number of approaches were used to try and elucidate the mech-
anism behind the elevation of citrate. These experiments also helped to further charac-
terise the metabolic phenotype of the senescent fibroblasts, which, from the metabolo-
mic screen, appeared to be glycolytic.
Regulation of glucose metabolism was assessed at the transcript level using a qPCR
array which showed that there were not many large changes in fold up or down regulation
of the metabolic enzymes involved in the TCA cycle, PPP or glycolysis but most of
the changes were in the glycolysis pathway, supporting the theory that senescent cells
predominantly use glycolysis to generate energy. However, this up-regulation could not
be seen at the protein level in the key enzyme PDK4, so it would be useful to use
labelled carbon glucose to measure how much of the glucose produces either lactate
or PPP intermediates and how much enters the TCA cycle, to show definitively which
pathways are preferentially used in senescence.
There was no change at the transcriptional level in enzymes that are directly involved
in the breakdown and production of citrate, namely ACLY, ACO1, ACO2 and CS. This
was confirmed at the protein level. Further work is needed to assess the activity of
these enzymes, as post translational modifications or antagonists may be affecting their
function.
219
Chapter 5
General Discussion
5.1 Introduction
The two key aims of this thesis were to firstly identify a candidate secreted biomarker of
senescent fibroblasts, because such a marker that could be measured non invasively in
vivo and non destructively in vitro would be extremely valuable in the study of senes-
cence and potentially as a means of tracking the effectiveness of anti-ageing treatments.
The second aim of the thesis was to elucidate the mechanism behind the elevation of
any identified biomarkers, as this information would ensure appropriate use of the bio-
marker within the bounds of any limitations and also could potentially facilitate the
manipulation of the senescence phenotype. In this chapter the extent to which these
aims have been achieved will be discussed, along with additional insights gained as a
consequence of the experiments undertaken in pursuit of the aims, and how the work
will impact on the field of senescence. Lastly, some ideas on expansion of the work in
the future will be discussed.
5.2 Citrate as a biomarker of senescent fibroblasts
The primary aim of the thesis was achieved in the identification of citrate as a secreted
marker of senescence (described in chapter 3 section 3.3 on page 138), a result that was
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specific to senescent fibroblasts and distinct from transiently growth arrested cells and
cells with repairable DNA damage, but common to senescent fibroblasts from several
tissue types. These factors make citrate an ideal candidate for a biomarker of senescence
in vivo. In this section the need for a biomarker of senescence will be discussed along
with an overview of the key achievements that faciltated the identification of citrate as
a candidate marker and limitations of the work.
5.2.1 The need for a senescence biomarker
Senescent cells are known to accumulate in vivo, in pathologies such as neoplasia (Yang
et al., 2006) and fibrosis (Pitiyage et al., 2011) as well as with age (Liu et al., 2009).
However, without a non invasive biomarker of senescent cells it is impossible to carry out
longitudinal studies to assess the role senescent cells are playing in these pathologies.
Current methodologies for identifying the presence of senescent cells in vivo usually
require the tissue of interest to be removed and stained for SAβ-gal activity or other
marker of senescence such as p16INK4A, making it difficult if not impossible to take
multiple measurements from the same individual over time and to monitor responses to
interventions. While genetic manipulations of mice have enabled researchers to monitor
accumulation of p16LUC cells in mice in vivo non destructively (Burd et al., 2013), this
is only useful for senescence via p16INK4A and cannot be extended to humans. So
far studying the general increase or decrease in senescent cells in humans has not been
achieved, although studies on peripheral T- lymphocyte senescence have been successful
(Liu et al., 2009).
Even the discovery of the SASP has not yet yielded any biomarkers; many of the
reported proteins and factors are not commonly seen in all modes of senescence or
tissue types tested, in fact recently a mode of senescence was described that did not
show any of the inflammatory elements of the SASP (Wiley et al., 2016). The SASP
therefore is not a direct result of the senescence growth arrest, rather it is related to
other associated molecular changes that may also be present in other conditions such
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as inflammation.
5.2.2 Biomarker discovery using metabolomics
The field of metabolomics has proven very useful for identifying biomarkers of disease
in human body fluids such as blood and urine, thanks to technological advances which
have brought down costs and increased throughput (reviewed in James and Parkinson,
2015). Increasing numbers of researchers are taking advantage of the ability to detect
changes in metabolite levels, which reflect changes in cellular processes, in specific dis-
ease conditions or in response to intervention. The challenge still remains to be able
to capture the entire metabolome; currently the separation techniques used each only
enable certain classes of molecule to be identified, therefore to get a complete picture
multiple platforms must be used. Thorough multi platform screens have been performed
using human blood serum with the aim of describing the human serum metabolome,
curated with metadata on age, gender, weight and lifestyle habits (Dunn et al., 2014)
which is a useful resource for those trying to identify biomarkers in smaller more specific
studies. Relevant to this work, several groups have used metabolomics to identify a sig-
nature of ageing, such as the study published by Christina Menni and colleagues in 2013
which identified a panel of 22 metabolites, including citrate, that strongly correlated
with age (Menni et al., 2013). It was unknown at the time if any of the metabolites
associated with ageing in humans were a direct consequence of increased senescent cells;
the work in this thesis showing extracellular citrate is specifically elevated in senescent
fibroblasts suggests there could be a link.
5.2.3 The contribution of this work to the field of senescence
and human ageing
In this thesis the metabolomes of normal human senescent cells are described, and
metabolite changes specific to permanent cell cycle arrest were identified, including the
elevation of extracellular citrate. Importantly, it was possible to distinguish metabolite
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changes that were common to aspects of the growth arrest that were reversible and those
which were specific to permanent growth arrest. This distinction could only be made
because of the robust controls used as part of the screening process; the characterisation
of the senescent cells and growth arrest controls (serum starved and confluent) was
necessary to determine the most appropriate experimental design but also highlighted
some interesting differences between the cell types used. By using several markers to
assess senescence, transient growth arrest and DNA damage, it was possible to optimise
the culturing conditions so that metabolomes from fully senescent cells, transiently
growth arrested cells and growing cells could be compared with confidence. Importantly
for the understanding of the place of this work in the context of the wider literature,
wherever possible at least two cell lines were used, including IMR90 which has been
used in many other publications in the field. This thorough approach makes it unlikely
that the findings of this work are a peculiarity of the cell type used.
The metabolomics screens revealed alterations to several metabolic pathways in sen-
escent cells that were consistent with observations in other published studies, including
redox homeostasis, protein metabolism, fatty acid metabolism and energy metabolism.
The increase in gamma-glutamyl amino acids (see figure 3.24 on page 158) is indicative
of increased gamma-glutamyl transferase activity; a key enzyme in the maintenance
of antioxidant glutathione levels, a finding that agrees with older studies (Takahashi
et al., 1978). Previous studies also show that the turnover of proteins decreases with
age (Makrides, 1983), which is supported by the finding in this study that several
dipeptides were depleted in the media of senescent cells (figure 3.3 on page 142). In the
case of energy metabolism, depleted pyruvate and elevated TCA intermediates such as
citrate and fumarate initially suggested the TCA cycle is very active in senescent cells.
However when the internal metabolome, which showed there were lower levels of citrate,
malate and succinate (but interestingly fumarate levels were sustained) inside senescent
cells was taken into consideration, along with qPCR analysis of the enzymes involved
in glucose metabolism that showed an increase in transcription of glycolytic enzymes; it
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becomes increasingly likely that senescent cells are actually predominantly using glyco-
lysis to generate ATP. As the TCA cycle enzymes are situated inside mitochondria, this
result is perhaps not surprising because it is well documented that senescent cells have
dysfunctional mitochondria (Passos et al., 2007). Previous work assessing the bioener-
getics of senescent cells found that although cells had a decreased oxygen consumption
rate, indicating decreased oxidative metabolism, the glucose taken up by the cells was
not all being converted to lactate, the end product of glycolysis, and so the authors
concluded that the cells must be using up the pyruvate in the TCA cycle (Zwerschke
et al., 2003). This conclusion did not allow for the possibility that substrate might be
shunted into the PPP, or that gluconeogenesis might be active. To address these issues
flux experiments using the labelled substrates glucose, glutamine and pyruvate should
be conducted over a combination of short (minutes) and long (hours) time-courses to
establish which pathways are being preferentially used by senescent cells (intermediates
in the favoured pathways will incorporate the labelled carbons from the substrates).
Not only would this information add further detail to our knowledge of senescent cell
biology, it may also be helpful in achieving the second aim of this project; understand-
ing the mechanism behind the elevation of extracellular citrate, which will be discussed
later.
The question of whether or not the in vitro work in this thesis will translate to
a useful tool for studying senescence in vivo remains to be properly tested, although
citrate has already been identified as highly correlated with human ageing in vivo in the
study carried out by Menni and colleagues (Menni et al., 2013) as well as more recent
studies (Dunn et al., 2014), proving that alterations in citrate levels in humans in vivo
are both detectable and highly correlated with a condition known to be associated
wit accumulation of senescent cells (ageing), making citrate an excellent candidate
as a biomarker of senescence. In other species citrate has also been identified as a
marker of ageing; for example in house flies (Yan et al., 1997), which is also important
because previous work characterising the metabolome of ageing in non-human species
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has shown many aspects of the metabolome to be species specific. For example, a
metabolomic study of ageing in mice, which focused on lipids, reported many changes
in lipid metabolism (Toma´s-Loba et al., 2013) that were not found to be similar in
our study of human senescent cells or the studies of human ageing already mentioned
(Dunn et al., 2014; Menni et al., 2013). Finding aspects of senescence and ageing that
are similar between species is vital if animal models are to be informative on human
conditions.
To summarise this point; the work presented in this thesis represents a novel contri-
bution to the field of senescence in two regards; firstly the wealth of data generated from
the untargeted screening of the extra cellular metabolome of senescent and growing cells
from multiple tissues, in two modes of senescence as well as growth arrest controls and
intracellular metabolomes of one line will be deposited in the Metabolights database for
other researchers to access and mine. Secondly, a candidate secreted biomarker of sen-
escence has been identified, using rigorous controls to ensure it is specific for senescence
and not related only to the induction stimulus or transient growth arrest.
5.3 The mechanism behind citrate elevation
The second aim of this thesis was to elucidate the mechanism driving the elevation
of extracellular citrate in senescent cells. While progress has been made towards this
goal, further work is needed to answer the two main questions: what pathway(s) is the
citrate coming from and how is it being transported out of the cell? Figure 5.1 depicts
the main candidates for investigation.
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Figure 5.1: Potential sources of citrate in the cell. Citrate (teal circle) is produced
from acetyl-CoA via the enzyme citrate synthase (CS). An increase in β-oxidation of
triacylglycerols or glycolysis could result in an increase in mitochondrial acetyl-CoA,
which could potentially result in n increase in citrate production via citrate synthase.
A decrease in activity of either mitochondrial aconitase (ACO2) or cytosolic aconitase
(ACO1) could result in a decrease in the rate of citrate breakdown, leading to its accu-
mulation. Similarly reduction in ATP citrate lyase (ACLY) activity would also impair
the breakdown of citrate and lead to its accumulation. The observation that citrate is
depleted inside the cell but elevated outside suggests either a decrease in transport of
citrate into the cell via NaCT/NaDC1/NaDC3 transporters (green channel), or trans-
port out of the cell via an unknown mechanism (green box with ?). Yellow boxes
containing ? signify unknown activity of neighbouring enzyme or transporter.
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5.3.1 Where is the citrate coming from?
There are three main logical explanations for the observation that senescent cells have
elevated extracellular citrate and lower levels of intracellular citrate than growing and
growth arrested controls, which could be occurring together or in isolation. Firstly, it is
possible that transport of citrate across the plasma membrane into the cell is somehow
impaired. Secondly, there could be an increase in CS activity to produce citrate that
is then transported out of the cell. Thirdly there could be a decrease in activity of the
enzymes that break down citrate. The use of a blank media sample, corresponding to
each collection of conditioned media, shows the relative increase in extracellular citrate
compared to controls is genuinely an increase in citrate over the baseline levels seen in
the media. This observation means we can probably discount the first of those options
just described as the sole driver of increased extracellular citrate levels, because clearly
some citrate at least must have exited the cell. The exit of citrate from the cell is
assumed not to be from random leakage or diffusion because the movement would be
against a concentration gradient, and furthermore overall the extracellular metabolome
of senescent cells showed specific metabolites were depleted or enriched; there does not
appear to have been a non specific leakage of intracellular metabolites. It is important
to note that the metabolomic screen of intracellular metabolites was untargeted and
not quantitative, so as yet it is not known if the amount of citrate outside the cell
represents the same amount of citrate found usually inside the growing cells. If the
amount of citrate in the extracellular compartment of the senescent cells is similar to
the amount found inside growing cells, it would seem probable that transport of citrate
across the plasma membrane from the cytosol to the extracellular space is the major
factor of interest. However, if the extracellular citrate from senescent cells is more
than the intracellular citrate in growing cells, then in addition to intracellular citrate
being transported out across the plasma membrane, there must either be an increase in
production of citrate or a decrease in the breakdown of citrate. Although the activity
of CS has not been tested here, this thesis showed there was no transcriptional up-
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regulation of the enzyme and based on current literature it is unlikely to have increased
activity levels. CS is a mitochondrial enzyme, an organelle that is reported to become
dysfunctional in senescence due to increased ROS (Passos et al., 2007) and additionally
it has been reported that citrate synthase activity decreases in senescence (Ghneim and
Al-Sheikh, 2010). The remaining options of decreased ACO or ACLY activity also have
not been tested in this thesis, although none of these enzymes were down-regulated
at the transcript or protein level. There is already substantial literature to suggest
that ACO2 (mitochondrial aconitase) is likely inhibited, either by fumarate (which is
sustained in senescent cells while other TCA intermediates declined, if the data are
normalised to protein, or elevated if considered on an amount per cell basis) through
succination of cysteine residues (Ternette et al., 2013) or carbonylation as a result of
increased ROS (Yan et al., 1997), and silencing of ACLY has been demonstrated to
induce senescence via p53 (Lee et al., 2015).
5.3.1.1 The role of senescence effector proteins
Given that extracellular citrate accumulation is specific to senescent cells, the impact
of senescence effector proteins seemed a good place to look for possible regulation of
the citrate accumulation. In chapter 2 it was observed that NHOF1 cells did not have
detectable levels of p16INK4A in either PEsen or IrrDSBsen models, and while IMR90
did show elevation of p16INK4A in PEsen it was not apparent in IrrDSBsen. These
varying levels of p16INK4A in groups that all showed elevated citrate suggests that the
elevated citrate was probably not directly linked to p16INK4A levels. Further evidence
in support of this came from the use of p16INK4A knock out cells (Leiden) and p21WAF1
knockout and p53 knockout cells, which showed that relative to controls and the other
knockouts, cells lacking p53 had elevated extracellular citrate; suggesting p53 restrains
citrate but not via p21WAF1.
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5.3.2 How does citrate exit the cell?
While there are obvious routes for further investigation of whether there is more citrate
being produced and whether or not its breakdown is being inhibited, the way forward
for identifying how citrate is transported out of the cell is more challenging. As already
mentioned it is unlikely that the extracellular citrate increase is due to leakage across
the cell membrane, because specific enrichment and depletion of metabolites was seen,
suggesting the cell membrane was not “leaky”. In almost all mammalian cells citrate is
not transported out of the cell across the plasma membrane, but is transported into the
cell if enough is not being produced in the mitochondria to sustain the TCA cycle and
acetyl-CoA production. One exception to this is luminal prostate epithelial cells, which
produce an increased amount of citrate due to inhibition of ACO2 by zinc (Costello and
Franklin, 1981), sequestered to the mitochondria due to hormone levels (Costello and
Franklin, 1994). The excess citrate is quickly exported across the plasma membrane
before it can be broken down by cytosolic enzymes, via a plasma membrane isoform of
the mitochondrial citrate transporter SLC25A1. This transporter is the same as the one
found in the mitochondria of all cell types except for a modification at the N-terminus
that causes it to be trafficked to the plasma membrane (Mazurek et al., 2010). It is
not known what causes this isoform to be expressed in prostate luminal epithelial cells,
but the possibility exists that the same isoform may be expressed in senescent cells
too, representing one potential mechanism behind citrate transport across the plasma
membrane. Transporters that normally exist in the plasma membrane are unlikely to
be the method of citrate export, as they are sodium linked and the gradient of sodium
is such that it always favours movement of citrate into the cell (Pajor, 1999, 2014) and
do not transport citrate against the concentration gradient (Wolffram et al., 1994).
5.3.3 Limitations of this work
The key to finding a robust biomarker of senescence is to ensure that the marker is
present/significantly elevated only as a result of senescence and not other similar condi-
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tions which could lead to false positives. In this thesis efforts were made to ensure that
the candidate biomarker was generic across different tissue types in vitro and across
two well characterised modes of senescence induction; IrrDSBsen and PEsen. However,
it was discovered that p16INK4A elevation was not required in either of these models of
senescence so the validity of the marker in a senescence state sustained by p16INK4A still
remains to be tested, along with oncogene induced senescence, to ensure that citrate
is indeed a marker of senescence growth arrest and not of some other related condi-
tion specific to the IrrDSBsen and PEsen models tested here. While this study did
cover several tissue types, all cells used were fibroblasts so it is not yet known whether
extracellular citrate is also elevated in other cell types such as blood cells and keratino-
cytes, and what effect differentiation would have on citrate levels. In addition, in vivo
validation is required.
Work has been started to address the mechanism behind the elevation of citrate,
however the data are preliminary. The observation that the telomere lengthening activ-
ities of telomerase alone, and not the non-canonical activities possessed by TERT HA,
are able to prevent senescence and elevation of extracellular citrate strongly supports
the conclusion that the citrate elevation seen in the PEsen model is a result of telomere
shortening and not just sustained time in culture however this needs to be verified with
repeats. The p16INK4A-/-cells used in this thesis did not have an isogenic p16INK4A+/+
control, instead other fibroblasts of the same tissue type were used and that was not
ideal so should be repeated using matched controls to ensure relative citrate levels are
accurately measured. Also as p53 is involved in so many aspects of cell biology, com-
plete knockout of p53 may have caused the cells to adapt and compensate its loss, so
results from these cells should be verified using a transient knockdown as well.
5.3.4 Future work
As is usually the case, in undertaking to answer just a few questions about the senes-
cence phenotype, many more questions have been raised and there are still some loose
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ends to tie up.
5.3.4.1 Addressing the remaining questions
To move forward on the question of the source of citrate in senescent fibroblasts it will
be useful to quantify the intracellular citrate in a normal population of young, growing
cells and compare it to the amount of extracellular citrate produced by a similar sized
population of senescent cells, to ascertain if the net amount is similar. The activity
of citrate synthase, ACO1, ACO2 and ACLY should also be measured in the relevant
cell fractions of senescent cells compared to controls. Further insight into the flux
through these enzymes should be attainable by using stable carbon isotope labelled
substrates, and monitoring the way in which the labelled carbons are incorporated
into citrate, isocitrate, acetyl-CoA, aconitate and other related metabolites to elucidate
which reactions must have occurred and therefore which enzymes are more active or
inactive than in controls cells under the same conditions. The next challenge, assuming
an altered enzyme activity will be identified, is to understand what is affecting the
enzyme(s). Depending on the affected enzymes, the degree of mitochondrial function
and ROS may be of interest, both of which could be assessed using fluorescent assays.
The role played by p53 (or lack of p53 activity on a background of other cellular
events specific to senescence) may be related to some or all of the above, so developing
transient knockdown of p53 or manipulating its activation could give important insights
into the connection between extracellular citrate elevation and the senescence state.
In terms of the question of citrate transport out of the cell the possibility that
a plasma membrane isoform of the mitochondrial citrate transporter SLC25A1 is ex-
pressed in senescence as in prostate epithelium and potentially gut luminal epithelium
should not be ruled out. If present, the protein should be detectable in the plasma
membrane using immunofluorescence microscopy and the mRNA identified using qPCR
using primers described for the isoform found in prostate. Other transporters should
also be investigated including NaDC1 and NaCT, which usually function as importers of
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citrate. Questions about their function in senescent cells could potentially be answered
using electrophysiological techniques; using pharmacological blocking agents to assess
how specific molecules are moving through the channels and in which direction.
As already mentioned, it is also important that other modes of senescence namely
OIS and p16INK4A dependent senescence are included in future investigations along with
other cell types such as keratinocytes. This information will inform whether citrate can
be used as a generic marker of senescence growth arrest or whether it is only useful for
monitoring senescent fibroblasts induced to senesce via PEsen and IrrDSBsen.
A measure of the sensitivity of citrate as a biomarker in vivo would also need to be
assessed to ensure its usefulness in detecting relevant changes in overall senescent cell
population in response to interventions.
5.3.4.2 Wider future applications of this work
In the event that further robust testing confirms that citrate is a specific biomarker of
senescence, across different cell types and induction methods, then finding the source
of the elevated citrate and mechanism for its transport would lead to a greater under-
standing of the fundamental molecular processes that underpin the senescence growth
arrest. This information would be extremely valuable for our understanding of cell
biology and facilitate the manipulation of the senescent state.
In addition, validity in animal models of senescence and ageing could be tested
by measuring serum levels of citrate in young and aged transgenic INK-ATTAC mice
(Baker et al., 2011) before and after selective removal of senescent cells; if senescent cell
accumulation in aged mice (which has already been shown (Baker et al., 2011, 2016))
was causing an elevation in extracellular citrate, the level of citrate should be reduced
in the aged mice to a level similar to that found in young mice, and the serum level of
citrate in young mice with few senescent cells should be largely unaffected. If shown
to be valid, the use of citrate as a marker of senescence could enable more efficient
animal use in studies designed to track the effects of senescent cell accumulation on
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physiological processes with other known readouts such as cognitive decline or muscle
wasting in ageing, or mobility in the case of fibrosis. Instead of sacrificing an animal at
each time point or after interventions to assess traditional senescence markers, multiple
serum citrate level measurements could be taken from the same animal as a readout
of senescence which would afford higher statistical power to the work in addition to
reducing the number of animals required.
Ultimately, having a biomarker of senescence that can be detected in human blood
would be extremely useful for the senescence field, and any other fields that are directly
affected by senescence including ageing, cancer and fibrosis. Some pathologies and
processes that had previously not had a known association with senescence may also be
identified by screening patients for elevated extracellular citrate. Using one clear marker
would facilitate much larger multi-site and even global studies to monitor large groups
of people throughout their lives, to see if there are any particular lifestyle, genetic or
environmental factors that influence the rate of accumulation of senescent cells and
any correlations to disease incidence or life span. The effects of interventions such as
“anti-ageing” products or specific diets could also be measured over long periods of
time. The effects of senescence- inducing cancer treatments could also be monitored for
success non-invasively, providing serum citrate levels are sensitive to localised changes
in senescent cell numbers.
5.3.5 Conclusions
To conclude, this thesis has made considerable progress towards identification of a
robust and specific secreted biomarker of senescent cells, which has the potential to
facilitate the long term study of the impact of senescence on human health, as well as
in animal models. While there is still work to do to ensure the robustness of citrate
as a marker of senescence, and questions still remain around the mechanism behind its
elevation, the data gathered so far on these points represents a novel contribution to the
field of senescence. The metabolic profiles of senescent fibroblasts along with matched
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growth arrested and growing controls will be particularly useful for the field in general,
as they represent information on many complex biological metabolic processes.
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